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CHAPTER I 
 
INTRODUCTION 
 
 Cancer is a disease of uncontrolled cellular growth. In the late stage, cancer cells may break 
the normal boundaries of their given cell type and invade surrounding tissue in a process called 
metastasis. Cancer can be classified into more than 100 distinct diseases that can affect nearly 
every cell and tissue in the human body and is ultimately a disease of genomic abnormalities (1). 
In 1982, strong evidence of the genetic component of cancer was discovered – Reddy et al. and 
Tabin et al. found a single mutation in the HRAS oncogene leading to cancer, as reported in two 
papers (2, 3). Since this breakthrough, hundreds of oncogenes and tumor suppressor genes have 
been discovered that may lead to cancer when their normal cellular mechanisms are disrupted 
through processes such as somatic mutations (4, 5). Although somatic mutations are important in 
cancer, the germline genome may also influence risk of cancer. 
The germline genome is the genome of the germ cells and is inherited. This DNA is the 
same in every cell in the human body (with the exception of de novo mutations). The somatic 
genomes consist of the genomes of every cell in the body with mutations that have been acquired 
during the lifetime of the individual. While the germline genome is passed on to offspring for the 
next generation, somatic mutations do not pass on. Both of these genomes have been found to be 
important in the process leading to cancer. However, many cancer researchers focus on one or the 
other genome and rarely study them in combination. It is important to study both because variants 
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in the germline genome could act in combination with variants in the somatic genome to cause 
cancer in a process known as Knudson’s two-hit hypothesis (6). 
Most cancers arise from somatic mutations to a given cell type. Although there are some 
cancers attributable to germline genetic abnormalities, all of these disruptions to the germline 
genome confer a greater risk for cancer rather than causal tissue-specific somatic mutations that 
directly lead to disease. Somatic mutations in cancer cells can be classified into two main types: 
driver mutations and passenger mutations. Driver mutations typically refer to those somatic 
mutations that confer uncontrolled growth to the cell or allow the cell to survive in conditions 
where apoptosis should normally occur. These are the typical cancer genes that are known and are 
often implicated in more than one cancer type (1). There are now over 600 driver genes that have 
been discovered in cancer (7), and more novel mutations, including those with regulatory roles in 
noncoding sequences, have been reported with potential driving roles recently (8, 9). Passenger 
mutations are somatic mutations in the cancer cell that are not specific to uncontrolled growth. The 
majority of somatic mutations are passenger mutations in cancer cells (1). Many of these mutations 
are benign and were in the cell prior to the driver mutation event (1). However, the determination 
of passenger versus driver genes is still an active area of research (10, 11). Overall, cancer is a 
genetic disease where mutations in one of hundreds, or thousands, of different genes may lead to 
abnormal cellular growth and disease state from the germline, somatic, or both genomes. This 
dissertation uses genetic data from the germline and somatic genomes to investigate three subtypes 
of lung cancer. 
Below, I give a brief overview of the history of lung cancer, environmental exposures 
associated with lung cancer, and genetic heritability. I also highlight the differences in lung cancer 
subtypes from a histological perspective. Finally, I summarize the genetic abnormalities in three 
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lung cancer subtypes using numerous examples from candidate gene studies, as well as genome-
wide studies, from the germline and somatic genomes. 
 
Overview and epidemiology of lung cancer 
 In 2012, there were ~8.2 million estimated deaths around the world attributable to cancer 
(12). The cancer types that were responsible for the most number of deaths were lung cancer in 
men and breast cancer in women. However, this trend is related to the income and status of the 
country – in developed countries, lung cancer is the leading cause of cancer related deaths for both 
sexes (13). Historically, this extremely high incidence of lung cancer around the world was not 
always true. Initially, lung cancer was a very rare cancer type with some institutions reporting it 
as comprising only ~1% of all tumors discovered (14). However, around the end of World War I 
(~1918), lung cancer cases began to skyrocket. Originally, there were several suspected links to 
lung cancer such as poison gas used in the trenches and the increase in pollution from the 
widespread use of the newly introduced automobiles (14). However, in Germany in the early 
1940s, the first suspected links between cigarette smoke and lung cancer were reported. As 
reviewed in (14, 15), Müller’s work (16), published in German, was one of the first studies to 
report a link between cigarette smoke and lung cancer. Additional studies in the UK and the US 
validated these claims in the 1950’s (15). A preliminary report, by Doll and Hill, in 1950 
demonstrated a link between smoking and lung cancer (17) while a much larger study (18) 
confirmed these findings in addition to the role of cigarette smoking in many other diseases. There 
are strong correlations with the prevalence of smoking and lung cancer for both sexes (19). 
Additionally, with an increase in cigarette smoking in developed nations, lung cancer has now 
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increased to become the number one diagnosed cancer type for men and the third most diagnosed 
cancer type for women around the world (13).  
 These worldwide trends are also prevalent in the United States (US). In the US, lung cancer 
is estimated to be the second leading cancer diagnosis for men (after prostate) and women (after 
breast) in 2017 (20). Although lung cancer is not estimated to be the number one diagnosed cancer 
type, it is predicted to be the leading cause of cancer related deaths in 2017 for both men and 
women. Current estimates place the total number of estimated deaths from lung cancer at ~85,000 
for men and ~71,000 for women in the US for 2017 (20). One explanation for such a high mortality 
rate for lung cancer in comparison to other cancer types is due to its late-stage diagnosis. Over 
50% of lung cancer diagnoses are made at the distant (metastasized to other organs) stage, while 
only ~15% of cases are discovered at a localized (constrained to the lung) level (20). There is a 
strong correlation between survival time and the stage at lung cancer diagnosis. At diagnosis, the 
5 year survival rate for localized stage lung cancer is ~55%, but if diagnosed at a distant stage, the 
5 year survival rate is <5% (21). In an attempt to increase the survival time of lung cancer sufferers, 
the US has rolled out an early screening program for lung cancer (22). Early results suggest that 
through the use of low-dose helical computed tomography (CT) scans, the mortality from lung 
cancer can be reduced (23). This program focuses on heavy smokers, but cigarette smoking is not 
the only known environmental agent associated with lung cancer. 
 
Risk factors associated with lung cancer 
 Cigarette smoking is the number one cause of lung cancer and worldwide is estimated to 
be the cause of 85% of lung cancer cases in men and 47% of lung cancer cases in women (24). 
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However, many other environmental risks pose a threat. For example, smoking tobacco in non-
cigarette forms such as pipes or cigars also increases a person’s risk for lung cancer (25). 
Additionally, indoor and outdoor pollution poses a risk for lung cancer (25), like using specific 
cooking pots in many Asian countries (26). Many other occupational exposures exist such as 
arsenic and asbestos, as well as many heavy metals such as nickel and chromium. In addition, 
naturally occurring radon gas and radiation all have been associated with lung cancer risk (25). 
Although environmental hazards play a large role in lung cancer risk, there is also a genetic risk 
for lung cancer. 
 In 2001, Hemminki et al. (27) used the Swedish Family-Cancer Database to estimate the 
genetic heritability for colorectal cancer, melanoma, and lung cancer. This database was the largest 
that was used at the time of publication and contained over 6 million people and ~550,000 cancers 
(28). They estimated liability for cancer using genotype, shared environment, childhood 
environment and non-shared environments among family members. The genotype variable used 
corresponded to overall relationships. For example, the coefficient of relatedness for first-degree 
relatives is 0.5, such as siblings and parent-offspring, while half-siblings is 0.25. The results of 
this study concluded that the heritability for lung cancer was estimated to be approximately 14% 
in this registry. A follow-up study, published in 2002 (29), used the updated version of the same 
database and found that genetic effects accounted for approximately 8% of susceptibility of lung 
cancer. Recently, heritability estimates for lung cancer have been determined through genome-
wide association studies (GWAS) (30). Sampson et al. (30) found that the heritability estimate for 
lung cancer is 0.206 in Europeans and 0.121 in Asians. Though these studies identified the percent 
of a genetic effect from lung cancer, earlier studies as far back as 1963 (31, 32) found familial 
aggregation of lung cancer. After 1963, many other studies have investigated the association 
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between family history and lung cancer including strong differences between ethnicity and lung 
cancer risk (33). For details about these studies, see the review this year by Musolf et al. (34). 
Importantly, these studies looked at the general category of lung cancer, and they did not separate 
lung cancer into its main subtypes.  
 
Histological classifications of lung cancer 
 There are two main histological types of lung cancer: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC) (35). As its name implies, SCLC (or sometimes referred to 
as small cell carcinoma or its archaic name oat cell carcinoma) is defined by the World Health 
Organization (WHO) by the small size of the tumor cells that they define as smaller than the size 
of 3 small resting lymphocytes (24). SCLC cases comprise only ~13% of total number of new lung 
cancer cases worldwide (36). Additionally, SCLCs are neuroendocrine tumors unlike other tumors 
of the lung that are epithelial (bronchial or alveolar) or squamous in origin. Although SCLC can 
be further differentiated into a number of rare subtypes, most common classifications put SCLC 
into one main type (24). SCLC is very aggressive, has strong potential for early metastasis, and is 
difficult to treat (37). 
Several classes of histologically different subtypes are classified under the larger lung 
cancer group NSCLC (24). Although NSCLC comprises many subtypes, the three most prevalent 
types are lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell 
carcinoma (LCC). LCC comprises only ~15% of all lung cancer cases and most lung cancer cases 
are either LUAD (40%) or LUSC (30%) (19, 38). Additionally, LUAD and LUSC are the most 
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widely studied lung cancer subtypes and will be the NSCLC subtypes that are studied in this 
dissertation.  
LUAD arises from epithelial cells and is most likely to occur on the periphery of the lung. 
The tumor cells range in size and usually resemble one of six macroscopic patterns. LUAD itself 
is comprised of many smaller subtypes, but like SCLC, it is often studied as a mixture of these 
histology types. LUAD is also the lung cancer subtype most likely to occur in never smokers and 
among women (24). 
LUSC arises from cells in the bronchial epithelium, and although several histological 
variations of LUSC exist, they are usually grouped into one subtype. The tumor cells usually 
exhibit irregular nuclei and are of an abnormal shape. Additionally, the tumors are often a very 
large size (24). Among lung cancer subtypes, LUSC usually has the strongest association with 
smoking, although it is second to SCLC in some studies (24, 39). 
 
Germline influence on lung cancer 
 
Familial lung cancer 
 Linkage studies have been performed to identify regions of the genome that are linked to 
lung cancer in families. For example, the Genetic Epidemiology of Lung Cancer Consortium 
(GELCC) performed a genome-wide linkage analysis and identified a region of the genome at 
6q23-25 associated with lung cancer (40). A follow-up study by You et al. (41) used 
microsatellites to fine-map this region to identify the gene responsible for the 6p23-25 peak from 
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the previous study. Their study concluded that the gene responsible for lung cancer in the linkage 
study was RGS17. An updated linkage analysis was performed by the GELCC in 2010. This new 
study replicated the earlier results on 6q using a larger number of families. Also, this study 
identified other regions on 6p, 1q, 8q, and 9p that may also be associated with lung cancer (42). In 
addition to the regions identified by linkage associated with lung cancer, there are a few cases of 
familial lung cancers discovered through gene-specific sequencing described below. 
 In 2005, Bell et al. (43) reported a potential inherited risk mutation for lung cancer in a 
European family. This study found that the T790M mutation in the Epidermal Growth Factor 
Receptor gene (EGFR) was mutated in multiple family members with lung cancer. This specific 
mutation has also been found in other families with lung cancer (44). Interestingly, this is a 
commonly observed mutation at the somatic level in lung tumor tissue that confers resistance to 
targeted EGFR inhibitors (45). Additionally, germline mutations in strong tumor suppressor genes 
such as p53 lead to an increased lung cancer risk (usually at a younger age) (46), along with many 
other cancer types.  
 
Candidate gene studies 
 While there are many genetic variants that have been reported for an association with lung 
cancer, few have been replicated in large studies according to a review by Brennan et al. (47). 
However, two notable genes that contain germline variants have been replicated in more than one 
large study or meta-analysis. Variants within the glutathione S transferase M1 (GSTM1) gene have 
been implicated in risk for lung cancer. In a meta-analysis in 2008 that analyzed over 19,000 lung 
cancer cases and over 25,000 controls, the authors found an increased risk for lung cancer in 
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European and Asian individuals with germline variants in GSTM1 (48). Another gene with 
germline variants associated with lung cancer is CHEK2 (47). The missense mutation I157T, 
among other mutations, in CHEK2 were found to lead to an increased risk of many cancer types 
in a Polish population (49). However, intriguingly, it was found that rare alleles of CHEK2 
decreased risk for lung cancer, while they increased risk of many other cancer types in a Polish 
population (50). However, one possibility for this observation is that the subjects died from the 
other cancers before they developed lung cancer and is therefore possible that risk for lung cancer 
may not have changed in this population. Many germline variants in lung cancer are thought to be 
of higher frequency in the population but of lower risk, so an ideal study design to discover these 
variants is through genome-wide association studies (GWAS). 
 
Genome-wide association studies 
The first successful GWAS was performed for age-related macular degeneration (AMD) 
in 2005 (51). Since then, this technique has been applied to an array of complex diseases or traits. 
As of February 13, 2017, the GWAS Catalog lists 31,394 unique SNP-trait associations for 2,000 
traits across 2,742 studies (52). This large number of identified variants in peer-reviewed articles 
suggests strong interest in using this approach for many disease types, including lung cancer.  
In 2008, there were four major GWA studies for lung cancer reported that identified several 
variants associated with lung cancer in European populations (53-56). Interestingly, all of the 
studies found strong genome-wide significant associated SNPs located in region 15q25. This 
region harbors a set of nicotinic cholinergic receptor (CHRNA) genes. This class of genes had 
previously been implicated in nicotine dependence (57). However, this region is associated with 
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lung cancer independent of smoking addiction (54). Additionally, other regions were found with 
associations in a subset of the studies such as 5p15 (55, 56) and 6p21 (56). Since 2008, there have 
been many more GWA studies (or meta-analyses) for lung cancer with larger samples sizes (58, 
59) and in other racial/ethnic populations (60-62). A summary of these findings is shown in Table 
1.1. Although large sample sizes and diverse populations provided additional regions of the 
genome to interrogate, there are several limitations to these studies. First, many of these studies 
did not analyze or stratify their results based upon all three major subtypes of lung cancer 
mentioned above. This made it difficult to investigate the level of association or similarity among 
the different subtypes. Secondly, since these are association studies, it is difficult to infer the 
correct causal SNP. It is also possible that the causal SNP may not have been genotyped and instead 
is detected through linkage disequilibrium (LD) (63). Finally, many of these detected variants are 
located in non-coding regions of the genome. This makes it difficult to infer a relationship between 
the non-coding SNP and its target gene(s). Therefore, many of the studies reported results with a 
set of “most likely” genes that are usually the closest ones in spatial proximity to the SNP based 
upon distance. Work has now demonstrated that the gene closest to the variant may not be its actual 
target (64). This lack of understanding for how non-coding variants are acting in lung cancer will 
be addressed in Chapter II where I will use two functional elements to identify regulatory SNPs 
and their target genes in three lung cancer subtypes: expression quantitative trait loci (eQTLs) and 
enhancers. 
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Table 1.1. Summary of GWA studies for lung cancer. 
Lead 
author 
Publication, 
year 
Population/study 
characteristics 
Initial discovery 
sample size 
GWAS platform Locus (or 
gene) 
reported 
Genes reported Outcome studied 
Spinola Cancer Letters, 
2007 
European 338 cases  
335 controls 
Affymetrix 100K  KLF6 KLF6  Risk of LUAD in 
discovery set and 
mixed NSCLC in 
replication set. 
Amos Nature 
Genetics, 2008 
European 1,154 cases  
1,137 controls 
Illumina 
HumanHap300 v1.1 
15q25.1 PSMA4 and 
CHRNA  
Risk of NSCLC. 
Hung Nature, 2008 European 1,989 cases 
2,625 controls 
Illumina Sentrix 
HumanHap 300 
15q25 CHRNA5, 
CHRNA3, CHRNB4 
Overall risk of lung 
cancer. 
Liu JNCI, 2008 Small family 
study GWAS 
194 cases 
219 controls 
Affymetrix 500K 
Affymetrix SNP 6.0 
15q24-25.1 CHRNA3, 
CHRNA5, 
CHRNB4, PSMA4 
Risk of familial lung 
cancer. 
Wang Nature 
Genetics, 2008 
European 1,952 cases 
1,438 controls 
Illumina 
HumanHap550 
15q25.1, 
6p21.33, 
5p15.33 
BAT3, MSH5, 
CLPTM1L 
Overall risk of lung 
cancer in initial 
analysis, replication, 
and meta-analysis. 
Also identified 
subtype specific risk 
for top SNPs.  
McKay Nature 
Genetics, 2008 
European 3,259 cases 
4,159 controls 
Illumina Sentrix 
HumanHap300 
5p15.33 TERT and 
CLPTM1L 
Overall risk of lung 
cancer.  
Broderick Cancer 
Research, 2009 
European 1,952 cases 
1,438 controls 
Illumina 
HumanHap550 
15q25.1, 
5p15.33, 
6p21.33 
CHNRA3, IREB2, 
PSMA4, TERT, 
CLPTM1L, BAT3, 
TNXB 
Overall risk of lung 
cancer in initial 
analysis and meta-
analysis. The three 
most significant loci 
were analyzed by their 
histologies. 
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Landi AJHG, 2009 European 5,739 cases 
5,848 controls 
Illumina HumanHap: 
317K+240S, 550K, 
610QUAD, 1M 
15q25, 
6p21,  
5p15.33 
(LUAD) 
CHRNA region, 
CLPTM1L and 
TERT (LUAD) 
Risk of lung cancer in 
LUAD, LUSC, and SCLC 
subtypes for initial 
analysis. Performed 
meta-analysis for all 
three subtypes in 
second study.  
Li  The Lancet 
Oncology, 2010 
Never smoking 
study. Mostly 
European 
754 cases  
377 controls 
Illumina  
HumanHap: 370K, 
610K 
13q31.3 GPC5  Overall risk of lung 
cancer in never 
smokers. 
Yoon Human 
Molecular 
Genetics, 2010 
Korean 621 cases  
1,541 controls 
Affymetrix 5.0 3q29, 5p15 C3orf21, TERT, 
SLPTM1L 
Risk of NSCLC. 
Hu  Nature 
Genetics, 2011 
Han Chinese 2,383 cases  
3,160 controls 
Affymetrix 6.0 3q28, 
5p15.33, 
12q12.12, 
22q12.2 
TP63, TERT, 
CLPTM1L, MIPEP, 
TNFRSF19, 
MTMR3, 
HORMAD2, LIF 
Overall risk of lung 
cancer. Stratified their 
six most significant 
SNPs by histology. 
Ahn Human 
Genetics, 2012 
Korean never 
smokers 
446 cases 
 and 497 controls 
Affymetrix 6.0 18p11.22  APCDD1, NAPG, 
FAM38B 
Risk of NSCLC in never 
smokers. 
Timofeeva Human 
Molecular 
Genetics, 2012 
European and 
Chinese meta-
analysis 
14,900 cases 
29,485 controls 
Illumina: 317K, 317K 
+ 240S, 370Duo, 
550K, 610QUAD, 
1.2M 
5p15, 6p21, 
15q25, 
12p13, 
9p21 
Several for each 
region  
Meta-analysis for risk 
of lung cancer in 
LUAD, LUSC, SCLC, and 
large-cell lung cancer 
(LCLC). 
Lan Q Nature 
Genetics, 2012 
Asian women 
never smokers 
5,510 cases 
4,544 controls 
Illumina: 370K, 
610Q, 660W 
10q25.2, 
6q22.2, 
6p21.32, 
5p15.33, 
3q28, 
17q24.3 
VTI1A, ROS1, 
DCBLD1, HLA 
class II region, 
among other 
potential genes 
Risk of lung cancer in 
never smoking women 
in initial study. 
Performed replication 
for 13 most significant 
SNPs in LUAD. 
Dong PLoS Genetics, 
2013 
Han Chinese 833 cases 
3,094 controls 
Affymetrix Genome-
wide Human SNP 
Array 6.0 
12q23.1 SLC17A8, NR1H4  Risk of LUSC. 
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Wang Y Nature 
Genetics, 2014 
European meta-
analysis 
11,348 cases 
15,861 controls 
Illumina: 317, 317 + 
240S, 370Duo, 550, 
610 1M 
3q28 
(LUAD) 
BRCA2, CHEK2 
rare variants for 
LUSC and TP63 
for LUAD 
Meta-analysis for risk 
of NSCLC. Stratified 
analysis by LUAD and 
LUSC. 
Zanetti Lung Cancer, 
2016 
African-American 1,737 cases 
3,602 controls 
Illumina HumanHap 
1M Duo 
5p15,15q25 CHRNA5 and 
TERT 
Risk of NSCLC. 
Stratified analysis by 
LUAD and LUSC. 
These studies were located using the GWAS Catalog (52). 
 
 
 
 14 
 
Functional elements  
 Non-coding functional variants can be classified into many categories, including 
transcription binding sites (TFBS), splice sites, methylation related CpG islands, eQTLs and 
enhancers. Among these non-coding variants, some are associated with a specific trait such as 
eQTLs and GWAS significant SNPs, while others, such as TFBS, are predicted to be functional 
based upon genomic context. Among these functional elements, eQTLs and enhancers have gained 
much attention due to their strong roles in gene regulation and disease association and the recent 
release of many high-quality data sets.  
 eQTLs are genetic variants in the genome that are correlated with variations in gene 
expression. These regulatory elements may be tissue specific, so it is necessary to use the correct 
disease related tissue for eQTL significance (65). Large collaborations such as the Genotype-
Tissue Expression (GTEx) project (66) have generated sets of eQTLs in over 40 different human 
tissue types. Additionally, GTEx also generated sets of multi-tissue eQTLs that act in multiple 
tissues (67). Past work has also demonstrated that GWAS hits are enriched in eQTLs (68) and 
other regulatory regions (69) of the genome. 
Enhancers are DNA sequences in the genome that can enhance the transcription of a gene 
or genes. They are mostly located in non-coding regions of the genome and can influence 
transcription of up-stream or down-stream genes. Additionally, enhancers may act on genes that 
are not their closest neighbors (70). Although identifying or predicting enhancers based on DNA 
sequence alone is difficult, many epigenetic marks associate with enhancers and their activity (70). 
This feature allows one to identify enhancers using experimental techniques such as Chip-Seq 
(70). Many methods are now available to predict enhancers in many different tissue types 
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integrating many different data types (71, 72). In addition to the epigenetic marks associated with 
enhancers, it was discovered that enhancers can also be transcribed into enhancer RNAs (eRNAs). 
The Functional ANnoTation of the Mammalian genome (FANTOM) project (73) used these 
eRNAs to identify enhancer regions across multiple tissue and cell-lines using the Cap Analysis 
of Gene Expression (CAGE) method (74). Recent work (75) has found that GWAS variants located 
in enhancers are important for many cancer types such as prostate cancer, breast cancer, and 
colorectal cancer. 
 
Lung cancer from a somatic perspective 
 Although germline studies of lung cancer can provide insight into risks involved with lung 
cancer, studying somatic mutations in lung tumor tissue can help identify the genomic aberrations 
driving the tumor growth (1). Therefore, there has been much effort involved in the determination 
of the genetic aberrations in lung tumor tissue. These studies can be separated into smaller 
candidate gene studies and larger genome-wide tests to identify any locations in the genome that 
may be linked with lung cancer.  
 
Candidate somatic studies 
 One approach to identify genetic alterations associated with lung cancer is to study gene 
sets that may have previous evidence for their involvement in cancer or cellular proliferation. 
Below, I summarize a single multi-gene study that has progressed the lung cancer research field 
for each lung cancer subtype.  
 16 
 
LUAD  
 One of the first major multi-gene investigations to identify mutated genes associated with 
LUAD using sequencing was performed in 2008. Ding et al. (76) sequenced 623 known cancer 
related genes to identify novel mutations in lung cancer. In addition to replicating known gene 
associations with lung cancer such as TP53, CDKN2A, STK11, KRAS, EGFR and NRAS, this work 
also identified novel mutations in lung cancer including tumor suppressor genes (TSGs) ATM, and 
RB1, and the proto-oncogene tyrosine kinase ERBB4.  
 
LUSC   
In 2011, Hammerman et al. (77) sequenced 201 genes including all known kinase genes at 
that time to identify somatic mutations in LUSC using 20 samples. They found mutations in 25 
genes (including p53) in this initial sample set. They performed a second screen with six kinase 
genes (DDR2, FGFR2, NTKRK2, JAK2, FLT3, and CDK8) that were mutated in the first phase. 
They identified many mutations in the DDR2 gene and replicated it in an additional five samples 
from a validation cohort of 222 samples, confirming its role in LUSC.  
 
SCLC 
 There are no large candidate-based sequencing studies for SCLC comparable to the studies 
mentioned above for LUAD and LUSC. However, smaller single gene studies have identified 
many genes with mutations that may be involved in the disease process such as p53, PTEN, 
PIK3CA, and RB (78). 
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Genome-wide somatic studies 
 In contrast to candidate gene studies, genome-wide studies for cancer interrogate the entire 
genome to identify genes that may influence lung cancer. Below, I highlight some of the most 
expansive genome-wide somatic studies for lung cancer in each subtype. 
 
LUAD 
 Since the introduction of genome-wide genetic technologies, there have been several 
efforts to search for driver mutations in lung cancer. In 2007, Weir et al. (79) used SNP arrays to 
determine a set of copy number alterations across the genome for 371 LUAD tumor samples. This 
analysis found over 50 copy number changes across the genome for the LUAD samples. This 
genome-wide analysis was able to identify CNVs in LUAD, but was not able to obtain the level 
of mutational data generated using DNA sequencing. In 2012, one of the first efforts to use NGS 
to interrogate lung cancer on multiple samples was done. Govindan et al. (80) performed whole 
genome sequencing (WGS) and transcriptome sequencing (RNA-Seq) on 17 patients with 
NSCLC. Intriguingly, this study identified many chromatin modification genes that were 
significantly mutated. They also discovered novel fusion genes through their RNA-Seq analysis. 
In that same year, Imilinski et al. (81) performed a combination of WGS and WES on over 180 
LUAD samples. Their work discovered several somatic mutations and insertions/deletions (indels) 
in LUAD. A few years later, The Cancer Genome Atlas (TCGA) working group published their 
results on LUAD (82). The TCGA group generated germline SNP data, somatic mutation data, 
mRNA sequencing data, microRNA sequencing data, methylation data, copy number alterations 
data, and protein expression levels using 230 LUAD tumor and matched normal samples. This 
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unprecedented level of data and methodological approaches discovered many new genomic 
alterations associated with LUAD (82). Work in Chapter III uses some of these results from 
somatic mutation calling and mRNA sequencing for the somatic analysis performed in that 
chapter. 
 
LUSC 
 In 2009, Bass et al. (83) used SNP arrays to investigate the copy number alterations 
associated with LUSC and esophageal squamous cell carcinoma (ESCC) in 40 ESCC samples and 
47 LUSC samples. This study identified amplifications and deletions in both cancer types. 
Interestingly, they found that genomic region 7p11.2 was amplified in both cancer types with 
EGFR as the target gene. EGFR is mutated in many NSCLC subtypes, but most are found in LUAD 
(35). Another region that was amplified in both cancer types was 8p12 that includes the candidate 
genes FGFR1 and WHSC1L1. Their study also discovered SOX2 as an amplified oncogene in both 
cancer types. The following year, Weiss et al. (84) used a much larger set of LUSC tumor samples 
(n = 155) to identify copy number alterations using a SNP array. Their study identified over 50 
amplifications and deletions and confirmed the previous year’s finding of FGFR1 and SOX2. 
Interestingly, they looked at previously published results from LUAD (85) and observed that 8p12, 
which contains FGFR1, is not amplified in LUAD. In 2012, TCGA published their initial analyses 
on LUSC (86). For their analyses, they generated genome-wide data for mRNA sequencing, 
microRNA sequencing, copy number alterations, somatic mutations, and methylation levels. Their 
results indicated many genomic alterations in LUSC that were previously unknown. Intriguingly, 
they found somatic mutations in the HLA-A for the first time in lung cancer that suggests an 
immune role in this cancer subtype. 
 19 
 
SCLC 
 In 1995, Levin et al. (87) examined copy number alterations in SCLC using comparative 
genomic hybridization (CGH) for ten SCLC samples. Their results indicated many regions of the 
genome that were increased (gain, or amplification) or decreased (loss) in copy number. Of note, 
they found copy number gains in regions that contained MYC, a known oncogene overexpressed 
in multiple cancer types (75). They also found decreased copy numbers in many genomic regions 
that harbor well-known TSGs p53 and RB. In 2012, two large SCLC studies were published in the 
same issue of Nature Genetics (88, 89). Peifer et al. (88) generated WES and copy number 
alterations for ~30 samples, and they performed WGS on two of the samples and RNA-Seq on 15 
of the samples. Their study found amplifications in 8p12, which contains the FGFR1 gene, and a 
single sample with amplification of the MYC region. Their work also identified a set of 
significantly mutated genes in addition to sets of fusion genes. Rudin et al. (89) generated WES, 
RNA-Seq, and copy number alteration data on over 50 SCLC samples. Their analysis identified 
thousands of somatic mutations and many copy number alterations. They replicated the MYC 
amplification from the previous study and also found amplifications in the SOX2 gene. They found 
many gene fusions, including four gene fusions involving kinase genes. Most recently, in 2015, 
George et al. (90) published the genomic profiles of WGS for 110 SCLC samples, RNA-Seq for 
71 of these samples, and SNP copy number arrays for 103 of the samples. This study revealed 
several new genomic alterations in SCLC in genes such as TP73 and many NOTCH signaling 
genes.  
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Overlap of genetic features in lung cancer subtypes 
 Results from the publication of the two large SCLC studies in 2012 (88, 89) highlighted 
above gave an indication of somatically mutated cancer driver genes, and oncogenic gene fusions, 
that are shared between LUAD, LUSC, and SCLC. These new results, in combination with 
previously discovered genomic alterations, reveled shared gene sets between subtypes (91). It was 
revealed that all three subtypes shared these somatic mutated driver genes: TP53, CDKN2A, 
PIK3CA, and PTEN. Only one gene, KEAP1, was uniquely shared between LUSC and LUAD, 
while two genes, FGFR1, and SOX2, were both driver genes shared between only LUSC and 
SCLC. This also revealed that many driver genes are unique to each subtype. These mutated driver 
genes and their comparison to each other are listed in Table 1.2. 
A recent study (92) performed a deep comparison of genomic features in LUAD and 
LUSC. Campbell et al. (92) used WES and copy number profiles to identify CNVs and somatic 
mutations in over 1,000 tumor-normal matched pairs. Interestingly, they found that only six 
mutated genes (TP53, RB1, ARID1A, CDKN2A, PIK3CA, and NF1) were shared between the two 
subtypes. Three of these genes (TP53, CDKN2A, and PIK3CA) were previously found in all three 
lung cancer subtypes, RB1 was previously only found in SCLC, and ARID1A and NF1 were not 
previously found to be driver genes in lung cancer. This dissertation will be the first effort as a 
comprehensive comparison of LUAD, LUSC, and SCLC across the germline and somatic 
genomes.  
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Table 1.2. Summary of mutated driver genes in three lung cancer subtypes. 
LUAD only LUSC only SCLC only LUAD-LUSC 
shared 
LUAD-SCLC shared LUSC-SCLC 
shared 
Shared by three 
EGFR NFE2L2 RB1 KEAP1 Nothing uniquely shared FGFR1 TP53 
KRAS TP63 RLF-MYCL1   SOX2 CDKN2A 
ERBB2 NOTCH1 MYCL1    PIK3CA 
BRAF  MYCN    PTEN 
ALK fusions  MYC     
ROS1 fusions       
RET1 fusions       
STK11       
Table is based off genes reported in Figure 1 in Pietanza and Ladanyi, Nature Genetics, 2012 (91). 
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Summary and overview of dissertation 
 Although cigarette use has strong correlations with lung cancer risk, genetic factors also 
play major roles. Lung cancer consists of several subtypes; the most common of these are LUAD, 
LUSC, and SCLC. Previous work has identified potential genetic risk for these subtypes from the 
germline level using small candidate-gene approaches and also GWA studies. Additionally, 
somatic studies have identified genes that have major roles in lung cancer tumor formation and 
growth. However, there is a lack of information on how genetically similar these three subtypes 
are across both genomes. This dissertation aims to perform a detailed interrogation of these three 
subtypes for the germline and somatic genomes.  
 In Chapter II, I investigate these three major subtypes from the germline perspective. I use 
common genetic variants discovered in a GWAS for LUAD, LUSC, and SCLC to investigate the 
common and distinct biology behind these three subtypes of lung cancer. Most GWA studies for 
lung cancer are not analyzed by each subtype separately, and most identified variants do not have 
a well-identified biological role or associated gene. Therefore, I identify a set of regulatory variants 
for each subtype. I also link these regulatory variants to their target genes using functional 
genomics data to provide insight into the biology behind each disease. Finally, I determine 
enriched biological pathways that contain these target genes. 
In Chapter III, I use biological data from the somatic perspective to investigate these 
subtypes. I utilize gene expression levels identified from RNA sequencing (RNA-Seq) and DNA 
mutations identified from whole exome sequencing (WES) to interrogate the disease processes 
underlying each subtype. I generate a set of genes that are differentially expressed in the tumor 
versus normal tissue using the RNA-Seq expression data and use these genes to identify perturbed 
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biological pathways for each subtype. I also identify somatic mutational signatures for each 
subtype. These signatures can be used to help identify similarities behind specific cancer types by 
utilizing their unique pattern of somatic mutational processes. I use filtering and expression 
methods to obtain a set of potential driver genes for each subtype and investigate their overlap 
among the subtypes.  
In Chapter IV, I explore the possibility of identifying somatic mutations using RNA-Seq 
in place of WES in lung cancer by performing a systematic comparison of variants identified in 
WES versus RNA-Seq. Specifically, I discover somatic mutations from lung cancer samples that 
have undergone WES and RNA-Seq and compare several technical and biological features of the 
mutations identified by each method.  
In Chapter V, I apply the approach to identify GWAS regulatory variants and their target 
genes from Chapter II to other disease types. I utilize other lung diseases, population types, and 
cancer types to expand the usefulness of this approach. This chapter demonstrates the approaches 
from Chapter II can be expanded beyond lung cancer. 
In Chapter VI, I summarize the major findings from Chapters II-IV. The main focus of the 
summary consists of ways that the germline findings from Chapter II and the somatic findings 
from Chapter III can be investigated together to identify unique new biological insights behind 
LUAD, LUSC, and SCLC. I finish with future directions that can be undertaken with these results 
to gain a clearer picture into the genetics and biology behind LUAD, LUSC, and SCLC. 
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CHAPTER II 
 
EXPLORTATION OF THE GERMLINE GENOME IDENTIFIES WEAK 
SHARING OF GENETIC ASSOCIATION SIGNALS IN THREE LUNG 
CANCER SUBTYPES: EVIDENCE AT THE SNP, GENE, REGUALTION, 
AND PATHWAY LEVELS. 
 
Introduction 
 
Out of the three major subtypes of lung cancer, the non-small cell lung cancer (NSCLC) 
subtypes LUAD, and LUSC comprise ~60% of newly reported lung cancer cases, while SCLC 
comprises only a small subset (~15%) (93). One commonly used approach to identify variants 
associated with these lung cancer subtypes is to perform a GWAS. In 2007, Spinola et al. (94) 
performed a small GWAS in a European population of ~ 300 cases and ~ 300 controls and 
identified a variant near the KLF6 gene associated with lung cancer. The following year in 2008, 
four GWA studies were published (53-56) with all of the studies identifying variants in the 15q25 
region that showed associations with lung cancer. Since 2008, several GWA studies and meta-
analyses, (26, 58-62, 95-99) have discovered several common variants associated with lung cancer 
risk. However, only about half of these studies (54, 58-60, 95, 96) had data for all three lung cancer 
subtypes.  
Additionally, most of these GWAS findings did not reach the stringent genome-wide 
significance in a single GWA study (p < 5 x 10-8), and most of the genome-level significant single 
nucleotide polymorphisms (SNPs) were located within non-coding regions of the genome, making 
it difficult to infer the underlying mechanism of the significant variants that could contribute to 
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disease. Since genome-wide significance level has been thought too stringent (i.e., by Bonferroni 
correction), those common SNPs with moderate association signals (e.g., p < 1 x 10-3) have been 
found informative in exploring the association evidence (100, 101). Moreover, recent studies have 
demonstrated that these marginally significant SNPs found from GWAS within non-coding 
regions of the genome may function in regulatory roles (68, 69). Therefore, one can use these 
results to obtain a set of regulated genes to investigate and compare the similarity of the three lung 
cancer subtypes at the germline gene level and at the regulation level.  
In this study, we first identified a set of SNPs with moderate association signals (p < 1 x 
10-3) from a prior GWAS (96) that covered three lung cancer subtypes, LUAD, LUSC, and SCLC. 
Then, we identified and compared regulatory variants associated with the three subtypes of lung 
cancer as well as their target genes. We used these results to investigate the similarity of the 
subtypes at the SNP, gene, regulatory, and pathway levels. We first remapped these SNPs to an 
updated genome reference (hg19) and expanded them using linkage disequilibrium (LD) patterns 
from a European population. We used this final set of SNPs to examine several lung tissue 
expression quantitative trait loci (eQTL) and enhancer datasets for evidence of regulatory function 
of each SNP and identified their target genes. When we compared the target genes of these 
regulatory SNPs, we observed that only five genes overlapped all three subtypes. Through this 
analysis, we have identified many genes that might have an important association with lung cancer 
for each specific subtype.  
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Methods 
 
GWAS dataset 
We used data from a previously performed multi-site GWAS for lung cancer in a European 
population that analyzed each sample by lung cancer subtype for the NCI GWAS for lung cancer 
(96). Briefly, this GWAS for lung cancer used cases and controls from four different studies, 
EAGLE, ATBC, PLCO, and CPS-II. After quality control (QC) of the genotyping results, there 
remained 5,739 cases and 5,848 controls of European ancestry and 515,922 SNPs. The analysis 
was stratified by lung cancer subtype with 1,730 LUAD cases, 1,400 LUSC cases, 678 SCLC 
cases, 5,848 shared controls, and was analyzed using unconditional logistic regression. We used 
the full set of significant lung cancer GWAS SNPs (p <1 x 10-3) separated by subtype for this 
analysis.  
 
Genomic annotation of GWAS SNPs 
The online web tool SNP Nexus (102, 103) (http://snp-nexus.org/) was used to annotate 
the genomic location of the significant SNPs by lung cancer subtype using the NCBI36/hg18 
genome assembly. We used the University of California Santa Cruz (UCSC) hg18 gene definitions 
for the genomic annotation of each region. 
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Converting hg18 SNPs to hg19 SNPs 
The results from the lung cancer GWAS were originally generated using coordinates from 
the hg18 reference of the human genome. We converted these SNPs to hg19 coordinates using the 
online tool Remap from the National Center for Biotechnology Information (NCBI) with default 
settings (http://www.ncbi.nlm.nih.gov/genome/tools/remap). This conversion allowed us to map 
the SNPs to the regulatory annotation information, which are based on hg19 coordination.  
We used these updated hg19 coordinates for the SNPs to obtain the updated SNP rsID 
numbers using dbSNP data for build 142 from the NCBI to account for any SNPs that may have 
been merged between assemblies. All the chromosomes with updated SNP IDs and coordinates 
for GRCh37.p13 (hg19) dbSNP b142 were downloaded from the NCBI ftp site 
(ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/human_9606_b142_GRCh37p13/chr_rpts/) on 
February 18, 2015 and matched with SNP results from Remap. 
 
Identification of SNPs in LD with the genotyped SNPs 
For each GWAS SNP, we retrieved all other SNPs in a 1Mb region both upstream and 
downstream from the SNP site using Tabix (104) (version 0.2.5). We obtained the SNP data from 
the European super population group from the 1000 Genomes Phase III data (v5.20120502). 
Vcftools (105) (version 0.1.12b) was used to convert the Tabix vcf files to the plink-tped file 
format. Then, we used the 1000 Genomes data for each GWAS SNP and applied PLINK (106) 
(version 1.07) to identify the final set of SNPs that were in LD with the tagging SNPs using an r2 
> 0.8 within the entire region 1Mb upstream and downstream of the SNP. The LD results from 
PLINK were combined for every SNP and any SNPs in LD that were duplicated across all SNP 
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sets were removed. These are the final set of LD SNPs for the analysis. Pipeline containing work 
flow is illustrated in Figure 2.1. 
 
GTEx eQTLs 
The full set of significant human lung tissue-specific eQTLs version 6 (V6) was 
downloaded from the GTEx website (https://www.gtexportal.org) on February 22, 2016. The 
eQTLs were identified using linear regression with the tool Matrix eQTL (107) with a +/- 1Mb 
region around the transcription start site in each individual tissue that had >70 samples. The 
significance of the eQTLs was determined by empirical p-values using permutations followed by 
a Storey false discovery rate (FDR). The eQTLs with a q-value ≤ 5% were considered significant.  
We also downloaded the full set of all multi-tissue eQTLs for nine different tissue types 
from the pilot phase of the GTEx Project on June 11, 2015. This file contained eQTLs discovered 
using two different methods, the University of Chicago (UC) model (108) and the University of 
North Carolina at Chapel Hill (UNC) model (109). We used the results that contained the average 
between both methods including calculated posterior probabilities for every gene-snp pair titled 
“res_final_amean_com_genes_com_snps_all.txt.” The whole SNP set (including LD SNPs) was 
used to detect eQTLs in this dataset. We plotted the distribution of posterior probabilities of all the 
eQTLs found using the SNPs and defined an eQTL as “significant” if its posterior probability was 
>80%. We removed all duplicated genes in each subtype to obtain the final GTEx set of genes. 
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Lung tissue eQTLs from Hao et al. study 
Hao et al. (110) investigated how genetic variation affects gene expression levels in human 
lung tissues. The authors used lung tissue and blood from more than 1,000 patients across three 
cohorts to identify a set of eQTLs in lung tissue and used their results to interrogate SNPs 
associated with asthma. We downloaded the entire set of cis-eQTLs in lung tissue identified from 
this study with FDR at 10%. We removed the target genes without annotated gene names in order 
to combine the genes with the results from our other analyses. If more than one SNP-gene pair 
were identified as eQTLs, but differed in their probes used, we considered them distinct eQTLs. 
We removed duplicated genes in each subtype to define the final Hao et al. set of genes.  
 
FANTOM5 transcribed enhancers 
The FANTOM consortium aims to identify and assign regulatory function to the 
mammalian genome. Part of this comprehensive project is to identify all transcribed enhancers and 
promoters in multiple human cell lines and tissue types. The entire set of permissive enhancers 
found in the FANTOM5 data was downloaded from 
http://enhancer.binf.ku.dk/presets/permissive_enhancers.bed on August 26, 2015. The gene-report 
function was used in PLINK v1.07 to search for any SNPs that were located within permissive 
enhancer regions defined by FANTOM. To identify the possible target genes of these enhancers, 
these enhancer regions were then matched with the set of FANTOM5 enhancer transcription start 
site’s significant associations downloaded from 
http://enhancer.binf.ku.dk/presets/enhancer_tss_associations.bed on August 25, 2015. 
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IM-PET predicted enhancers 
He et al. (72) developed a novel approach to identify the targets of histone-derived 
enhancers using a random forest classifier. The authors used this approach to define a set of 
enhancer target genes for 12 different cell types. We used the results for two lung cell types, IMR90 
and NHLF, from the supplemental tables of their publication (72) for our analysis. We used 
Bedtools (111) version 2.17.0 to identify lung cancer GWAS SNPs located within the enhancer 
regions that had an associated target gene. To remove non-expressed genes, we filtered the results 
to remove target genes with Reads Per Kilobase per Million mapped reads (RPKM) = 0. The 
enhancer targets were originally formatted as Ensembl defined transcripts, so we converted them 
to gene symbols using the BioMart tool from Ensembl using the archived site pertaining to genome 
assembly CRCh37.p13 (112).  
 
Locus level analysis 
 biomaRt (113) was used to annotate the genomic locations for the germline-regulated genes 
discovered from each dataset for each subtype using gene start and stop coordinates from Ensembl 
gene definitions using genome build GChR37.3. Genomic locations that were not defined from 
Ensembl, were manually annotated using NCBI’s Gene online web resource 
https://www.ncbi.nlm.nih.gov/gene. The function “cluster” from Bedtools (111) was used to 
cluster the genes into independent 1Mb regions. 
 
  31 
Pathway enrichment analysis 
The final set of germline-regulated genes was uploaded to the WebGestalt online resource 
(114). The hypergeometric test was used for enrichment with specific pathways followed by 
Benjamini & Hochberg multiple test correction (115). 
 
GWAS Catalog SNPs 
We downloaded all SNPs from the GWAS Catalog using the search term “lung cancer” on 
January 13, 2016. We removed the SNPs where the initial or replication population was other than 
European. We also removed the SNPs that were reported in Landi’s original lung cancer GWAS 
report (96) because we used them for our analyses, so we could not use them for any replication 
purposes.  
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Figure 2.1. Pipeline to identify a set of germline genes for SNPs that were moderately associated 
with three subtypes of lung cancer from the genome-wide association studies (GWAS) (96). SNPs 
were run through the pipeline separately for each lung cancer subtype: lung adenocarcinoma 
(LUAD), lung squamous cell carcinoma (LUSC) and small cell lung cancer (SCLC). After LD 
expansion, two eQTL and two enhancer datasets were used to identify expanded or original SNPs 
that were within regulatory regions with an identified, or predicted, target gene. 
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Results 
 
Description of data and SNP expansion 
We obtained SNPs (p < 1 x 10-3) for three lung cancer subtypes, LUAD, LUSC, and SCLC, 
from a National Cancer Institute (NCI) GWAS for lung cancer (96). This GWAS utilized cases 
and controls from four smaller studies: Environment and Genetics in Lung Cancer Etiology 
(EAGLE), Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC), Prostate, Lung, Colon, 
Ovary (PLCO) screening trial, and the Cancer Prevention Study II (CPS-II) nutrition cohort. 
Subjects from these four smaller studies were genotyped at two institutions. The EAGLE samples 
and part of the PLCO samples were genotyped at the Center for Inherited Disease Research 
(CIDR). The ATBC, CSP-II, and part of the PLCO samples were genotyped at the Core 
Genotyping Facility (GCF) at the NCI. Table 2.1 shows the characteristics of these samples and 
their study origin.  
 
 
Table 2.1. Summary of data used from GWAS for lung cancer. 
Study Cases  Controls Population Illumina HumanHap platform 
EAGLE* 1917 1978 European ancestry 550K, 610QUAD 
ATBC** 1732 1270 European ancestry 550K, 610QUAD 
PLCO*/** 1355 1896 European ancestry 317K, 240S, 550K, 610QUAD  
CSP-II** 695 674 European ancestry 550K, 610QUAD, 1M 
Total 5699  5818     
Number of cases for the three subtypes: lung adenocarcinoma (LUAD) = 1730, lung   
squamous cell carcinoma (LUSC) = 1400, small cell lung cancer (SCLC) = 678.  
* Genotyped at the Center for Inherited Disease Research (CIDR). 
** Genotyped at the Core Genotyping Facility (GCF). 
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Figures 2.2-2.4 are Manhattan plots for each lung cancer subtype. These plots illustrate the 
significance and location of variants we used for our analysis. This stratified GWAS by subtype 
confirmed previous lung cancer associations at the 15q25 locus (53, 54) for each subtype. Table 
2.2 shows the total number of cases genotyped for each subtype, the total number of SNPs 
discovered by selection criterion (p < 10-3), and distribution of their locations within the genome. 
Interestingly, only 10 SNPs (<1%) overlapped all three subtypes (Figure 2.5A). We found that, 
similar to many GWA studies for various disease types, only 2-3% of variants were located within 
coding regions of the genome.  
 
 
Table 2.2: Summary of SNP results from lung cancer GWAS. 
Subtype Sample size 
 SNPs (p < 1x10
-3
) 
Total SNPs Coding Intron UTR Intergenic 
LUAD 1730 544 13 228 7 296 
LUSC 1400 598 18 299 16 265 
SCLC 678 558 14 247 10 287 
LUAD: lung adenocarcinoma. LUSC: lung squamous cell carcinoma. SCLC: small cell lung 
cancer. 
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Figure 2.2. Manhattan plot of GWAS results for LUAD. Red line represents genome-wide significance for GWAS (p < 5 x 10-8). Blue 
line represents significance level of the SNPs (p < 1 x 10-3) used in this study. 
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Figure 2.3. Manhattan plot of GWAS results for LUSC. Red line represents genome-wide significance for a GWAS (p < 5 x 10-8). Blue 
line represents significance level of the SNPs (p < 1 x 10-3) used in this study. 
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Figure 2.4. Manhattan plot of GWAS results for SCLC. Red line represents genome-wide significance for a GWAS (p < 5 x 10-8). 
Blue line represents significance of the SNPs (p < 1 x 10-3) used in this study. 
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We generated a set of SNPs in LD with these genotyped SNPs for each subtype (see 
Methods), and summarize the LD expansion in Table 2.3. After we removed duplicated SNPs 
within each subtype, we found 8295 SNPs associated with LUAD, 8734 with LUSC, and 8361 
with SCLC (Figure 2.5B). As illustrated in Figure 2.5C, we found very little correlation (Pearson 
Correlation Coefficient (PCC) < 0.03) between the p-values of the subtypes.  
 
 Table 2.3. Sample results and LD expansion. 
 LUAD LUSC SCLC 
SNPs (GWAS, p < 10-3) 544 598 558 
SNPs (LD, r2 > 0.8, within 1Mb) 14312 16021 13104 
duplicated SNPs 6561 7885 5301 
Final SNPs 8295 8734 8361 
The details of SNP data processes are provided in main text. LD: linkage disequilibrium. 
LUAD: lung adenocarcinoma. LUSC: lung squamous cell carcinoma. SCLC: small cell lung 
cancer. 
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Figure 2.5. Comparison of SNPs from GWAS for lung cancer. Venn diagrams show overlap of 
SNPs found in GWAS (p < 10-3) for lung cancer by subtype (A) and after LD expansion (B). (C) 
Plots show the top 100 variants for each subtype plotted against each subtype. All evidence shows 
very little overlap or correlation between GWAS significant SNPs per subtype.  
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Lung tissue eQTLs 
We first utilized three sets of lung eQTLs to annotate the SNPs. The first lung eQTL dataset 
was retrieved from the Genotype-Tissue Expression (GTEx) project (67). Using this dataset, we 
found 1,297 SNPs for LUAD, 1,429 for LUSC, and 1,171 for SCLC (Figure 2.6A) that acted as 
eQTLs using a set of pre-compiled significant lung tissue-specific eQTLs in GTEx. To explore all 
eQTLs for lung, including non-tissue-specific eQTLs, we used a second set of eQTLs identified 
using a multi-tissue model from GTEx. These eQTL results were generated using a statistical 
model different from the single tissue eQTLs (see Methods). We gauged significance based upon 
the distribution of multi-tissue eQTLs in each subtype (Figure 2.7). We combined the single and 
multi-tissue eQTLs represented by the SNPs to form the final set of GTEx eQTLs. Many of these 
eQTL SNPs were within strong LD of each other and controlled the expression of the same target 
gene, so we collapsed all eQTLs to the specific genes they control. As illustrated in Figure 2.6B, 
we found a total of 71 genes for LUAD, 108 for LUSC, and 67 for SCLC. Three genes overlapped 
from one unique signal in all three subtypes (CHRNA5, PSMA4, and RP11-650L12.2). CHRNA5 
is in the nicotinic acetylcholine region that has well-known associations with lung cancer (53, 54, 
116), while PSMA4 has also been reported to be associated with lung cancer (117). 
We examined a third set of lung tissue eQTLs generated from a meta-analysis that used 
lung tissue samples from three different recruitment sites (not including GTEx data) (110). We 
refer to this set of eQTLs as the Hao et al. eQTLs. We found 25 SNPs for LUAD, 34 for LUSC, 
and 16 for SCLC that acted as eQTLs (Figure 2.6C). We reduced the number of eQTLs to unique 
target genes (see Methods) and found no genes that overlapped all three subtypes, no genes that 
overlapped LUAD and SCLC, two genes that overlapped LUSC and SCLC in one genomic region 
(MYL4 and RPRML), and one gene (IREB2) that overlapped the two NSCLC subtypes (Figure 
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2.6D). IREB2 has previous associations with both chronic obstructive pulmonary disease (COPD) 
and lung cancer, but recent work suggests that IREB2 has a stronger association for lung cancer 
than COPD (118). 
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Figure 2.6. Lung tissue eQTLs in three lung cancer subtypes. (A) Total number of significant 
eQTLs found in each lung cancer subtype using lung tissue specific data (q-value ≤ 5%) and multi-
tissue data (posterior probability > 0.8) from GTEx. (B) Venn diagram shows the overlap of genes 
discovered from the GTEx eQTLs. For each lung cancer subtype, we obtained the final gene set 
by collapsing all SNPs from (A) into genes. (C) Total number of eQTLs (false discovery rate, FDR 
< 10%) found in the lung tissue specific dataset from Hao et al. (110). (D) Venn diagram shows 
the overlap of genes based on Hao et al. eQTLs. Duplicate genes were removed from (C) for this 
comparison. 
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Figure 2.7. Determination of significance for GTEx multi-tissue eQTLs. Posterior probabilities in lung tissue for all multi-tissue eQTLs 
are plotted for each subtype. The posterior probabilities of the eQTLs for each subtype, LUAD (A), LUSC (B) and SCLC (C), resemble 
a bimodal distribution. We chose a significance threshold to capture the second distribution of values. Red line indicates the cutoff used 
of a posterior probability of 0.8. 
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Finding transcribed enhancers and their target genes 
We next examined SNPs located within enhancer regions of the genome that had associated 
target genes. We used data from The Functional ANnoTation Of the Mammalian genome 
(FANTOM) (73) collaborative project that identified transcribed enhancer regions of the genome 
known as “eRNAs” using the Cap Analysis of Gene Expression (CAGE) method (74). We used 
this permissive set of enhancers and their corresponding transcribed target genes from the 
Promoter Enhancer Slider Selector Tool (PrESSTo) website (73, 119). We found the number of 
genes that were targeted by the enhancers were 45 for LUAD, 104 for LUSC, and 43 for SCLC 
(Figure 2.8A). We removed duplicated genes in each subtype and found no overlap for these 
enhancer target genes among all three subtypes (Figure 2.8B). We also observed no overlap among 
LUAD and SCLC or SCLC and LUSC. However, we did find five target genes from two genomic 
loci that overlapped LUAD and LUSC (EPB49, LGI3, LPCAT1, NPM2 and PHYHIP). 
 
Finding epigenetically defined enhancers and their predicted target genes 
To find SNPs located within epigenetically defined enhancers, we used a dataset that 
defined enhancers using histone modifications such as H3K4me1 (120) and H3K27ac (121). 
Specifically, we used the results from a newly developed software tool, Integrated Methods for 
Predicting Enhancer Targets (IM-PET), that uses specific histone marks to identify enhancers and 
other data types to predict their targets using a sophisticated random forest classifier (72). We 
found more than 100 enhancer targets in all subtypes across two lung related cell lines (IMR90 
and NHLF) (Figure 2.8C). These enhancer targets are reported as mRNA transcripts. Therefore, 
to perform a comparison similar to the previous datasets, we collapsed all transcripts into single 
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genes (see Methods). We merged the genes found across both cell lines and removed the duplicated 
genes within subtypes. There were only two genes from one unique signal that overlapped all 
subtypes (ID3HA and TBC1D2B) (Figure 2.8D). IDH3A is an enzyme in the metabolic 
tricarboxylic acid (TCA) cycle that is frequently altered in cancer cells (122). 
 
Figure 2.8. Comparison of the SNPs located within the enhancer regions and their target genes 
among three lung cancer subtypes. (A) Total number of enhancer target genes identified by 
FANTOM5. (B) Venn diagram shows the overlap of FANTOM5 enhancer target genes by subtype. 
(C) Total number of enhancer target transcripts identified by IM-PET for two lung-related cell 
lines. (D) Venn diagram shows the overlap of the lung cancer predicted enhancer target genes for 
IMR90 and NHLF identified by IM-PET. 
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Final set of germline-regulated genes and comparison to the original study 
We collected all of the genes identified by all of the above methods, removed duplicated 
genes within subtypes, and refer to this final collection of genes as germline-regulated genes. There 
were only five genes shared by all of the subtypes: CHRNA5, IDH3A, PSMA4, RP11-650L12.2, 
and TBC1D2B (Figure 2.9A). Although we found five unique genes, these genes are all located 
together in one unique genomic region on 15q25 and probably represent only one unique signal. 
We also compared the genes found across all of the different methods per subtype. Surprisingly, 
we observed very little overlap between the different methods across all lung cancer subtypes 
(Figure 2.10). 
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Figure 2.9. Comparison of the germline genes and their enriched biological pathways by subtype. 
(A) Venn diagram shows the overlap of germline-regulated genes identified in the present study 
for the three lung cancer subtypes. (B) Venn diagram shows the overlap of the germline-regulated 
genes from (A) represented as unique genomic loci. (C) Venn diagram shows the overlap of KEGG 
pathways enriched with the germline-regulated genes. 
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Figure 2.10. Comparison of the final germline-regulated genes discovered in each subtype 
separated by the different data sources. Venn diagrams show the overlap between genes found 
from each data source for (A) lung adenocarcinoma (LUAD), (B) lung squamous cell carcinoma 
(LUSC), and (C) small cell lung cancer (SCLC). 
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A common approach used to report genes that may be associated with SNPs found from 
GWA studies is to report genes that are the closest in proximity up-stream or down-stream of the 
genotyped SNP. Therefore, we next verified that our approach to identifying target genes from 
GWAS SNPs identified a different set of genes than the genes reported using the “closest gene” 
approach in the original Landi et al. study (96). To perform this comparison, we ran the same 
pipeline described above, and used the same set of SNPs reported in Landi’s original paper’s (96) 
supplemental tables with a defined significance p < 1 x 10-4. We found that only ~25% of the 
germline-regulated genes that we found using our approach were reported in the original GWAS 
publication (Figure 2.11A). 
We further applied our approach to analyze the data from the GWAS Catalog and obtained 
a set of SNPs for matched European population type from the GWAS Catalog (52) using the search 
term “lung cancer” (see Methods). After removing the SNPs from the original study, we identified 
17 SNPs to run through our pipeline. We ran the SNPs through the pipeline and identified six 
germline-regulated genes from the GWAS Catalog SNPs: CHRNA5, CLPTM1L, PSMA4, RP11-
650L12.2, TP63 and ZSCAN29. Three of these genes, CHRNA5, PSMA4, and RP11-650L12.2 are 
located in the 15q25 locus, while the other three genes are in three independent genomic locations. 
We examined the overlap between these genes and our defined germline-regulated genes by lung 
cancer subtype. There was a strong overlap (67%) between the genes in at least one subtype from 
our analysis and the target genes associated with lung cancer from the GWAS Catalog (Figure 
2.11B).  
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Figure 2.11. Comparison of germline-regulated genes to original study by Landi et al. and the 
GWAS Catalog. In panel A, we show the proportion of germline-regulated genes we discovered 
that were reported in the original GWAS publication by Landi et al. (96). The genes originally 
reported were discovered at significance level p < 1 x 10-4 and were based upon their physical 
location to the significant SNPs. The numbers above the bars are the total number of germline-
regulated genes found in this study that were originally reported. The majority of germline-
regulated genes discovered in this chapter were initially missed in the original report because the 
authors reported them based only upon physical location. Panel B shows the overlap of germline-
regulated genes found using SNPs from the GWAS Catalog with the three lung cancer subtypes. 
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Pathway enrichment analysis of germline-regulated genes  
 To gain a deeper understanding of the biology driven by these germline-regulated genes, 
we performed biological pathway enrichment analysis of the genes in each subtype. We used the 
web-based tool, WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) (114, 123), to identify 
significantly enriched pathways with the set of germline-regulated genes for each subtype using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (124). We list the full 
sets of pathways enriched in each subtype for the KEGG pathways in Tables 2.4-2.6. We found 
that all three subtypes had genes enriched in the Metabolic pathways and Proteasome pathways 
(Figure 2.9B). We note that many of the pathways found for LUSC represent only one genomic 
locus (HLA region, chromosome 6p21) that contains the same sets of genes (Table 2.5).
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Table 2.4. KEGG pathway enrichment results of germline-regulated genes for LUAD.  
KEGG 
pathway name 
# enriched genes 
in pathway 
Gene symbols Unique genomic 
regions 
# genes 
in pathway Raw p 
BH 
Adjusted p 
Metabolic pathways 17 
HIBADH, NT5C2, 
PIGN, GAPDH, 
AMT, IDH3A, 
IMPDH2, MDH2, 
ACOX1, QARS, 
POLR3D, UGCG, 
UGT2B4, LPCAT1, 
COX4I2, GGPS1, 
CD38 
 
 
 
 
 
 
 
 
 
15 1130 1.49E-05 0.0006 
Tight junction 4 
MYH9, MYH4, 
CLDN23, LLGL2 
 
4 132 0.003 0.024 
Viral myocarditis 3 
MYH9, MYH4, 
CAV1 
 
3 70 0.0039 0.024 
Endocytosis 5 
NEDD4L, CAV1, 
ASAP1, CAV2, 
CHMP6 
 
 
4 201 0.0022 0.024 
Bacterial invasion  
of epithelial cells 3 
CAV1, SHC4, CAV2  
2 70 0.0039 0.024 
Insulin signaling pathway 4 
TSC1, SHC4, 
FOXO1, PRKAR1A 
 
4 138 0.0035 0.024 
Nicotinate and  
nicotinamide metabolism 2 
NT5C2, CD38  
2 24 0.0052 0.0275 
Apoptosis 3 
ENDOD1, BCL2L1, 
PRKAR1A 
 
3 87 0.0071 0.0328 
Citrate cycle (TCA cycle) 2 IDH3A, MDH2 2 30 0.008 0.0329 
Focal adhesion 4 
LAMB2, CAV1, 
SHC4, CAV2 
 
3 200 0.0127 0.047 
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Proteasome 2 PSMA4, PSMD14 2 44 0.0167 0.0492 
Lysosome 3 
GGA3, GGA1, 
CTSH 
 
3 121 0.0173 0.0492 
Aldosterone-regulated  
sodium reabsorption 2 
NEDD4L, SFN  
2 42 0.0153 0.0492 
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Table 2.5. KEGG pathway enrichment results of germline-regulated genes for LUSC. 
KEGG pathway name 
# enriched 
genes 
in pathway 
Gene symbols Unique 
genomic 
regions 
# genes in 
pathway Raw p 
BH 
Adjusted p 
Staphylococcus aureus 
infection 15 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, C4A, 
HLA-DMB, C5, CFB, 
HLA-DOA, HLA-
DOB, HLA-DPB1, 
HLA-DRB5 
 
 
 
 
 
 
 
 
 
2 55 1.44E-20 1.15E-18 
Asthma 12 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, HLA-DOA, 
HLA-DOB, HLA-
DRB5, HLA-DPB1 
 
 
 
 
 
 
 
 
1 30 4.65E-19 1.86E-17 
Type I diabetes mellitus 13 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, HLA-DOA, 
HSPD1, HLA-DOB, 
HLA-DRB5, HLA-
DPB1 
 
 
 
 
 
 
 
 
 
2 43 1.17E-18 3.12E-17 
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Antigen processing and 
presentation 15 
HLA-DRB1, HLA-
DRA, HSPA1L, HLA-
DMA, HLA-DPA1, 
HLA-DQA2, HLA-
DQA1, HLA-DQB1, 
HLA-DMB, TAP1, 
TAP2, HLA-DOA, 
HLA-DOB, HLA-
DPB1, HLA-DRB5 
 
 
 
 
 
 
 
 
 
 
1 76 3.04E-18 6.08E-17 
Allograft rejection 12 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, HLA-DOA, 
HLA-DOB, HLA-
DRB5, HLA-DPB1 
 
 
 
 
 
 
 
 
1 37 9.56E-18 1.53E-16 
Graft-versus-host disease 12 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, HLA-DOA, 
HLA-DOB, HLA-
DRB5, HLA-DPB1 
 
 
 
 
 
 
 
 
1 41 3.98E-17 5.31E-16 
Intestinal immune network for 
IgA production 12 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
 
 
 
1 48 3.37E-16 3.85E-15 
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HLA-DQB1, HLA-
DMB, HLA-DOA, 
HLA-DOB, HLA-
DRB5, HLA-DPB1 
 
 
 
 
 
Autoimmune thyroid disease 12 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, HLA-DOA, 
HLA-DOB, HLA-
DRB5, HLA-DPB1 
 
 
 
 
 
 
 
 
1 52 9.75E-16 9.75E-15 
Viral myocarditis 13 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, EIF4G3, HLA-
DOA, HLA-DOB, 
HLA-DRB5, HLA-
DPB1 
 
 
 
 
 
 
 
 
 
2 70 1.29E-15 1.15E-14 
Leishmaniasis 13 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, 
NFKBIA, HLA-DMB, 
HLA-DOA, HLA-
 
 
 
 
 
 
 
2 72 1.91E-15 1.53E-14 
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DOB, HLA-DRB5, 
HLA-DPB1 
Rheumatoid arthritis 13 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, 
ATP6V1G2, HLA-
DMB, HLA-DOA, 
HLA-DOB, HLA-
DRB5, HLA-DPB1 
 
 
 
 
 
 
 
 
 
1 91 4.61E-14 3.35E-13 
Phagosome 15 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, 
ATP6V1G2, HLA-
DMB, TAP1, TAP2, 
HLA-DOA, HLA-
DOB, HLA-DPB1, 
HLA-DRB5 
 
 
 
 
 
 
 
 
 
 
1 153 1.50E-13 1.00E-12 
Toxoplasmosis 14 
HLA-DRB1, HLA-
DRA, HSPA1L, HLA-
DMA, HLA-DPA1, 
HLA-DQA2, HLA-
DQA1, HLA-DQB1, 
NFKBIA, HLA-DMB, 
HLA-DOA, HLA-
DOB, HLA-DRB5, 
HLA-DPB1 
 
 
 
 
 
 
 
 
2 
132 3.30E-13 2.03E-12 
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Systemic lupus erythematosus 14 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, C4A, 
HLA-DMB, C5, HLA-
DOA, HLA-DOB, 
HLA-DPB1, HLA-
DRB5 
 
 
 
 
 
 
 
 
 
2 136 5.00E-13 2.86E-12 
Cell adhesion molecules 
(CAMs) 13 
HLA-DRB1, HLA-
DRA, HLA-DMA, 
HLA-DPA1, HLA-
DQA2, HLA-DQA1, 
HLA-DQB1, HLA-
DMB, HLA-DOA, 
ALCAM, HLA-DOB, 
HLA-DRB5, HLA-
DPB1 
 
 
 
 
 
 
 
 
 
2 133 6.70E-12 3.57E-11 
Spliceosome 6 
HSPA1L, PPIL1, 
RBM25, ZMAT2, 
SF3A1, DDX39B 
 
 
5 127 0.0002 0.0009 
Metabolic pathways 19 
PPT2, EARS2, 
ALDH6A1, GNPDA1, 
IDH3A, UQCR10, 
PMM2, GAL3ST1, 
LCLAT1, PON1, 
SDHA, NT5C2, 
PON2, POLR3D, 
NDUFA2, PON3, 
 
 
 
 
 
 
 
14 
1130 0.0002 0.0009 
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ATP6V1G2, LPCAT1, 
CYP17A1 
Wnt signaling pathway 6 
TCF7, CSNK2B, 
NFATC3, PSEN1, 
BTRC, DAAM2 
 
 
6 150 0.0005 0.0022 
Aminoacyl-tRNA biosynthesis 4 
HARS2, VARS2, 
EARS2, HARS 
 
3 63 0.0008 0.0034 
Huntington's disease 6 
GNAQ, DNAL1, 
NDUFA2, SDHA, 
UQCR10, TBPL1 
 
 
6 183 0.0015 0.006 
Proteasome 3 
PSMB8, PSMB9, 
PSMA4 
 
2 44 0.0032 0.0122 
Jak-STAT signaling pathway 5 
LIF, SPRED1, PIM1, 
CBLB, OSM 
 
4 155 0.0039 0.0142 
Alzheimer's disease 5 
GNAQ, NDUFA2, 
PSEN1, SDHA, 
UQCR10 
 
 
5 167 0.0054 0.0188 
Pathways in cancer 7 
TCF7, FGF17, 
SUFU, NFKB2, 
NFKBIA, E2F3, 
CBLB 
 
 
6 
326 0.0065 0.0217 
NOD-like receptor signaling 
pathway 3 
CARD8, NFKBIA, 
NLRC4 
 
3 58 0.0069 0.0221 
Shigellosis 3 
DIAPH1, BTRC, 
NFKBIA 
 
3 61 0.0079 0.0243 
Biosynthesis of unsaturated 
fatty acids 2 
ACOT2, ACOT1  
1 21 0.0085 0.0252 
RNA degradation 3 
SKIV2L, HSPD1, 
PATL1 
 
3 71 0.0119 0.0317 
Complement and coagulation 
cascades 3 
C5, CFB, C4A  
2 69 0.0111 0.0317 
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Oxidative phosphorylation 4 
NDUFA2, 
ATP6V1G2, SDHA, 
UQCR10 
 
 
4 132 0.0119 0.0317 
Chronic myeloid leukemia 3 
NFKBIA, E2F3, 
CBLB 
 
3 73 0.0129 0.0333 
Collecting duct acid secretion 2 
SLC12A7, 
ATP6V1G2 
 
2 27 0.0139 0.0347 
Citrate cycle (TCA cycle) 2 IDH3A, SDHA 2 30 0.017 0.0412 
Hematopoietic cell lineage 3 
HLA-DRB1, HLA-
DRA, HLA-DRB5 
 
1 88 0.0211 0.0496 
Prostate cancer 3 
TCF7, NFKBIA, 
E2F3 
 
3 89 0.0218 0.0498 
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Table 2.6. KEGG pathway enrichment results of germline-regulated genes for SCLC. 
KEGG 
pathway name 
# enriched genes 
in pathway Gene symbols 
Unique genomic 
regions 
# genes 
in pathway Raw p BH adjusted p 
Metabolic pathways 13 
MGAT3, EPRS, REV3L, 
DHRS4L2, PLA2G7, 
DPM1, GNPDA1, 
IDH3A, AMD1, 
OXSM, BPNT1, 
ATP6V1E1, DHRS4 10 1130 0.0002 0.003 
Retinol metabolism 3 
DHRS4L2, DHRS4, 
CYP26A1 2 64 0.0015 0.0112 
Focal adhesion 4 
ACTN4, TNN, 
ILK, PAK4 3 200 0.0055 0.0275 
Proteasome 2 PSMD8, PSMA4 2 44 0.0105 0.0387 
N-Glycan biosynthesis 2 MGAT3, DPM1 2 49 0.0129 0.0387 
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Discussion 
 
Understanding the regulatory roles that common genetic variants play in the development 
of many disease types, including lung cancer, is an important research question because the 
majority of common variants that increase risk for a diverse set of diseases are located within non-
coding regions and most likely act as regulators of gene expression. These results can also be used 
to interrogate the differences between different subtypes of cancer. To address these questions, we 
performed a detailed analysis of common genetic variants (SNPs) associated with three subtypes 
of lung cancer (LUAD, LUSC, and SCLC).  
We used marginally significant GWAS results (p < 1 x 10-3) to search for regulatory roles 
for common variants associated with LUAD, LUSC, and SCLC. We expanded this set of results 
to include all SNPs in LD with the genotyped SNPs using data from the 1000 Genomes Phase III 
project. This expansion resulted in ~15,000 more SNPs to test per subtype that may be acting as 
the actual causal variant (63). We used a diverse set of regulatory data to identify SNPs that were 
within regulatory regions of the genome that had an identified target gene. It is important to use 
data that contain the target genes for regulatory SNPs, because most regulatory looping 
interactions influence distant genes rather than the closest gene(s) (125). We first examined lung 
tissue eQTL data from the GTEx project and the Hao et al. study. Interestingly, our results 
indicated there was little overlap in the eQTL genes identified from these separate datasets. This 
is not surprising because they were analyzed using different methods and with different sample 
sizes, but a more thorough examination into the details of this small overlap would be interesting. 
Although the methods differ, they are from the same tissue and a detailed analysis of the 
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differences may reveal further insight into the heterogeneity of whole tissue eQTL analyses. This 
issue is rarely discussed in the literature, but is important for phenotypes where the specific type 
of cell within the mix of cells in the entire tissue directly affects disease. Through the search of the 
FANTOM5 set of permissive enhancers and their target genes, we observed that several SNPs 
from each subtype were within enhancer regions of the genome. This finding may be important 
because recently one SNP (rs6983267) within a gene desert at 8q24, which harbors many SNPs 
associated with several cancers, was found to disrupt an enhancer region that controls expression 
of the oncogene MYC, an important gene involved in many cellular growth pathways. Also, MYC 
is tightly regulated due to its essential role in cell proliferation where it is implicated in the genesis 
of many cancer types (126). This regulatory mechanism highlights the importance of enhancers in 
the maintenance of cell division and growth (75). For our final data source, we used IM-PET, a 
machine classifier method that has high predictive power to detect the target genes of enhancers 
(72). Specifically, we used the results from two lung related cell lines, NHLF and IMR90. We 
found the largest number of regulatory target genes for all three subtypes using the combined 
results from both cell lines for IM-PET (LUAD = 115, LUSC = 161 and SCLC = 82). Overall, our 
results indicated very small overlap between all three subtypes at the SNP, gene, pathway, and 
regulatory levels. Of note, we found similar lack of overlap between all subtypes when we used 
SNPs with p < 1 x 10-4 (Appendix B). Importantly, the weak overlap we observed at the gene level 
between all subtypes was from five separate genes, but was only representative of one genomic 
region. Therefore, there is likely only one independent region on 15q25 that overlaps all three 
subtypes of lung cancer and is likely driven by the lead peak in the GWAS Manhattan plot. 
It is worth highlighting that three (CHRNA5, IDH3A, and PSMA4) out these five genes 
shared in all three subtypes of lung cancer have been previously reported to be associated with 
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lung cancer. CHRNA5 has strong implications in its association with lung cancer (53, 54, 116). 
CHRNA5 encodes a nicotinic acetylcholine receptor (nAChR). nAChRs are a class of ligand-gated 
ion channels that are activated by the neurotransmitter acetylcholine to allow the flow of ions 
across the cell membrane (127). There is still an ongoing debate about CHRNA5’s role in lung 
cancer risk versus its risk for lung cancer through nicotine addiction (128), but finding this gene 
in all three subtypes of lung cancer that have biological and environmental differences suggests it 
may be playing a direct role in lung cancer risk. IDH3A encodes an isocitrate dehydrogenase 
(IDH). IDHs are important enzymes in the regulation of the TCA cycle (129). Recently, IDH3A 
was shown to promote tumor growth by activating hypoxia-inducible factor 1 (HIF-1) alpha and 
promoting the stability of HIF-1 to participate in angiogenesis and was also associated with poor 
survival in lung cancer (130). Additionally, IDH3A acts in the conversion of metabolism that 
occurs with cancer fibroblasts (131). PSMA4 encodes a subunit of the proteasome. Experimental 
studies have shown that PSMA4 mRNA is increased in lung tumor versus normal samples and also 
plays a major role in cell proliferation using data from lung carcinoma cell lines (132). Another 
gene, RP11-650L12.2, has not been characterized. It warrants future experimental studies due to 
its association with all three subtypes of lung cancer. The final gene shared by all subtypes, 
TBC1D2B, is a protein coding gene that may have GTPase activity and may play a role in 
autophagy (133). 
In addition to the five overlapping genes above, our pathway enrichment analysis revealed 
two biological pathways shared by the three subtypes. Among them, all three subtypes shared 
Metabolic pathways. Metabolic pathways are frequently modified in cancer to provide the over 
proliferating cells with required nutrients (134). We also observed that the oxidative 
phosphorylation pathway was significantly enriched in LUSC (adj. p < 0.05). It is interesting to 
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find this pathway dysregulated in the germline genome, because it has strong associations in the 
transition from oxidative phosphorylation to the less efficient aerobic glycolysis, known as the 
Warburg effect, that takes place in cancer cell proliferation (135). Although the Warburg effect 
may be attributable to glycolysis inhibiting a still active oxidative phosphorylation pathway, this 
result still suggests that commonly occurring variants in LUSC may lead to some disruption in the 
oxidative phosphorylation pathway that makes this process easier to arrest or inhibit and enhance 
cell proliferation after some somatic disruption in lung tissue. We also found several cancer related 
pathways in LUSC such as Pathways in cancer, Prostate cancer and many signaling pathways 
associated with cancer. We discovered that the focal adhesion (adj. p < 0.01) pathway was 
significantly enriched with genes from SCLC. This is an intriguing finding because genes in this 
pathway are involved in the epithelial-mesenchymal transition (EMT), which is important in 
cancer metastasis (136). Although this pathway is also found in LUAD (adj. p = 0.047), it is more 
significant in SCLC (adj. p = 0.028) and may help explain the much higher rate of metastases seen 
in SCLC compared to NSCLC (137). In summary, this pathway-based evidence suggests both 
shared subtype and unique subtype associations. 
To ensure that our approach to identify target genes from GWAS SNPs was not just 
identifying genes found in the original study, or reporting the closest gene to each SNP, we ran the 
SNPs found in Landi’s original paper’s supplemental tables through our pipeline. These SNPs 
were reported at a more stringent threshold (p < 1 x 10-4) than we used in our analysis (p < 1 x 10-
3). We compared the germline-regulated genes identified using these SNPs to the genes reported 
in the original study. We found little overlap, ~25%, suggesting the reported genes (closest to the 
SNPs) may not be the correct target genes. We also looked at this overlap using the set of germline-
regulated genes that we discovered with our pipeline using SNPs at p < 1 x 10-4 and observed 
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overlap of ~15%. These findings agree with the studies that have reported that the gene closest to 
a non-coding variant is oftentimes not the target gene (125, 138). One well-known example is the 
FTO locus and obesity. A recent study (64) discovered that a SNP within an intron in FTO was 
not controlling the expression levels of the gene FTO, but instead the more distant gene IRX3. We 
observed similar findings when we investigated lung cancer genes reported from the GWAS 
Catalog. We compared the reported genes for lung cancer from the GWAS Catalog to our 
germline-regulated genes and found only CHRNA5 and PSMA4 overlapped all subtypes. In total, 
out of ~50 reported genes in the Catalog, we observed overlap of two, six, and three genes for 
LUAD, LUSC, and SCLC, respectively. To determine if this weak overlap occurred because the 
Catalog links SNPs to the closest gene, we ran the SNPs from the GWAS Catalog through our 
pipeline. The results showed a strong overlap (67%) between the germline-regulated genes 
obtained using the GWAS Catalog SNPs and our set of germline-regulated genes in any subtype. 
This finding suggests that the target gene of a non-coding regulatory SNP may not be the closest 
gene. 
In addition to the analysis reported in this chapter for SNPs (p < 1 x 10-3), we also 
performed the same analysis using a more stringent p < 1 x 10-4. Our results from that analysis 
agreed with our discoveries in this chapter that indicated very small overlap between the lung 
cancer subtypes. At p < 1 x 10-4, we only observed three genes (CHRNA5, IDH3A, and RP11-
650L12.2) that overlapped between all subtypes in comparison to five genes (CHRNA5, IDH3A, 
PSMA4, RP11-650L12.2, and TBC1D2B) that overlapped at p < 1 x 10-3. Both sets of genes are 
located within the same single genomic locus. 
There are several limitations to this study. First, we utilized a set of marginally significant 
SNPs. Although previous studies (139, 140) have shown it is a practical approach, this may have 
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resulted in some false positive SNPs in our study. Second, we did not impute the GWAS data to 
obtain a larger set of SNPs for the analysis. This would have resulted in more SNPs that could 
have been tested for significance. We will integrate such SNPs in future analyses. Third, for 
validation of our results, we were limited to a small set of SNPs reported in the GWAS Catalog 
because we only focused on SNPs specifically found in one population. Though we saw a strong 
overlap (67%), it would have been better to include a larger set of SNPs for better power of 
confirming the validity of our pipeline. Whether similar patterns are in other populations remains 
for further investigation when such data becomes available. Another limitation of our study is that 
we may have discovered several different genes that may represent only one unique signal because 
we used SNPs in LD for our analysis. For example, if we found five genes that were shared by all 
subtypes, but these genes were clustered in one genomic location, it may represent a single unique 
signal. To account for this potential bias, we separated the gene sets into unique signals to give a 
better idea of the true overlap of subtypes while still including all discovered germline-regulated 
genes. 
In summary, we used common genetic variants found in three lung cancer subtypes to 
interrogate the similarity between them at four biological levels. We found that there is very little 
overlap between the three subtypes at the SNP, gene, regulatory and pathway levels. At the most 
basic level (SNPs), we observed less than a 1% overlap between the subtypes. Similarly, we found 
only five genes (< 1%) (all five from one unique genomic locus) overlap that were discovered in 
all three subtypes, but three of the five (CHRNA5, IDH3A, and PSMA4) are well-known lung 
cancer genes. We observed the same trend at the pathway level and found only two KEGG 
pathways (~4%) overlapped all three subtypes. At the regulatory level, we found many differences 
in how the genetic variants in non-coding regions control their target genes. Not much work has 
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been done comparing all three subtypes at the somatic level, but recent work interrogating the 
differences between LUAD and LUSC concluded similar findings of little overlap between these 
two subtypes at the molecular level in somatic lung tumor tissue (92). Overall, this study provides 
some important insight into the genetic architecture of three subtypes of lung cancer. 
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CHAPTER III 
 
EXPLORATION OF SOMATIC MUTATION AND GENE EXPRESSION 
FEATURES IN THREE LUNG CANCER SUBTYPES  
 
Introduction 
 
 The interrogation of genetic variants detected in the germline genome of lung cancer 
subjects through approaches such as GWA studies may reveal risks associated with this disease. 
However, many agents used in lung cancer therapies target somatic alterations in tumor tissue. For 
example, treatments such as erlotinib (141) and gefitinib (142) target actionable somatic mutations 
in EGFR in NSCLC. These molecularly targeted therapies have better success rates than the 
traditional non-targeted platinum-based chemotherapy (143, 144). Additionally, many new driver 
genes have been discovered in somatic lung tumor tissue that are effectively targeted by 
pharmaceutical compounds (35). These studies support current efforts to identify genes at the 
somatic level that are critical for lung cancer treatment.  
 The TCGA is one of the largest collaborative consortia with its main goal to uncover the 
landscapes of the genetic alterations at the genome level in major tumor types. TCGA has 
characterized genomic alterations for both LUAD (82) and LUSC (86). In addition to TCGA, 
several other groups have studied mutations in LUAD (76, 80) and LUSC (77, 84). SCLC was not 
studied as part of TCGA, likely due to its unavailability of tumor samples. However, two recent 
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studies (88, 89) investigated this tumor type. Collectively, these two SCLC studies found several 
new driver genes and genomic alterations in SCLC. Importantly, most of the aforementioned 
studies included the investigation of genetic aberrations at both DNA and RNA levels. Studying 
gene expression at the RNA level is important because it can identify over-expressed or under-
expressed genes in tissues that may not be mutated but can still cause disease (70, 145). Combined, 
both data types may reveal a more complete genomic picture of the tumor in each lung cancer 
subtype. 
 Although recent somatic work (92) has compared the two most common NSCLC subtypes, 
LUAD and LUSC, much less is known how these subtypes compare to SCLC. Investigating all 
three subtypes together at the DNA and RNA somatic levels is important because it may lead to 
the discoveries for SCLC treatment options that currently work with NSCLC. This is vital because 
there are currently few treatments for SCLC, which is the most aggressive lung cancer subtype 
(137).  
 In this study, we used somatic data from lung tumor tissue to compare three lung cancer 
subtypes at the DNA and RNA levels. First, we identified a set of differentially expressed genes 
(DEGs) in each subtype and used these gene sets to perform a pathway enrichment analysis. We 
next examined the proportion of the substitution types, transitions and transversions, among the 
somatic non-synonymous mutations. We also generated mutational signatures for each subtype. 
We further used the somatic mutations to identify a set of potential driver genes for each subtype. 
Overall, this work suggests both shared and distinct genes that are altered among three subtypes 
of lung cancer at the somatic level. Deeper interrogation of these genes may give greater insight 
into the biology and potential therapeutic targets of each subtype.  
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Methods 
 
Summary of somatic mutations  
We downloaded the full set of somatic mutations called at the Broad Institute for LUAD 
and LUSC from tumor samples with matched normal controls from the TCGA Web Portal 
(updated link https://gdc-portal.nci.nih.gov/) on September 23, 2015. Rudin et al. (89) performed 
a study that identified genomic features in SCLC. They performed WES, RNA-Seq, and copy 
number analysis (CNA) for multiple SCLC samples. We extracted the full set of somatic mutations 
identified in this study from the publication’s Supplemental Table 3. 
 
Extracting mutational information  
 We used the R package “maftools” (146) version 1.0.40 to extract mutational information. 
We used the “titv” function to generate a list of transitions and transversions in each subtype. We 
generated a matrix of each single nucleotide variant (SNV) and its preceding and proceeding base 
using human genome reference 19 (hg19). We downloaded the hg19 file in 2bit format from 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/hg19.2bit on January 31, 2017. We 
used the TwoBitToFa script, downloaded from 
http://hgdownload.cse.ucsc.edu/admin/exe/linux.x86_64/, to convert the 2bit file to a FASTA file. 
We used the FASTA file for the location of the SNVs and then used non-negative matrix 
factorization (NMF) (147) to generate the mutational signatures in each subtype. We used up to 6 
signatures to search for the top 3 signatures for each subtype separately, based upon the parameters 
set up in the R package. This tool then used cosine similarity (148) to determine the closest 
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matching signature from Catalogue of Somatic Mutations in Cancer (COSMIC) to the top three 
mutational signatures generated from the NMF analysis.  
 
Generating the final set of somatic mutated genes  
We used several filtering steps to define a list of possible driver genes to compare the lung 
cancer subtypes (Figure 3.1). We first filtered our lists to exclude any genes that are not part of the 
Cancer Genome Census (CGC) list from COSMIC since these have evidence of driving tumor 
growth (149). We acknowledge that this approach may miss novel driver genes, but since lung 
cancer is overwhelmed by passenger mutations (150), this approach helps to identify the actual 
driver genes. The current build we used was downloaded on October 10, 2016, and contained 602 
cancer genes. Our primary filter only kept mutations from each cancer type that were within any 
of the 602 cancer genes. We then removed duplicated somatic mutations per gene per sample. For 
example, if one subject had 20 TP53 mutations, we only kept one of the mutations so that we could 
filter by total mutations in more than one subject. We note this may be a limitation, but for our 
purpose we only needed information if a gene had at least one mutation in a subject. We further 
filtered by genes mutated in more than one subject. We made two lists at different thresholds 
defined below that we refer to as “strict” and “lenient.” To find a suitable cutoff for these 
thresholds, we plotted the histograms (Figure 3.2) of the somatic mutations filtered by COSMIC 
per subtype and manually defined the thresholds as follows. The histograms showed one large 
peak to the left of the plot, followed by a trailing set of genes mutated in many samples. For our 
lenient threshold, we chose a cutoff that allowed most of the large bar to be represented, while for 
our strict threshold, we removed all genes from the primary bar on the histogram that represented 
the genes that were mutated in only a small number of samples. However, for SCLC, we relaxed 
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this threshold due to the much smaller set of somatic mutations so we could have a large enough 
set to use for our analysis. After obtaining a set of possible somatic driver genes for each subtype, 
we further filtered the list of genes by their expression levels. Rudin et al. (89) previously filtered 
their somatic mutation gene list using expression levels from RNA-Seq, so we only filtered the 
somatic genes from TCGA for LUAD and LUSC, which had not been previously filtered. We 
removed genes that had read counts < 10 per gene in the RNA-Seq expression data. 
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Figure 3.1. Pipeline to obtain somatic mutated genes for three lung cancer subtypes. SCLC somatic mutations were previously filtered 
by expression levels (89).  
Expressed in tumor: ≥ 10 reads 
Expressed in normal: ≥ 10 reads 
LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, SCLC = small cell lung cancer 
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Figure 3.2. Histogram of somatic mutated genes across multiple samples. We show the distribution of somatic mutated genes across 
multiple samples for LUAD (A), LUSC (B), and SCLC (C). The blue line represents our cutoff for lenient, and the red line represents 
our cutoff for strict. 
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Extracting mRNA-Seq raw count values for LUAD and LUSC 
 Rahman et al. (151) reprocessed all of the RNA Sequencing data that was available in 
TCGA. Briefly, the authors obtained the raw FASTQ formatted RNA-Seq files from the NCI’s 
Cancer Genomics Hub. They also obtained all of the clinical records for the RNA-Seq files. The 
data were run through their pipeline that relied heavily on the Rsubread package (152). In addition 
to raw read counts, the authors also normalized the results using two standards in the field: 
transcripts per million (TPM) (153) and fragments per kilobase of exon per million reads mapped 
(FPKM) (154). The authors made all of the results freely available on the GEO website: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62944. To extract the raw counts files 
for LUAD and LUSC, we downloaded the file GSE62944_RAW.tar that contained several data 
matrices. We unzipped the file and used two data frames for the extraction. For tumor samples, we 
used: GSM1536837_06_01_15_TCGA_24.tumor_Rsubread_FeatureCounts.txt; and for normal 
samples, we used: GSM1697009_06_01_15_TCGA_24.normal_Rsubread_FeatureCounts.txt. 
We also downloaded other files for annotation from the website: 
GSE62944_06_01_15_TCGA_24_CancerType_Samples.txt.gz for the tumor samples and 
GSE62944_06_01_15_TCGA_24_Normal_CancerType_Samples.txt.gz for the normal samples. 
We observed that many sample IDs were duplicated in the tumor sample files. We found this 
resulted from some RNA-Seq data being generated for more than one part of a tumor tissue for 
each sample. To keep one sample ID for our analysis, we removed duplicated RNA-Seq results 
from the same patient by keeping the first mention of a tumor sample and removing additional 
results from the same tumor sample but having a secondary portion or RNA-Seq run. We matched 
the LUAD tumor and normal samples and the LUSC tumor and normal samples with these sample 
names and imported them into DESeq2 (155). 
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Differential expression analysis using DESeq2 
 All tumor and normal RNA-Seq samples above were used for differential expression 
analysis. We imported the raw read counts for all three subtypes into R version 3.2.3 and used the 
R package DESeq2 version 1.10.1 (155) for the analysis. DESeq2 uses raw non-normalized read 
count data for its estimation of differential expression. We first filtered our RNA-Seq data to 
remove low expressed genes (counts ≤ 1). The data were normalized following a negative binomial 
distribution. We then determined differential expression using a generalized linear model (GLM).  
 
Identification of TSGs and oncogenes 
 Zhao et al. (4) catalogued a set of human tumor suppressor genes (TSGs) through a 
comprehensive literature review. We downloaded the set of human TSGs from 
https://bioinfo.uth.edu/TSGene/download.cgi on January 31, 2017. 
 Liu et al. (5) completed an exhaustive literature review to obtain a high-confidence set of 
oncogenes. We downloaded the entire set of human oncogenes from http://ongene.bioinfo-
minzhao.org/download.html on January 31, 2017.  
 
Pathway enrichment analysis 
 We used the online WebGestalt resource (114) to identify pathways enriched with the 
DEGs. We separated our analyses into up-regulated and down-regulated gene sets. We used the 
KEGG pathways (124) for the analysis and filtered out pathways that contained less than five 
genes. 
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Results 
 
RNA-Seq data used for DEG analysis  
 We collected RNA-Seq raw read count tumor and normal samples for LUAD and LUSC 
from reprocessed TCGA data (151). TCGA did not study SCLC, so we obtained tumor and normal 
RNA-Seq raw read counts for SCLC from a previous study (89). We removed duplicated samples 
per subtype to generate our final set of samples. The total number of tumor samples we studied 
included 515, 501, and 54 for LUAD, LUSC, and SCLC, respectively. We had 59, 51, and 25 
matched normal samples for LUAD, LUSC, and SCLC, respectively. The numbers of samples by 
data source are summarized in Table 3.1. 
 
Table 3.1. Summary of RNA-Seq data. 
Subtype # tumor samples # normal samples Data source 
LUAD 515 59 TCGA 
LUSC 501 51 TCGA 
SCLC 54 25 Rudin et al. (89) 
Total 1,070 135  
 
 
 Differentially expressed genes for three lung cancer subtypes 
 We used DESeq2 to generate DEGs for all three subtypes (Figure 3.3). To define 
significant DEGs, we used |log2FC| > 2 and Benjamini-Hochberg (BH) adj. p < 0.05. By first using 
the adjusted p < 0.05, we found a total of 3,710, 5,623, and 3,888 DEGs for LUAD, LUSC, and 
SCLC, respectively. We further filtered the BH adjusted DEGs by log2FC > 2 and detected 1,818, 
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2,377, and 1,470 up-regulated DEGs for LUAD, LUSC, and SCLC, respectively (Figure 3.4A). 
We also generated a set of down-regulated DEGs by requiring log2FC < -2. This revealed 604, 
1,328, and 1,798 DEGs for LUAD, LUSC, and SCLC, respectively (Figure 3.4B). The SCLC 
results were originally reported using Ensembl gene ID’s. In our analysis, we removed 45 Ensembl 
Gene IDs that did not map to Gene Symbols. Accordingly, we found 554 up-regulated genes and 
325 down-regulated genes that were shared by all three subtypes (Figure 3.4C, Figure 3.4D). Our 
results indicated that the number of up-regulated DEGs shared between LUAD and LUSC was 
significantly higher than that between LUSC and SCLC (p = 2.2 x 10-16, binomial test). 
Surprisingly, we observed the opposite trend in overlap for the down-regulated genes. We found 
that more genes were shared between SCLC and LUSC than between LUAD and LUSC (p = 0.01, 
binomial test). To verify that this lack of overlap between all subtypes was not due to a single 
threshold of DEGs, we generated overlap for three separate expression thresholds (log2FC < -1, 
log2FC < -2, log2FC < -3, log2FC > 1, log2FC > 2, and log2FC > 3) and observed the same trend in 
the overlap between subtypes (Figure 3.5).  
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Figure 3.3. MA (log ratio over mean) plots for DEGs. Log fold change is plotted on the y-axis 
versus mean expression on the x-axis. LUAD, LUSC, and SCLC are plotted in A, B, and C, 
respectively. Red colored dots indicate significant DEGs at Benjamini-Hochberg (BH) adj.p < 
0.05. 
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Figure 3.4. DEGs found in three lung cancer subtypes. Panel A shows the total number of DEGs 
up-regulated in lung tumor tissue versus normal controls. Panel B shows the total number of down-
regulated DEGs in lung tumor versus normal controls. Panel C illustrates the overlap between up-
regulated DEGs per subtype. Panel D illustrates the overlap between down-regulated genes per 
subtype. LFC = log2fold change. 
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Figure 3.5. Overlap of DEGs for each subtype at multiple differential expression thresholds. Venn 
diagrams show the overlap in DEGs between subtypes. Panels A-C show up-regulated DEGs and 
D-F show down-regulated DEGs. LFC = log2fold change. 
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Tumor suppressor genes 
 We used the Tumor Suppressor Gene 2.0 (TSGene 2.0) database (156) to investigate the 
sets of down-regulated DEGs. The tumor suppressor genes (TSGs) found in all uniquely down-
regulated genes per subtype and among overlapping gene sets are summarized in Appendix C. We 
calculated the percentage of TSGs per unique subtype and overlap and found that the largest 
percentage of TSGs were in the genes that overlapped SCLC and LUAD (Table 3.2). However, 
there was no significant difference between the sets (p = 0.064, test of proportions). 
 
Table 3.2. Summary of TSGs found in down-regulated DEG sets. 
Gene set # genes in set # TSGs % overlap 
LUAD unique 67 5 7.4 
LUSC unique 393 34 8.7 
SCLC unique 981 93 9.5 
LUAD overlap LUSC 165 9 5.5 
LUAD overlap SCLC 47 8 17.0 
LUSC overlap SCLC 445 50 11.2 
All overlap 325 21 6.5 
 
 
Oncogenes 
 We used the oncogene database ONGene (5) to investigate the up-regulated DEGs found 
in all subtypes (Appendix D). We calculated the percentage of oncogenes found in each subtype 
and the overlapping gene sets. The results are listed in Table 3.3. There was a significant difference 
in the oncogenes found between all sets of genes (p = 2.802 x 10-10, test of proportions). The largest 
percentage of oncogenes were in the overlapping set of DEGs.  
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Table 3.3. Summary of oncogenes found in up-regulated DEG sets. 
Gene set # genes in set # oncogenes % overlap 
LUAD unique 442 8 1.8 
LUSC unique 850 26 3.1 
SCLC unique 575 15 2.6 
LUAD overlap LUSC 727 28 3.9 
LUAD overlap SCLC 95 3 3.2 
LUSC overlap SCLC 246 11 4.5 
All overlap 554 54 9.7 
 
 
Pathway enrichment of DEGs 
 To determine the biological activity driven by these DEGs, we performed biological 
pathway enrichment of the DEGs in each set of genes. We used WebGestalt (123) for the 
enrichment analysis with KEGG (124) as the source of the pathway definitions. Table 3.4 shows 
the 20 pathways that overlapped all three subtypes for the up-regulated genes and the 35 pathways 
for the down-regulated genes. We show the overlap of these pathways for all three subtypes in 
Figure 3.6. 
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Table 3.4. Enriched KEGG pathways from overlapping DEGs. 
KEGG pathways up-regulated DEGs KEGG pathways down-regulated DEGs 
Alanine, aspartate and glutamate metabolism African trypanosomiasis 
Axon guidance* Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 
Calcium signaling pathway* Axon guidance* 
Cell cycle Bile secretion 
ECM-receptor interaction* Calcium signaling pathway* 
Gastric acid secretion Cardiac muscle contraction 
Homologous recombination Cell adhesion molecules (CAMs) 
Long-term potentiation Chemokine signaling pathway 
Maturity onset diabetes of the young Complement and coagulation cascades 
Melanoma Cytokine-cytokine receptor interaction 
Metabolic pathways Dilated cardiomyopathy 
Neuroactive ligand-receptor interaction* Drug metabolism - cytochrome P450 
Nitrogen metabolism ECM-receptor interaction* 
Oocyte meiosis Endocytosis 
p53 signaling pathway Focal adhesion 
Pathways in cancer* Hematopoietic cell lineage 
Progesterone-mediated oocyte maturation Hypertrophic cardiomyopathy (HCM) 
Protein digestion and absorption* Jak-STAT signaling pathway 
Salivary secretion* Leukocyte transendothelial migration 
Systemic lupus erythematosus Long-term depression 
 Malaria 
 MAPK signaling pathway 
 Metabolism of xenobiotics by cytochrome P450 
 Neuroactive ligand-receptor interaction* 
 Pancreatic secretion 
 Pathways in cancer* 
 Phagosome 
 PPAR signaling pathway 
 Protein digestion and absorption* 
 Regulation of actin cytoskeleton 
 Retinol metabolism 
 Salivary secretion* 
 Staphylococcus aureus infection 
 Tight junction 
 Vascular smooth muscle contraction 
* Enriched with both up-regulated and down-regulated genes. 
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Figure 3.6. KEGG pathways that overlap between all three subtypes. Panel A shows the up-
regulated DEGs shared between all three subtypes. Panel B shows the down-regulated genes 
shared by subtype. 
 
Somatic mutations in three lung cancer subtypes 
 We selected all somatic mutations for LUAD and LUSC generated from TCGA. There 
were 234,278 mutations for LUAD and 65,305 for LUSC. SCLC was not studied as part of the 
TCGA, so we obtained a set of somatic mutations for SCLC from the same study that generated 
the RNA-Seq results (89). There were 7,945 somatic mutations for SCLC. For the following 
explorations of the specific somatic mutations per subtype, we removed synonymous SNVs. First, 
we determined the transition (Ti) to transversion (Tv) (Ti/Tv) ratio per subtype. We found that all 
three subtypes shared similar ratios of Ti (~35%) to Tv (~65%) (Figures 3.7A – 3.9A) based upon 
the average values across all samples per subtype. Specifically, the mean percentages of Tv 
mutations were 61.95, 63.87, and 65.20 for LUAD, LUSC, and SCLC, respectively. The mean 
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percentages of Ti mutations were 38.05 for LUAD, 36.13 for LUSC, and 34.80 for SCLC. To 
obtain greater insight behind the mutational profiles of each subtype, we generated their mutational 
signatures. We used non-negative matrix factorization (NMF) to generate the mutational 
signatures for each subtype. The three most significant signatures are plotted in Figures 3.7B-3.9B. 
Next, we compared the mutational signatures to a compiled set of known signatures in cancer from 
COSMIC (7). The top 3 signatures for each subtype and their relationships (see Methods) to 
COSMIC signatures are listed in Table 3.5. Interestingly, all three subtypes share the 4th COSMIC 
signature in common. This signature has recently been shown to be increased in cancers derived 
from smokers versus non-smokers (157). Also, LUAD and SCLC both share the 5th signature, 
while LUAD and LUSC share the 13th signature. 
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Figure 3.7. Summary of Ti/Tv ratios and mutational signatures for LUAD. Panel A shows the Ti/Tv ratio in LUAD. Panel B shows the 
frequency of mutations in the top three mutational signatures in LUAD. 
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Figure 3.8. Summary of Ti/Tv ratios and mutational signatures for LUSC. Panel A shows the Ti/Tv ratio in LUSC. Panel B shows the 
frequency of mutations in the top three mutational signatures in LUSC. 
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Figure 3.9. Summary of Ti/Tv ratios and mutational signatures for SCLC. Panel A shows the Ti/Tv ratio in SCLC. Panel B shows the 
frequency of mutations in the top three mutational signatures in SCLC. 
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Table 3.5. Summary of mutational signatures. 
Mutational signature Closest match in COSMIC Cosine-Similarity 
LUAD sig 1 Sig 5 0.77 
LUAD sig 2 Sig 4 0.91 
LUAD sig 3 Sig 13 0.77 
LUSC sig 1 Sig 13 0.81 
LUSC sig 2 Sig 30 0.85 
LUSC sig 3 Sig 4 0.91 
SCLC sig 1 Sig 5 0.84 
SCLC sig 2 Sig 4 0.85 
SCLC sig 3 Sig 4 0.92 
 
 
The mutation rate for lung cancer is much higher than many cancer types (158), and the 
tumor genomes may harbor many passenger mutations, so we used several filtering steps to attempt 
to remove many of the genes that carried passenger mutations. (see Methods). Importantly, for our 
filtering process we did not exclude synonymous variants in LUAD or LUSC as was done in the 
previous analysis for mutational signatures (for details, see Discussion). The original number of 
genes that harbored at least one somatic mutation were 18,068, 14,789 and 5,180 for LUAD, 
LUSC, and SCLC, respectively. We applied our filtering steps to determine a list of possible lung 
cancer driver genes for each subtype at two different thresholds. The final genes are listed in Table 
3.6. We refer to these sets of genes as the lenient and strict set of somatic mutated genes. Using 
our lenient threshold, we found 382, 247, and 67 genes for LUAD, LUSC, and SCLC, respectively 
(Figure 3.10A). Using our strict threshold, we found 106, 57, and 26 genes for LUAD, LUSC, and 
SCLC, respectively (Figure 3.10B). We illustrate the overlap of the somatic mutated genes in 
Figures 3.10C-D, 
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Table 3.6. Summary of filtered somatic mutated genes. 
 LUAD LUSC SCLC 
# samples 538 178 42 
# initial mutations 234,278 65,305 7,945 
# mutations in COSMIC 10,604 3,080 364 
# genes mutated in COSMIC 560 513 193 
# lenient genes 411 260 67 
# strict genes  113 59 26 
# genes expressed in normal tissue 410 (lenient), 112 (strict) 260 (lenient), 59 (strict) N/A 
# genes expressed in tumor tissue 410 (lenient), 112 (strict) 260 (lenient), 59 (strict) N/A 
# genes > 10 counts in normal tissue 379 (lenient), 106 (strict) 245 (lenient), 57 (strict) N/A 
# genes > 10 counts in tumor tissue 377 (lenient), 104 (strict) 238 (lenient), 56 (strict) N/A 
# final genes - lenient 382 247 67 
# final genes - strict 106 57 26 
Lenient thresholds: LUAD = mutated in at least 20 different subjects, LUSC = mutated in at least 
7 different subjects, SCLC = mutated in at least 2 different subjects 
Strict thresholds: LUAD = mutated in at least 5 different subjects, LUSC = mutated in at least 3 
different subjects, SCLC = mutated in at least 2 subjects 
N/A = genes for SCLC were previously filtered for expression, so did not include filtering step 
for this subtype. 
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Figure 3.10. Final somatic mutated genes. Panel A shows the total number of lenient defined 
somatic mutated genes for each subtype. We show their overlap between subtypes in panel B. 
Panels C and D show the total number of strict defined somatic mutated genes and their overlap, 
respectively. 
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Discussion 
 
The identification of the similarities and differences in three lung cancer subtypes at the 
somatic level is an important question to help ascertain and differentiate the molecular 
characteristics of the subtypes. This level of data is crucial because previous studies (159, 160) 
have demonstrated that typical chemotherapy-based options do not perform as well as targeted 
therapies in lung cancer. In this study, we used DNA mutations and RNA expression levels to 
characterize and compare three subtypes of lung cancer. We used RNA expression levels to 
generate a set of DEGs that are dysregulated in lung tumor tissue. We then used the DEGs to 
perform a pathway enrichment analysis. Additionally, we used somatic mutations to generate a 
Ti/Tv ratio and mutational signatures between subtypes. We then filtered a set of broad somatic 
mutations to identify a set of potential driver genes for each subtype.  
 
RNA level analyses 
 We first generated a set of DEGs for all subtypes. We found that there not strong overlap 
between all of the three subtypes. We identified KEGG biological pathways that were enriched 
with the sets of DEGs. We also found that LUSC and SCLC shared many immune-related 
pathways that were not shared with LUAD, such as Antigen processing and presentation, Intestinal 
immune network for IgA production, and Antigen processing and presentation. Additionally, 
immune-related genes are affected in many cancer types such as breast cancer (161), so this 
warrants future investigation.  
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DNA level analyses 
 We generated the Ti/Tv ratio for all three subtypes. Our results showed that all subtypes 
had much higher transversions (~65%) than transitions (~35%). This finding agrees with previous 
work that suggested high transversions in NSCLC due to cigarette smoking (92). Specifically, we 
see a very high percentage of C>A transversions (~30% of mutations) in all subtypes. This pattern 
has been well-established in LUAD and LUSC (162). The observation of this same pattern in 
SCLC suggests it shares somatic mutation features with the NSCLC subtypes attributable to 
smoking. However, we would have expected to see much higher C>A mutations in this subtype 
because studies have found the strongest smoking association with SCLC (39). To expand upon 
this mutational investigation, we generated mutational signatures in each subtype. We identified 
the top three signatures and compared them to a set of COSMIC signatures. The COSMIC 
signatures are based upon a set of over 10,000 exomes and ~1,000 genomes over 40 different 
cancer types (7). Our results indicated that all subtypes shared the Signature 4 from COSMIC. This 
signature has been found in all three subtypes previously and appears to be associated with tobacco 
smoke (7). Additionally, recent work has found that this signature is more common in cancers that 
are found in smokers compared to non-smokers (157). The mutational signatures for SCLC were 
overwhelmed by smoking, and therefore, out of the three top signatures for SCLC, two of them 
matched to COSMIC signature 4. This suggests that there are not even three distinct mutational 
signatures and that a lot of the mutation pattern may be attributed to cigarette smoke in SCLC. 
This result indicates that the mutational signature for SCLC is overwhelmed by tobacco smoke 
related mutations. We also identified that COSMIC signature 5 matched signatures in LUAD and 
SCLC but not LUSC. The etiology of this signal is unknown. Overall, we found that the three 
subtypes shared most of their mutational signatures with at least one other subtype. However, one 
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signature for LUSC, signature 30 from COSMIC, was unique to LUSC. This pattern deserves 
attention because it has only been previously found in a small set of breast cancers (7). We also 
filtered a set of previously identified (82, 86, 89) somatic mutations to generate a set of possible 
driver genes in each subtype. We filtered out the majority of the mutated genes by initially 
removing genes not in the CGC list from COSMIC (7).  
 
Study limitations and summary 
 There are several limitations to this study. First, the sample size for SCLC was much 
smaller than the NSCLC sample size. More comparable sample sizes between SCLC and NSCLC 
may have revealed more significant associations, but we were limited by available data. Second, 
the somatic mutations were identified using different approaches for NSCLC versus SCLC. 
Previous work (163, 164) has compared mutation callers and found differences, so there may be 
some issues with comparing the called variants. We also included silent mutations for LUAD and 
LUSC for filtering the somatic mutations to identify potential driver genes, but we did not include 
synonymous mutations for SCLC because they were already filtered out of the results. We did not 
want to remove the silent mutations in the NSCLC subtypes because previous work (165, 166) has 
demonstrated that synonymous variants may contribute to cancer (167). For future work, we can 
also exclude all silent mutations from LUAD and LUSC to compare with our results in this study. 
Finally, if clinical data is sufficient and sample size is large enough, we will consider smoking and 
other clinical factors like drug treatment as co-variates in our future analyses. 
 In summary, we used DNA somatic mutations and RNA expression data to compare three 
lung cancer subtypes. We calculated DEGs and a set of potential driver genes. We determined 
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mutational signatures for each cancer subtype. We identified the overlap between all three 
subtypes for somatic mutations and DEGs. Overall, this study provided strong insight into the 
biological similarities and differences at the somatic level for three subtypes of lung cancer. 
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CHAPTER IV 
 
INVESTIGATION INTO THE CHALLENGES OF IDENTIFYING SOMATIC 
MUTATIONS IN LUNG CANCER USING RNA SEQUENCING VERSUS 
WHOLE EXOME SEQUENCING* 
 
Introduction 
 
 As demonstrated in Chapter III, investigations into the somatic alterations in lung cancer 
are best approached at both the DNA and RNA levels. However, unless the analyses are done in 
large consortia such as TCGA (86), it may be cost prohibitive to generate DNA sequencing to call 
somatic variants and RNA sequencing (RNA-Seq) to identify expression levels. It would be ideal 
if one could use RNA-Seq as a tool to call somatic variants in addition to its role of determining 
RNA expression levels. In order to determine the effectiveness of using RNA-Seq to call variants 
compared to traditional based DNA whole exome sequencing (WES), we performed an integrative 
analysis for both techniques on the same set of lung cancer samples. Due to the restrictions 
mentioned above, we limited our analysis to the non-small cell lung cancer (NSCLC) subtype. We 
specifically focus on RNA-Seq’s role to identify a single type of mutation, the single nucleotide 
variant (SNV). SNVs are the most abundant form of genetic variation in genome sequences and 
somatic SNVs play critical roles in disease including lung cancer (150). The discovery of many 
driver SNVs has led to new targets for therapeutic treatments and preventive measures.  
* Adapted from O’Brien et al. Methods 2015. 83:118-127 (168) 
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Examples include vemurafenib specifically targeting BRAF V600 mutations in melanoma 
(169, 170) and gefitinib, erlotonib, and afatinib for EGFR mutations in lung cancer (142). The 
recent advances in next-generation sequencing (NGS) technologies, especially WES and whole 
transcriptome sequencing (RNA-Seq), have helped investigators generate a massive amount of 
NGS data, from which genetic variants, including SNVs, are detected. Many tools are now 
available for the detection of somatic SNVs from NGS data (163). 
Both whole genome sequencing (WGS) and WES have been applied to detect SNVs in 
large scale cancer studies. While WGS can detect the full spectrum of variants, including SNVs, 
insertions/deletions (indels), copy number variations (CNVs), and structural variants (SVs), across 
the whole cancer genome, WES is more cost-effective in detecting SNVs and indels located in the 
1-2% of the genome that encodes for functional proteins (171). There is good evidence that SNVs 
within the exome are responsible for many diseases, so WES has been applied extensively in 
research and clinically (171-173). RNA-Seq is commonly used for the measurement of gene 
expression levels, detection of gene fusions, and identification of splicing events. Because RNA-
Seq is based on direct sequencing of cDNA, the product of the mRNA through reverse 
transcription, it may be feasible to detect SNVs from RNA-Seq data (174, 175). This is a unique 
feature that is different from the traditional microarray-based gene expression. RNA-Seq also has 
the ability to detect RNA editing, which is a post-transcriptional process that modifies RNA 
transcripts. One of the most common mechanisms of RNA editing is the deamination of adenosine 
to inosine by the protein Adenosine Deaminase Acting on RNA (ADAR). The inosine is 
interpreted in a similar way to guanosine and, thus, results in an adenosine to guanine (A → G) 
change (176). 
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RNA-Seq has been extensively applied to genomic and transcriptomic studies, including 
cancer. For example, a large-scale RNA-Seq study of lung adenocarcinoma identified several 
cancer driver genes (177), indicating its utility in a transcriptome analysis of cancer samples. This 
study demonstrated that in addition to identifying fusion genes and differential gene expression, 
RNA-Seq could detect well-known cancer driver genes. RNA-Seq has also been combined with 
WGS to better understand the mutational landscape of lung cancer (80, 178). These studies, in 
addition to showing the standard applications of RNA-Seq in gene expression analysis, highlight 
its usefulness as a technology platform for SNV detection, though challenges remain (179). As 
was demonstrated in the previous chapter, large consortia such as TCGA have applied both WES 
and RNA-Seq, as well as other platforms, to comprehensively catalog the cancer genome 
landscape (82, 86). The combination of WES and RNA-Seq data from the same tumor samples 
allows for large-scale examinations of somatic mutations in both the DNA and RNA. By applying 
these two types of technology together, one can improve the detection of various mutations, 
including those in the expressed genes with different splicing and expression levels, and those in 
non-transcribed regions. However, sequencing the same tumor using both platforms is rarely used 
due to cost and analysis issues.  
 A detailed comparison of SNVs called from WES and RNA-Seq data using the same lung 
cancer samples can not only reveal the technical differences of these two technologies, but also 
help us better understand the underlying biological processes that lead to the ambiguous 
observations of SNVs at the DNA and RNA levels, respectively. Such a comparison can provide 
guidance on the utility of WES and RNA-Seq in SNV detection. So far, there have been only a 
few attempts to unveil the advantages and disadvantages of WES and RNA-Seq in SNV detection. 
For example, Cirulli et al. (180) recently compared WGS with RNA-Seq in detecting SNVs using 
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peripheral blood mononuclear cells from the same subjects. They highlighted many important 
aspects for SNV detection such as expression levels and read depth, but its conclusions are yet to 
be validated due to the limited sample size. Another recent review compared WES and RNA-Seq 
(181), but it only discussed several global features without a systematic comparison of detailed 
features. 
In this study, we compared the features of SNVs from WES and RNA-Seq using a 
collection of 27 NSCLC tumor and matched normal samples from the same patients. Through our 
systematic analyses, we attempted to unveil the unique features of SNVs from each platform and 
determined why variants are missed between these platforms. Because of the high false calling 
rate of indels, we only focused on SNVs. We observed only a small overlap of SNVs between 
WES and RNA-Seq, and identified multiple technological and biological reasons leading to 
discrepancies in SNV calling.  
 
Methods 
 
Samples and sequencing  
Twenty-seven paired tumor and normal NSCLC samples from patients undergoing lung 
cancer surgery at Massachusetts General Hospital were used for this analysis. For all 27 paired 
tumor and normal lung cancer samples, we performed both WES and RNA-Seq experiments. All 
participants provided written informed consent. Tumor content was assessed with an average of 
60% across samples. The exome regions were captured using the Agilent SureSelect Human All 
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Exon kit and then sequenced on an Illumina HiSeq 2000 platform (paired end, 100 bp) in a 
Massachusetts General Hospital (MGH) core. We obtained a total of 3,677,811,274 paired-end 
reads with an average sequencing depth of 121×. For RNA-Seq, Illumina Tru-Seq v2 RNA-Seq 
kit was used for enrichment of mRNA, cDNA synthesis, and library construction. Then, RNA 
sequencing was performed on an Illumina HiSeq 2000 platform in the Vanderbilt Technologies 
for Advanced Genomics (VANTAGE) core (paired end, 100 bp). We obtained a total of 
4,778,766,598 paired end reads with an average of 88,495,678 paired end reads per sample. We 
used FASTQC to check the quality of reads of all samples 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
 
WES data analysis 
We mapped the WES reads to the human reference genome hg19 (GRCh37) using 
Burrows-Wheeler Aligner (BWA) (version 0.5.9c) (182). In order to further process the data, we 
used Picard (version 1.95) (183) to mark duplicate reads and used GATK (version 1.0.3825) to 
perform local realignment and recalibration (184, 185). After post-alignment processing of the 
data, we called SNVs with MuTect (version 1.1.4). To generate mpileup files for each tumor and 
normal sample, we used the “mpileup” function in Samtools (version 0.1.19) (186). Read count 
values were obtained from the mpileup files using VarScan2 (version 2.3.5) (187) with the 
“readcounts” function. Read count values were split up into categories of values: not covered 
(NA), single read (1), low coverage (2-7) and high coverage (≥ 8). 
 
 103 
 
RNA-Seq data analysis 
We used TopHat2 (version 2.0.0) (188) to map RNA-Seq reads to the human reference 
transcriptome and genome (hg19). TopHat2 first attempts to map reads to the reference 
transcriptome and then for the unmapped reads, it attempts to map them to the human genome 
reference. As we did for WES data, we called SNVs using MuTect (version 1.1.4). Specifically, 
we generated mpileup files using Samtools and obtained read count values using VarScan2. We 
used Cufflinks (version 2.1.1) (189) to obtain gene-based FPKM (Fragments Per Kilobase of exon 
per Million fragments Mapped) values for all samples. FPKM values corresponding to degrees of 
expression were as follows: not covered (NA), no expression (FPKM < 1), very low expression 
(FPKM 1-5), low to moderate expression (FPKM 5-20), and high expression (FPKM > 20). 
 
Read counting for the RNA-Seq SNVs covered by the WES capture kit 
We used Bedtools (version 2.17.0) to determine whether the SNVs identified from RNA-
Seq were covered by the WES capture kit using the “-intersectBed” function. SNVs were 
categorized into four groups by read count values as was done for the aforementioned read count 
analysis: not covered (NA), single read (1), low coverage (2-7) and high coverage (≥ 8).  
 
Mutation pattern categorization for all SNVs  
We categorized SNVs into six groups according to their nucleotide changes: A:T→C:G, 
A:T→T:A, A:T→G:C, C:G→A:T, C:G→G:C, and C:G→T:A. 
The computational tools that we used for all analyses are summarized in Table 4.1. 
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Table 4.1. Tools used for comparing WES versus RNA-Seq data. 
Method/tool Purpose URL 
FASTQC Check quality of WES and RNA-Seq reads http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
BWA Map WES reads to the reference genome http://bio-bwa.sourceforge.net/ 
Picard Mark duplicate WES reads http://broadinstitute.github.io/picard/ 
GATK Perform local realignment and recalibration of WES 
reads 
https://www.broadinstitute.org/gatk/ 
MuTect Detect SNVs in WES and RNA-Seq http://www.broadinstitute.org/cancer/cga/mutect 
Samtools Generate mpileup files for WES and RNA-Seq http://samtools.sourceforge.net/ 
VarScan2 Generate read counts for WES and RNA-Seq http://varscan.sourceforge.net/ 
TopHat2 Map RNA-Seq reads to the human reference 
transcriptome and genome 
http://ccb.jhu.edu/software/tophat/index.shtml 
Cufflinks Calculate FPKM gene expression levels for RNA-Seq https://github.com/cole-trapnell-lab/cufflinks 
Bedtools Intersect RNA-Seq SNVs with WES capture kit https://github.com/arq5x/bedtools2 
R Perform the analysis for SNV comparisons http://www.r-project.org/ 
This table summarizes the computational tools used in our WES versus RNA-Seq comparative analysis. We include each tool used in 
our analysis, our use for the tool, and the URL link to the website. Further details including citations for all tools listed above are in the 
main methods section of the text
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Results 
 
Figure 4.1 illustrates the concept of our SNV comparison from WES and RNA-Seq data. 
There are several factors that may cause a difference in detecting SNVs from WES and RNA-Seq 
data, even from the same samples. First, the two sequencing technologies and their sequencing 
strategy will have variation in the enrichment of sequence regions. Second, at the biological level, 
SNVs detected from DNA-Seq (i.e., WES) may not be detectable by RNA-Seq due to low 
coverage, or tissue-specific expression and alternative splicing. In contrast, SNVs in the 
transcriptome may not be detected in WES because of low coverage, RNA editing, or their location 
outside of the WES capture regions. With these factors, we performed an in-depth comparison 
between SNVs detected by the two sequencing techniques. 
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Figure 4.1. Comparison between WES data and RNA-Seq data. This figure shows the motivation 
and the concept behind our study. WES reads are generated on the exon captured regions. RNA-
Seq reads are generated on the content of gene expression conditions. SNVs may exist in various 
locations of the genome including introns adjacent to exons in the DNA, and for locations within 
the transcriptome. SNVs for the intronic, WES and RNA-Seq shared, WES only, RNA-Seq only 
are colored with dark grey, light grey, blue and pink, respectively. SNVs not included in WES by 
the low coverage or WES kit failure or RNA editing are represented with pink dotted circles. SNVs 
not included in RNA-Seq by the low expression or coverage are represented with blue dotted 
circles. 
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Poor concordance for SNVs called in WES and RNA-Seq data 
We obtained WES and RNA-Seq data for 27 lung cancer tumor samples and their matched 
normal samples. We applied a standard pipeline to analyze the samples and detect somatic SNVs 
(Figure 4.2). We refer to the SNVs that were uniquely detected in WES but not in RNA-Seq data 
as “WES unique SNVs,” the SNVs that were uniquely detected in RNA-Seq but not in WES data 
as “RNA-Seq unique SNVs,” and those observed in both WES and RNA-Seq as “WES shared 
SNVs” or “RNA-Seq shared SNVs.” Note that although the WES shared SNVs and the RNA-Seq 
shared SNVs have the same genomic coordinates, they may have different alternative allele 
frequencies, or even different alternative alleles, in the WES data and in the RNA-Seq data. Thus, 
we referred to them separately as WES shared SNVs and RNA-Seq shared SNVs. Overall, we 
identified 15,662 SNVs from the WES data, with an average of 580 ± 517 SNVs per sample, and 
15,473 SNVs from the RNA-Seq data, with an average of 573 ± 332 SNVs per sample. 
Surprisingly, only ~14% (2,150) of these SNVs were detected by both WES and RNA-Seq (Table 
4.2).  
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Figure 4.2. Work flow for the overall analysis. The blue color scheme is for the WES work flow. 
The pink color scheme is for the RNA-Seq work flow. Typical pipelines for WES data and for 
RNA-Seq data were used. From the SNVs called using MuTect, we performed several 
comparisons. For the WES data sets, we compared SNV lists from RNA-Seq, and analyzed gene 
expression patterns. For the RNA-Seq data sets, we compared SNV lists from WES and compared 
the mutation patterns. 
 
WES data flow 
Post analysis 
- Covered by WES kit 
- Coverage in WES 
- Mutation pattern (MuTect) 
Map to hg19 genome (BWA) 
Pre-processing for SNV calls 
- Mark duplicates (Picard) 
- Local realignment (GATK) 
- Base quality recalibration (GATK) 
Map to refSeq   
Remap unmapped reads to  
hg19 genome (TopHat2) 
SNV detection (MuTect) 
- Make mpileup files (Samtools) 
- Get read counts (VarScan2) 
- Read counts (NA, 1, 2-7, ≥ 8) 
Intersect with WES kit (Bedtools) 
RNA-Seq data flow Shared flow 
Calculate expression  
(Cufflinks) 
FPKM (NA, <1, 1-5, 5-20, >20) 
Post analysis 
- Coverage in RNA-Seq 
- Expression in RNA-Seq 
- Mutation pattern (MuTect) 
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Table 4.2. Summary of all SNVs detected in RNA-Seq and WES by MuTect. 
Sample ID  RNA-Seq WES  Overlap 
Overlap with  
RNA-Seq (%) 
Overlap with  
WES (%) 
1 452 388 52 11.5 13.4 
2 1,082 1,206 263 24.3 21.8 
3 731 902 175 23.9 19.4 
4 531 62 9 1.7 14.5 
5 572 83 4 0.7 4.8 
6 640 619 92 14.4 14.9 
7 317 94 8 2.5 8.5 
8 220 85 5 2.3 5.9 
9 659 168 23 3.5 13.7 
10 524 78 8 1.5 10.3 
11 529 447 36 6.8 8.1 
12 597 773 112 18.8 14.5 
13 432 335 54 12.5 16.1 
14 533 1,360 124 23.3 9.1 
15 403 540 30 7.4 5.6 
16 768 892 143 18.6 16.0 
17 590 296 56 9.5 18.9 
18 753 172 26 3.5 15.1 
19 313 1,060 42 13.4 4.0 
20 422 1,017 125 29.6 12.3 
21 188 716 9 4.8 1.3 
22 1,425 901 158 11.1 17.5 
23 348 309 19 5.5 6.1 
24 310 227 45 14.5 19.8 
25 97 66 1 1.0 1.5 
26 508 577 58 11.4 10.1 
27 1,529 2,289 473 30.9 20.7 
Mean ± SD 573 ± 332 580 ± 517 80 ± 102 13.9 ± 9.0 13.7 ± 6.0 
Total 15,473 15,662 2,150     
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We explored the reasons why such a small portion of WES SNVs was detected in the RNA-
Seq data. One possibility is that the positions of the WES SNVs are not well covered in RNA-Seq. 
A large proportion of the WES unique SNVs (41.0%) are not covered in RNA-Seq. However, the 
majority (96.9%) of the WES shared SNVs have at least eight RNA-Seq reads mapped to their 
position (Figure 4.3). There is a small proportion of WES unique and WES shared SNVs 
moderately covered in RNA-Seq (2-7 reads), 8.8 – 24.2% and 0 – 33.3% respectively. 
Interestingly, 11.2 – 58.8% of the WES unique SNVs have a high number (≥8) of RNA-Seq reads 
aligned to their position. However, these are still undetected in RNA-Seq. Only one WES shared 
SNV was not covered (NA) in RNA-Seq, and this is likely a false positive detected from the 
MuTect analysis. We hypothesized that some of the WES unique SNVs may be located in genes 
which are not expressed, or have very low expression levels, and therefore are undetected by RNA-
Seq. 
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Figure 4.3. VarScan2 read count values determine why WES unique SNVs are not called by RNA-
Seq. (A) Stacked column graph showing read counts results in RNA-Seq for WES unique SNVs. 
(B) Bar plot showing read counts results in RNA-Seq for WES shared SNVs. Blue represents read 
counts NA (not covered), orange represents read counts 1, grey represents read counts 2-7, and 
yellow represents read counts ≥ 8. Around 50% of WES unique SNVs are not covered in RNA-
Seq. Samples ordered by decreasing NA (in A) and decreasing ≥ 8 (in B). 
 
 112 
 
We further explored the features of WES unique SNVs regarding their gene expression 
levels. We used the software Cufflinks to generate FPKM values from RNA-Seq data for the 
chromosomal loci of WES SNVs (Table 4.3). We categorized FPKM values as not covered (NA), 
not expressed (< 1 FPKM), low expression (1-5 FPKM), low to moderate expression (5 – 20 
FPKM) and high expression (> 20 FPKM) (Figure 4.4). Many of the WES unique SNVs are 
located in genes that are not expressed (51.0%). In contrast, 77.7% of WES shared SNVs are 
located in genes with FPKM > 5, including 0 – 66.7% of WES shared SNVs located in genes with 
low to moderate expression (FPKM 5-20), and 11.1 - 100% WES shared SNVs located in genes 
with high expression levels (> 20 FPKM).  
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 Table 4.3. Summary of FPKMa levels from RNA-Seq for SNVs detected by WES.  
  NAb < 1  1 − 5  5 – 20 > 20 Total  
WES unique SNVsc        
     Mean ± SD 24 ± 20 255 ± 220 109 ± 106 79 ± 68 33 ± 31 500 ± 429  
     Range 2 - 90 25 - 948 9 - 449 9 - 240  3 - 114 53 - 1816   
     Range of % 2.1 - 10.1% 35.0 - 63.5% 13.7 - 30.0% 9.6 - 32.5% 2.8 - 12.1%   
WES shared SNVsd        
     Mean ± SD 2 ± 3 1 ± 2 15 ± 23 38 ± 47 24 ± 31 80 ± 102  
     Range 0 - 10 0 - 7 0 - 103 0 - 224 1 - 132 1 - 473  
     Range of % 0 - 11.5% 0 - 5.3% 0 - 27.2% 0 - 66.7% 11.1 - 100%  
  a FPKM: Fragments Per Kilobase of transcript per Million mapped reads.  
     FPKM gene expression values were generated by Cufflinks. 
  b NA: SNV positions from WES that are not covered at the gene level in RNA-Seq.   
  c WES unique SNVs: SNVs detected only in WES.                                                                                                 
  d WES shared SNVs: SNVs detected in both WES and RNA-Seq. 
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Figure 4.4. Cufflinks analysis to determine gene expression levels of WES unique SNVs in RNA-
Seq. (A) FPKM values for WES unique SNVs. (B) FPKM values for SNVs shared between WES 
and RNA-Seq. Most WES unique SNVs are located within genes which are not expressed in RNA-
Seq. FPKM NA: not covered, FPKM < 1: not detected; FPKM 1-5: not expressed; FPKM 5 -20: 
low to moderate expression; and FPKM > 20: high expression. Samples ordered by decreasing 
percentage of SNVs FPKM < 1 (in A) and decreasing percentage of FPKM > 5 (in B). 
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Feature analysis of RNA-Seq unique SNVs 
We then examined the features of RNA-Seq unique variants. We first explored RNA-Seq 
unique SNVs that may be located outside of the WES capture regions. RNA-Seq does not contain 
a specific exome capture step, so the variants detected are not constrained to the specific 1-2% of 
the genome sequenced by WES, and are only limited to the genomic regions that are being 
transcribed. We first explored the proportion of RNA-Seq unique SNVs that lie outside of the 
WES capture region. We used the “-intersectBed” command in Bedtools to identify RNA-Seq 
unique SNVs that are not covered by the WES capture region. For the 13,323 RNA-Seq unique 
SNVs, 9,513 (71.4%) are located outside of the WES capture regions (Figure 4.5). We used 
VarScan2 to identify the read count values for the positions that are covered by the WES capture 
kit. We discovered that for the RNA-Seq unique SNVs covered by the kit, an average of ~93% 
(82.2 – 98.3%) are in locations that are highly covered (≥ 8 reads) (Table 4.4). This is an interesting 
observation - it means that only approximately 7.0% of the SNVs uniquely called in RNA-Seq are 
potentially missed in WES due to low coverage of sequencing. Thus, the remaining SNVs are not 
missed due to technical issues, but due to biological issues. 
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Figure 4.5. RNA-Seq unique SNVs not covered by the WES kit and coverage levels. (A) Bar plot 
shows the percentage of RNA-Seq unique SNVs within each sample that are not covered by the 
WES capture kit. Also included are VarScan2 read count values for covered positions. Figure 4.5A 
shows that most SNVs are not covered by the WES kit. Here, ‘not covered by kit’ represents RNA-
Seq SNVs outside of the capture kit region; read counts values represented by NA, 1, 2 – 7, and ≥ 
8. (B) Bar plot containing VarScan2 read counts values for only the positions covered by the WES 
kit. Most SNVs covered by the WES kit have high coverage. Read counts values represented by 
NA, 1, 2 – 7, and ≥ 8. 
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Table 4.4. Summary of WES coverage for RNA-Seq SNVs that are covered by the WES capture 
kit. 
  NA 1 2 - 7 ≥ 8 Total in kit  
Mean 1 ± 1 1 ± 1 8 ± 5 130 ± 64 140 ± 68  
Range 0 - 3 0 - 4 0 - 22 29 - 280 34 - 299  
Range of % 0 - 5.9% 0 - 5.9% 0 - 16.4% 82.2 - 98.3%    
 
 
We hypothesized that RNA editing is another factor leading to the RNA-Seq SNVs being 
undetected in WES. Although there are known difficulties detecting RNA editing in NGS data 
(190-192), we explored this mechanism as a potential reason for inconsistencies in mutation 
calling between WES and RNA-Seq. We used the results from MuTect to analyze the base-pair 
mutation pattern across all SNVs for signatures of RNA editing. Interestingly, the most common 
mutation pattern for the RNA-Seq unique SNVs was the A:T→G:C mutation pattern, occurring in 
55.3% of SNVs (Figure 4.6). Another interesting finding was that 21.4% of the RNA-Seq unique 
SNVs that were covered by the WES capture kit (but not detected in WES) also shared this same 
mutation pattern. In comparison, only 6.7% of the total number of overlapping SNVs called in 
both WES and RNA-Seq had this mutation pattern. The A→G mutation is a common RNA-editing 
mechanism arising from A→I editing acted upon by Adenosine Deaminase Acting on RNA (176). 
We summarize the list of factors that may lead to inconsistencies in detecting SNVs in RNA-Seq 
versus WES in Table 4.5. 
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Figure 4.6. Mutation pattern for all SNVs. Mutation pattern was determined for all categories of 
SNVs and percentages plotted. Several patterns are more highly enriched than others, such as the 
A:T→G:C mutation in RNA-Seq. 
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Table 4.5. Summary of factors that may lead to inconsistencies in detecting SNVs in WES versus 
RNA-Seq. 
Factors causing 
RNA-Seq unique 
SNVs 
Observation Factors causing WES 
unique SNVs  
Observation 
SNVs outside of the 
WES capture regions 
71.4% of RNA-Seq 
unique SNVs 
Low coverage of 
SNVs in RNA-Seq  
41.0% of WES-
unique SNVs have no 
RNA-Seq coverage 
Low coverage of 
SNVs in WES 
8.0% of RNA-Seq 
unique SNVs that are 
within the WES 
regions, have low or 
no WES coverage 
SNVs located in non-
expressed genes (< 1 
FPKM) 
51.0% of WES-
unique SNVs  
RNA-editing 55.3% of RNA-Seq 
unique SNVs were 
A:T→G:C mutations 
SNVs potentially 
edited in RNA-Seq 
55.3% of RNA-Seq 
unique SNVs were 
A:T→G:C mutations  
 
 
 
Discussion 
 
Few studies have examined mutation detection from both WES and RNA-Seq data of the 
same samples. However, such information is critical in assessing the mutations at different 
biological stages as well as their effects on disease. In this study, our comparison of WES and 
RNA-Seq data from the 27 pairs of NSCLC tumor and matched normal samples revealed that on 
average only ~14% of SNVs overlap. This value is quite low considering that the samples are 
identical. Thus, we explored possible reasons that cause this small overlap. We found that many 
of the WES unique SNVs are not called in RNA-Seq because they are poorly covered in RNA-Seq 
with many SNVs mapping with less than eight reads. This information is important for using a 
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SNV-calling software tool like MuTect, where the coverage limitations allowed to call an SNV is 
at least 14 reads in the tumor and at least 8 in the normal. 
We noticed that although low coverage levels explained why most WES unique SNVs were 
not detected in RNA-Seq, many other SNVs had high read counts values but were still missed. We 
decided to interrogate gene expression levels to determine if this may explain why some SNVs are 
not detected in RNA-Seq. We used FPKM values, and found that the majority of WES unique 
SNVs are located in genes which are not expressed. In contrast, the SNVs that were shared between 
sequencing methods were found to have moderate to high expression levels. This is an important 
finding, because many studies use WES as the single method for somatic mutation detection in 
cancer, and this analysis demonstrates that it is important to measure expression levels when trying 
to determine deleterious variants. Many SNVs may be called in WES, but may not have an impact 
at the biological level because the variant is located within a non-expressed gene.  
After determining these potential causes for the WES unique SNVs not being called in 
RNA-Seq, we next focused on the reasons why RNA-Seq unique SNVs were missed by WES.  
We first thought that many of the RNA-Seq unique SNVs may be missed by WES because 
they fall outside of the WES capture regions. This is an important aspect to consider, because while 
RNA-Seq covers the whole transcriptome, WES is limited to detecting variants in the exons and 
their flanking regions. Currently, many exon capture kits are designed to have their probes 
covering well-annotated coding genes using representative gene models like Consensus CDS 
(CCDS) and RefSeq. And the capture method using target-probe hybridization has the limitation 
of GC-content bias. To compare the regions covered by the kit with the RNA-Seq, we used 
Bedtools and found that 71.4% of the RNA-Seq unique SNVs are not covered in WES. This 
suggests that many potentially important SNVs not located in exome regions would be missed if 
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WES were applied. This is becoming more important as ENCODE data has determined that many 
non-exonic regions in the genome are expressed, and that they may be playing important roles in 
gene regulation (193). It also implies that only performing WES on a tumor sample may miss 
potential variants that may be of important function.  
Another biological reason why RNA-Seq unique SNVs may be missed in WES is due to 
RNA editing. We used the output from MuTect to generate the mutation pattern for all samples. 
An interesting mutation pattern in RNA-Seq unique SNVs was A:T→G:C. This pattern is 
indicative of RNA editing occurring by deamination of the adenosine to inosine, which gets 
interpreted as a guanine, editing in RNA achieved by the Adenosine Deaminase Acting on RNA 
proteins (176). This result has two implications for tumor sequencing. First, there may be a defect 
in the RNA editing machinery that leads to over-editing occurring in loci that normally do not get 
edited. Studies have shown that increased and decreased levels of RNA-editing may occur in 
different types of cancer (194, 195). This editing may give rise to new functions, or lose functions 
of important proteins in the tissue of interest. These mutations would be completely missed if 
sequencing were only focused on the whole genome or whole exome. Second, these mutations 
edited at RNA level are not expected to be detected by WES or WGS; therefore, their potential 
causative or deleterious effects will remain hidden.  
Although we discovered many important differences between variants detected in WES 
versus RNA-Seq, there are some limitations to the interpretation of the results. Our samples were 
exclusively from tumor material, and we focused on an important category – somatic SNVs. It will 
be interesting to see if these results are similar for non-tumor tissue and germline mutations. We 
only used a total of 27 pairs of samples, and while this is large number and adequate for this 
analysis, it may miss some important conclusions. Furthermore, while the number of reads per 
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sample in our RNA-Seq is large, it is not sufficient enough for RNA splicing analysis. 
Experimental validation of RNA editing variants is also required. Finally, the SNVs called in each 
tumor type and sequencing type vary widely, so a pan-cancer study may identify additional reasons 
for the small overlap of variants detected in WES versus RNA-Seq. 
In conclusion, our systematic comparison of SNVs from WES and RNA-Seq NSCLC data 
revealed a low overlap. We pinpointed multiple reasons for the inconsistencies in SNV detection 
with RNA-Seq and WES. It was discovered that most WES SNVs were undetected by RNA-Seq 
because of low coverage or low expression levels. We found that most SNVs detected by RNA-
Seq were missed in WES because they are located outside the boundary of the WES capture 
regions. Lastly, we found that many SNVs detected by RNA-Seq had a mutational signature of 
RNA editing. This analysis has provided answers to our original posed question above about the 
feasibility to detect WES level SNVs using only RNA-Seq. Although we found that many variants 
would be missed using RNA-Seq alone, many of them may be of less importance because they are 
not expressed at high enough levels to cause damage. However, the SNVs detected by RNA-Seq 
may have potentially undergone RNA-editing and therefore would be difficult to target in DNA 
due to the converted base change at the RNA level. 
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CHAPTER V 
 
APPLICATION OF THE GWAS-BASED REGULATORY PIPELINE AND 
APPROACH TO OTHER DISEASE TYPES 
 
Introduction 
 
Chapter II illustrated that it is possible to identify a set of regulatory variants and their 
target genes in lung cancer using several tissue-specific data sources and methods. However, that 
approach can be extended to other disease types beyond lung cancer and other populations besides 
European. In this chapter, we applied the approach developed in Chapter II to another disease of 
the lung, other cancer types, and other instances of lung cancer in non-European populations using 
SNPs with p < 1 x 10-4 from three GWA studies.  
 We selected a lung related disease that sometimes co-occurs with lung cancer: chronic 
obstructive pulmonary disease (COPD). COPD was originally defined as a disease that 
encompassed emphysema and chronic bronchitis, but recent efforts have determined it is a much 
more complex disease. COPD patients usually present with shortness of breath and other 
symptoms of lung dysfunction (196). There are several known risk factors for COPD, but like lung 
cancer, the most well-known risk factor is cigarette smoking (197). COPD is currently diagnosed 
when patients have a post bronchodilator Forced Expiratory Volume in one second (FEV-1) to 
Forced Vital Capacity (FVC) ratio < 70% (198). We use this lung disease to demonstrate our 
pipeline is applicable to lung diseases other than cancer. We also illustrate the applicability of the 
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approach to lung cancer in an Asian population of never smoker women. Interestingly, ~50% of 
lung cancer cases in women occurred in never smokers worldwide (199). The risk of never 
smoking lung cancer is especially high in Asian countries where many women cook with 
traditional stoves that emit toxic fumes. Overall, there are many differences between risk factors 
and the biology for smoking versus never smoker lung cancer (200). For an extensive discussion 
of this subject, see the review from Sun et al. in Nature Reviews Genetics 2007 (200). These data 
allow us to extend our pipeline to lung cancer identified in non-European populations to identify 
regulatory mechanisms of disease. Finally, we extend our approach to two histologically different, 
but anatomically close, cancer types: gastric cancer (GC) and esophageal squamous cell carcinoma 
(ESCC). These cancer types are usually combined and categorized as upper gastrointestinal 
cancers. The highest incidence of these cancer types occur in areas of China, although rates are 
decreasing (201). Interestingly, although alcohol consumption and cigarette smoking are major 
risk factors for these cancers in the west, they have decreased influence for Chinese populations 
(202). This suggests a different mechanism of disease for these cancers between different 
populations. Additionally, the different environmental exposures between these populations may 
influence risk of these cancer types. For example, dietary factors, such as the consumption of 
moldy bread (203) that is consumed in Linxian China may be a stronger constituent of disease in 
China versus the west. 
In this study, we applied our approach from Chapter II on three different GWA studies to 
highlight the pipeline’s generalizability to other disease types. The three studies consisted of five 
different disease types. Three of the diseases are lung related: COPD, never smoking LUAD (N.S. 
LUAD) and never smoking LUSC (N.S. LUSC). The other two diseases, ESCC and GC, expand 
the usefulness of our approach to non-lung related cancer subtypes. We also looked at the overlap 
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between many of the diseases and cancer subtypes. We give a brief overview of each study below 
and our combined results. 
 
Methods 
 
Datasets 
 
COPD GWAS dataset 
 Pillai et al. (204) performed the first GWAS for COPD using subjects from a case-control 
study for the Bergen cohort in Norway. Cases and controls were required to have at least 2.5 pack-
years of smoking history. COPD cases were defined by a post-bronchodilator FEV1 of < 90% and 
FEV1/FVC < 0.7. Controls were defined by FEV1 > 80% and FEV1/FVC > 0.7. After quality 
control (QC) of the samples, 823 cases and 810 controls of European ancestry remained. The 
subjects were genotyped with Illumina’s HumanHap550 chip. After QC of the SNPs, there were 
538,030 SNPs left for the association analysis. The authors analyzed the data using a logistic 
regression model including age, sex, smoking status, pack-years, and 12 principal components. 
We used the set of significant SNPs (p < 1 x 10-4) from the discovery phase of the GWAS in 
Supplementary Table 1 of the Pillai publication for our analysis. 
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Lung cancer in never smoking women GWAS dataset 
 Lan et al. (26) performed a GWAS for never-smoking women of Asian ancestry. This 
GWAS used subjects from 14 smaller studies that were scanned at six different centers. The 
genotypes were combined using a clustering approach described in their publication (26). The 
authors performed QC of the genotyped data to remove samples and SNPs that did not reach their 
QC criteria. After QC, 5,510 cases and 4,544 controls for the discovery analysis with 512,226 
SNPs remained. The authors analyzed the data using logistic regression including age, study group, 
and eigenvectors. The authors also stratified their analysis based upon histology. We used all SNPs 
(p < 1 x 10-4) from the study’s discovery phase for LUAD and LUSC. We obtained the SNP results 
from dbGaP study ID phs000716.v.1.p1. To download the SNP results separated by subtype, we 
utilized the Analyses tab on the webpage. This tab gave results in the online browser for LUAD 
http://www.ncbi.nlm.nih.gov/projects/SNP/gViewer/gView.cgi?aid=3852&pvf=0 and for LUSC 
http://www.ncbi.nlm.nih.gov/projects/SNP/gViewer/gView.cgi?aid=3853. To download the data, 
we chose no log(P-value_filter) and clicked to download the displayed data. We did this same 
procedure for each subtype to download all SNPs associated with each subtype. We further filtered 
this list to include SNPs p < 1 x 10-4 using the statistics analysis software R (205). 
 
GWAS datasets for gastric cancer and esophageal cancer 
 Abnet et al. (206) performed a GWAS for GC and ESCC in an ethnic Chinese population. 
For the discovery phase, the authors used participants from two studies: the Shanxi Upper 
Gastrointestinal Cancer Genetics Project (Shanxi) and the Linxian Nutrition Intervention Trial 
(NIT). After QC of the genotyping and subjects, 3,523 cases and 2,100 controls for the association 
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analysis and 551,152 SNPs remained. The SNPs were analyzed using logistic regression including 
age, study, and sex. We obtained all significant SNPs from dbGaP study ID phs000361.v1.p1. To 
download the SNP results for both cancer types, we clicked on the Analyses tab, and under the 
Analyses folder, we chose both cancer types. The results were displayed in the online browser, 
and we downloaded all unfiltered results. We then filtered the list to include SNPs p < 1 x 10-4 
using R.  
 
Methods to obtain final germline-regulated genes 
 The same approach and datasets used in this chapter were extensively explained in the 
methods for Chapter II. Below, we briefly discussed data used and any modifications to the 
approach used in Chapter II. We do not go into depth about every method, as was done in Chapter 
II. We point the reader to the methods section of Chapter II for full details and explanation of the 
data sets used in this current chapter. 
 
Remapping SNPs between genome builds and updating SNP rs ID numbers 
 The online tool Remap from NCBI (http://www.ncbi.nlm.nih.gov/genome/tools/remap) 
was used to remap SNPs between genome builds. For COPD, we remapped SNPs from hg18 to 
hg19 using default settings. The updated SNP positions were used to extract updated SNP rsID 
values using build 142 of dbSNP from NCBI. We used dbSNP files downloaded from 
ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/human_9606_b142_GRCh37p13/chr_rpts/. The SNPs 
for the other two disease types were downloaded from dbGaP (207), so we had to preprocess them 
first before we remapped. For example, data on dbGaP is structured differently than our data from 
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dbSNP and their positions are shifted by -1 bp relative to dbSNP. For N.S. LUAD and N.S. LUSC, 
we added +1 bp to each position before we remapped. The new positions were then remapped from 
hg38 to hg19. These new positions were updated to new rsID values as explained previously. For 
GC and ESCC, we also added +1 bp to their position. However, these SNPs were already in hg19, 
so we just matched the new positions directly to the files from dbSNP. 
 
Generation of SNPs in LD for all diseases 
 We used each SNP for all disease types to obtain a set of all SNPs in a 1Mb region upstream 
and downstream from each SNP using Tabix (104) version 0.2.5. For COPD, we obtained the SNP 
data from the European Super Population Group, and for all other disease types we used the Asian 
Super Population Group. All data were obtained from the 1000 Genomes Phase III data 
v5.20120502 (208). We used Vcftools (105) version 0.1.12b to convert the Tabix vcf files to plink-
tped file format. PLINK version 1.07 (106) was used in combination with the 1000 Genomes 
population genotype data to extract all SNPs in LD using r2 > 0.8 within 1Mb of each genotyped 
SNP. We combined all SNPs in LD from PLINK for each disease type and removed any duplicated 
SNPs from the LD expansion. 
 
GTEx eQTLs 
 We used the full set of human tissue-specific eQTLs version 6 (V6) that was downloaded 
from the GTEx website (www.gtexportal.org) on February 22, 2016 (67). For full details of how 
the eQTLs were generated, see methods in Chapter II. We used lung tissue for COPD and the never 
smoking lung cancer samples. For ESCC, we combined the eQTLs found in two esophageal 
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tissues: Esophagus Mucosa and Esophagus Muscularis. For GC, we used stomach tissue. We also 
used multi-tissue eQTLs generated by GTEx in lung tissue for COPD, N.S. LUAD, and N.S. 
LUSC. There were no appropriate tissues to use for GA or ESCC in the multi-tissue analysis. We 
plotted the distribution of posterior probabilities for lung tissue eQTLs to determine the threshold 
for significance.  
 
Hao et al. lung eQTLs (110) 
 The full set of cis-eQTLs in lung tissue with FDR at 10% identified from this study was 
used to identify eQTLs in COPD, N.S. LUAD, and N.S. LUSC.  
 
FANTOM5 transcribed enhancers 
 We used the entire set of permissive (all identified) enhancers downloaded from 
http://enhancer.binf.ku.dk/presets/permissive_enhancers.bed on August 26, 2015. We used 
PLINK v1.07 (106) to find any SNPs within enhancer regions using the gene-report function. To 
find the target gene of the enhancer regions with SNPs, we used the FANTOM5 enhancer 
transcription start site’s associations downloaded from 
http://enhancer.binf.ku.dk/presets/enhancer_tss_associations.bed on August 25, 2015. Enhancer 
target genes were determined for every disease studied. 
 
 
 130 
 
IM-PET predicted enhancer target genes 
 Data from a study by He et al. (72) was used to find enhancer target genes for COPD, N.S. 
LUAD, and N.S. LUSC. Two lung related cell lines, IMR90 and NHLF, were used. Target genes 
with Reads Per Kilobase per Million mapped reads (RPKM) = 0 were removed, and Ensembl 
transcript IDs were mapped to gene symbols using BioMart (112). 
 
Results 
 
Description of data 
 We obtained SNPs (p < 1 x 10-4) from the discovery phases for three GWA studies. The 
first dataset was obtained from the first GWAS for COPD (204). This GWAS for COPD was 
performed in Norway using the Bergen Cohort. All cases and controls were current or former 
smokers. This GWAS contained 823 cases and 810 controls of European ancestry. A summary of 
the participants is listed in Table 5.1. The second GWAS dataset was obtained for lung cancer 
cases in never smoking women of Asian descent (26). This GWAS was performed using data from 
14 different studies. There were 5,458 cases and 7,457 controls of Asian ancestry. A summary of 
the participants is listed in Table 5.2. The third GWAS dataset was obtained for GC and ESCC in 
an ethnic Chinese population (206). This GWAS was performed using data from two studies in 
China and contained 3,523 cases and 2,100 controls of Asian ancestry. A summary of the 
participants is listed in Table 5.3.  
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Table 5.1. Summary of GWAS for COPD. 
 # Cases # Controls 
Participants 823 810 
Post-FEV1 in liters (±SD) 
Post-FEV1 % pred (±SD) 
1.59 (±0.71) 
50.26 (±17.33) 
3.25 (±0.74) 
93.91 (±9.22)  
Post-FEV1/FVC ratio (±SD) 0.52 (±0.13) 0.79 (±0.04) 
Population European ancestry European ancestry 
Adapted from Pillai et al. PLoS Genetics 2009 (204). 
 
 
Table 5.2. Summary of GWAS for never smoking women in Asia. 
Study # LUAD samples # LUSC samples # Controls 
CAMSH 555 32 334 
FLCS 212 49 386 
GDS 535 7 123 
GEL-S 120 8 296 
GELAC 1,059 75 1,095 
HKS 226 0 666 
JLCS 407 10 549 
SKLCS 419 28 1,082 
SLCS 378 98 1,024 
CNULCS 498 51 480 
SWHS 78 9 200 
TLCS 49 32 237 
WLCS 0 14 343 
YLCS 179 330 642 
Total 4,715 743 7,457 
Adapted from Supplementary Table 1. Lan et al. Nature Genetics 2012 (26). 
 
Table 5.3. Summary of GWAS for GC and ESCC in ethnic Chinese. 
Study # GC # ESCC # controls 
Shanxi 1,368 1,399 1,650 
NIT 257 499 450 
Total 1,625 1,898 2,100 
Adapted from Supplementary Table 1. Abnet et al. Nature Genetics 2010 (206). 
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Remapping SNPs to an updated genome and LD expansion 
 We remapped the SNPs for each disease to hg19 (see Methods) and updated the SNP rs ID 
numbers in the new genome build using dbSNP b142. The datasets are from two different 
population types, so first we used these hg19 SNPs, and data from the 1000 Genomes Phase III 
European Super Population, to expand our COPD SNP list to include all SNPs in LD (r2 > 0.8) 
within 1Mb of each updated SNP. We used the 1000 Genomes Phase III Asian Super Population 
data for N.S. LUAD, N.S. LUSC, GC, and ESCC to obtain all SNPs in LD (r2 > 0.8) within 1Mb 
of each SNP. The results from the LD expansion are listed in Table 5.4. We used the same pipeline 
as in Chapter II to obtain a set of functional SNPs and their target genes for the lung related 
diseases. We modified the pipeline for the gastric related diseases by removing the SNP mapping 
steps for the Hao et al. eQTLs, IM-PET enhancers, and the GTEx multi-tissue eQTLs. 
 
Table 5.4. Summary of LD SNP expansion for all SNPs. 
SNP category COPD N.S. LUAD N.S. LUSC GA ESCC 
SNPs genotyped 538,030 512,226 512,226 551,152 551,152 
SNPs from GWAS p < 1 x 10-4 58 95 69 61 98 
SNPs in LD r2 0.8 within 1 Mb 1,341 3,195 2,278 2,084 2,594 
Duplicated SNPs 494 1,276 945 519 1,251 
Final SNPs 847 1,919 1,333 1,565 1,343 
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Regulatory variants for all disease types 
 
GTEx single tissue eQTLs 
 We first determined regulatory variants and their target genes from the data sources that 
contained tissue types other than lung and could be broadly used in the other disease types. 
Initially, we used single tissue eQTLs generated from the GTEx project (66) to identify regulatory 
SNPs. We used the lung tissue eQTL results and identified a set of SNPs that acted as eQTLs for 
COPD (n = 8), N.S. LUAD (n = 2,400), and N.S. LUSC (n = 52). There are two ESCC related 
tissues with eQTLs: esophagus mucosa (EMC) and esophagus muscularis (EMS). We used these 
two tissue types and discovered 438 eQTLs and 560 eQTLs for EMC and EMS, respectively. For 
GC, we used stomach tissue and found 129 eQTLs (Figure 5.1A). The eQTLs found above may 
be acting to control the same gene, so we collapsed all eQTLs to the genes they controlled for the 
final gene sets.  
 
FANTOM transcribed enhancers and their target genes 
 We next determined the SNPs from each disease type that were located within enhancer 
regions of the genome with associated target genes. We used the FANTOM data (73) for the 
enhancer definitions. We used the set of permissive enhancers and their correlated transcribed 
target genes from the Promoter Enhancer Slider Selector Tool (PrESSTo) website (119). We 
discovered the number of enhancers with an associated target gene for each disease type. For the 
lung diseases, we found 1, 104, and 6 enhancers with target genes, for COPD, N.S. LUAD, and 
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N.S. LUSC, respectively. For the non-lung diseases, we found 2 enhancers with target genes for 
GC and 8 enhancers with target genes for ESCC (Figure 5.1B). 
 
 
 
 
Figure 5.1. Regulatory elements discovered in all diseases. Panel A shows the total number of 
single tissue eQTLs discovered in each disease type. We combined the eQTLs for ESCC found in 
two esophageal tissues: EMC and EMS. Panel B shows the number of enhancers with target genes 
that contained SNPs from each disease type. 
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Regulatory variants for lung diseases 
 
GTEx multi-tissue eQTLs 
 Next, we determined the additional regulatory information that could be obtained using the 
lung related diseases. Although, as we demonstrated above, our approach can be used across 
different cancer types, it was designed for a lung disease, and therefore additional data can be 
applied to the lung diseases. The GTEx project identified a set of multi-tissue eQTLs in addition 
to the single tissue eQTLs (for full details see Chapter II). There are no GC or ESCC related tissues 
used in the multi-tissue analysis; therefore, we only used the lung tissue results for COPD, N.S. 
LUAD, and N.S. LUSC. The eQTLs identified in the multi-tissue approach differed from the single 
tissue approach (see Chapter II, Methods), so we plotted the distribution of each set of eQTLs to 
determine a significance threshold. Based upon the distributions, we selected posterior 
probabilities of 0.7 for COPD and N.S. LUAD and 0.8 for N.S. LUSC. As illustrated in Figure 
5.2A, we found 40, 1310, and 101 multi-tissue eQTLs for COPD, N.S. LUAD, and N.S. LUSC, 
respectively. Similar to the single tissue eQTLs, many of these eQTLs controlled the same target 
gene, so we combined all results to their unique target genes for the final gene sets.  
 
Hao et al. lung tissue eQTLs 
 We used a third source of lung eQTLs for our final eQTL dataset for the lung diseases. We 
used the lung tissue eQTLs derived in the study by Hao et al. (110) that is described in Chapter II. 
We only discovered two eQTLs for COPD and N.S. LUSC and only one eQTL for N.S. LUAD.  
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Epigenetically defined enhancers and their predicted target genes 
 We used the data generated using the software IM-PET (72) for two lung related cell lines: 
IMR90 and NHLF. We first used the IMR90 cell line data and discovered 5, 6, and 4 target 
transcripts for COPD, N.S. LUAD, and N.S. LUSC, respectively. We found a greater number of 
target transcripts using the NHLF results for each disease type. Specifically, we found 8 for COPD, 
13 for N.S. LUAD, and 8 for N.S. LUSC. We plotted these results in Figure 5.2B. 
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Figure 5.2. Total number of regulatory elements for lung related diseases. In panel A, we show the 
number of lung tissue eQTLs found from the multi-tissue analysis. For panel B, we show the 
number of enhancer target genes for each lung related disease colored by cell type. 
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Little overlap between the different histological cancer types 
 We next determined the overlap between diseases by utilizing the target genes discovered 
in the regulatory data sets. We first determined the overlap between all cancer types using the 
GTEx single tissue and FANTOM5 data. We used all four cancer types because the two non-lung 
related cancers are the same histological class as the never smoking lung cancer subtypes. 
Histologically, the GCs are adenocarcinomas like LUAD, and the ESCCs are squamous cell 
carcinomas like LUSC. Surprisingly, we discovered there were no single tissue eQTLs or 
FANTOM enhancer targets that were shared among any of the four cancers. We originally 
hypothesized we would see sets of eQTLs and enhancers shared in histologically similar cancer 
types based upon previous evidence that showed some cancers are more similar by histological 
subtype than by tissue-specific cancer type (209). Solely for the lung related diseases, we also 
examined their overlap using the multi-tissue eQTL target genes (Figure 5.3A), and the IM-PET 
combined enhancer target genes (Figure 5.3B). Using the GTEx multi-tissue eQTL target genes, 
we found only one gene that overlapped between COPD and N.S. LUAD and no other genes that 
overlapped between the lung diseases. Our results also indicated that there were no genes from 
IM-PET that overlapped between any of the lung diseases. We did not illustrate the Hao et al. 
eQTL overlap because there are only one or two genes identified for each disease and they do not 
overlap. 
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Figure 5.3. Overlap between lung-related diseases for multi-tissue eQTLs and predicted enhancer 
targets. Panel A shows the overlap between lung tissue eQTLs from GTEx that are active in 
multiple tissue types. Panel B shows the overlap between IM-PET predicted enhancer targets that 
were combined for two lung cell lines: IMR90 and NHLF. 
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Generation of final germline regulated genes for each disease 
 We combined all results from the datasets for each disease type, and removed duplicated 
genes that were discovered using more than one dataset, to obtain the final germline-regulated 
genes. The summary of the final germline-regulated genes per data source is listed in Table 5.5. 
We also determined the overlap between all diseases using these germline-regulated genes (Figure 
5.4). Overall, our final germline gene results indicated very little overlap between disease types. 
 
Table 5.5. Summary of final germline-regulated genes. 
Disease GTEx 
S.T. 
eQTLs 
GTEx 
M.T. 
eQTLs 
Hao et al. 
eQTLs 
FANTOM 
enhancer 
targets 
IM-PET 
combined 
Germline-
regulated 
genes 
COPD 1 5 2 1 5 14 
N.S. LUAD 16 19 1 29 5 48 
N.S. LUSC 4 9 2 4 6 23 
GC 8 NA NA 1 NA 9 
ESCC 28 NA NA 6 NA 34 
S.T. = single tissue. M.T = multi-tissue. 
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Figure 5.4. There is little overlap between all germline-regulated genes for each disease.  
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Discussion 
 
 In this chapter, we demonstrated that we can apply the approach developed in Chapter II 
for lung cancer to other diseases and ethnicities. Although we could not use all of the datasets on 
the non-lung related diseases, we still identified a large set of germline-regulated genes (Table 
5.5). For the lung related diseases, we discovered a set of germline-regulated genes using all of the 
datasets from Chapter II. 
 We first identified a set of target genes using the single tissue eQTL results from GTEx. 
Surprisingly, we observed no overlap between the eQTLs identified in each cancer type with any 
other cancer type. Also, we did not observe any single tissue eQTLs that overlapped between 
COPD and the two never smoking lung cancer subtypes. These results are intriguing because it 
suggests that even though these subtypes are of the same histology (GC and N.S. LUAD, ESCC 
and N.S. LUSC), or the same cancer type (N.S. LUAD and N.S. LUSC), they may not share 
common regulatory mechanisms at the single tissue eQTL level. Next, we determined the overlap 
between all cancer subtypes and their FANTOM5 defined enhancer target genes. Similar to the 
eQTL results, we did not observe any overlap between any subtypes. This lack of overlap between 
regulatory elements is surprising because in Chapter II, we observed at least some overlap between 
lung cancer subtypes. However, in Chapter II, we had many more eQTLs and target genes to 
compare. 
 Next, we focused on the lung specific diseases where we could obtain more results using 
our lung-specific regulatory datasets. First, we used the GTEx multi-tissue eQTL data to find lung 
tissue eQTLs that are active in multiple tissues. We determined the overlap between the three lung 
diseases, and we found that one gene overlapped between COPD and N.S. LUAD: LINC01137. 
 143 
 
Second, we identified predicted enhancer targets from two lung related cell lines using IM-PET. 
We discovered that no target genes were shared between any of the lung diseases. This is an 
interesting result and, combined with the lack of overlap of enhancers from FANTOM, may 
indicate separate regulatory programs for each lung disease. 
 Finally, we determined the overlap between all diseases using the final sets of germline-
regulated genes. This comparison revealed some interesting overlapping genes. For example, we 
found that ESCC had two genes, from a single genomic region, HLA-DQA1 and HLA-DQB2, 
which overlapped N.S. LUAD and none that overlapped N.S. LUSC. This is surprising because 
these two subtypes are of different histologies. We hypothesized that we would see overlap 
between different cancer types of the same histology, but we did not observe that with these results. 
Intriguingly, we found one gene that overlapped between GC and ESCC: NOC3L. The original 
publication by Abnet et al. (206) reported one gene that was shared between both subtypes: 
PLCE1. This finding was reported because of SNPs within the genic region. However, our analysis 
also discovered several SNPs within PLCE1, but they are eQTLs for a more distant gene NOC3L. 
This finding suggests that the original study may have reported the wrong affected gene that was 
shared between subtypes. This is one example of how we used the approach from Chapter II to 
discover new biology that may contribute to two non-lung cancer types. 
 Although we found several germline-regulated genes using our approach, there are several 
limitations. First, we did not identify enough genes to perform any more meaningful analyses, such 
as pathway analyses, as we did in Chapter II. We hypothesize this is because we used a more 
stringent p-value here (p < 1 x 10-4) instead of the cutoff used in Chapter II (p < 1 x 10-3). In future 
studies using this approach, it is advised to use the second p-value threshold for more meaningful 
results. Second, it is difficult to obtain a set of GWAS values at the above threshold. Although 
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many times the data can be requested from repositories such as dbGaP (207), it is more difficult 
to obtain than thresholds such as p < 1 x 10-4 that may be reported in supplemental tables (96). 
Third, we relied on datasets that have their own limitations. Although GTEx uses > 70 samples 
per tissue for their eQTL analyses, more results could be obtained with greater sample sizes. 
Therefore, we may have used incomplete sets of eQTLs. Additionally, we rely on regulatory 
features that are generated for either tissue-wide data or for cell-lines. Since many different cell 
types make up each tissue, there may be noise in the datasets from this heterogeneity of cells types. 
Fourth, we are limited in the application of our approach to non-lung related disease types. 
Although we found an interesting result with the GC and ESCC subtypes, we did not have the 
same sensitivity as the lung-related diseases because of the limitation with the datasets. However, 
if GTEx expands their multi-tissue analysis to more tissue types, future work can be completed 
outside of lung tissue. 
 In conclusion, we utilized the pipeline and approach from Chapter II on non-lung cancer 
GWAS results. We demonstrated that the approach identified regulatory variants and their 
corresponding germline-regulated in non-lung cancer samples. We identified a shared germline-
regulated gene between GC and ESCC that may have been missed in the original study. We also 
discussed several limitations to our results. Overall, we discovered that our approach to the 
determination of regulatory variants from GWA studies and the identification of their target genes 
is applicable across disease types and population types, but caution remains. Approaches like this 
are needed to help unravel the unknown nature of many non-coding variants found in GWAS for 
many phenotypes, which currently is a challenging but important research topic. 
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CHAPTER VI 
 
CONCLUSION 
 
 In this dissertation, I discussed my work studying the germline and somatic genomes in 
three subtypes of lung cancer, as well as some extended work for other cancer types and lung 
diseases. Although previous studies have investigated single lung cancer subtypes on a germline 
or somatic level (see Chapter I, Introduction), it is not well understood how to integrate these 
findings. Additionally, due to different study designs and methodologies, it has been difficult to 
systematically compare the different subtypes of lung cancer amongst each other. My aims in this 
thesis work were to perform exhaustive interrogations of both genomes across lung 
adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and small cell lung cancer 
(SCLC). In addition to studying each subtype alone and in one genome (somatic or germline), I 
determined overlaps that exist across genomes and subtypes. This integrative analysis approach is 
important because outside of environmental hazards, the causal factors behind the genetic basis of 
lung cancer remain largely unknown. Therefore, I used a combination of genetics and functional 
genomics to study both genomes. 
In Chapter II, I developed novel approaches to interrogate non-coding variants associated 
with lung cancer. Specifically, I used a functional genomics approach to identify regulatory 
variants in each subtype. Interestingly, I found that on a single nucleotide polymorphism (SNP) 
level, the subtypes are quite distinct from each other. Through the identification of regulatory 
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variants and their target genes, I found that this lack of overlap extended beyond the SNP level 
and this observation will be discussed below. 
In Chapter III, I used DNA sequencing (WES) and RNA-Sequencing (RNA-Seq) to 
explore the differences in the subtypes at the somatic level. This analysis also revealed an overall 
lack of overlap between subtypes, but not as severe as at the germline level. I used RNA-Seq data 
to generate a set of genes that were differentially expressed in the tumor-versus-normal tissue for 
each subtype. These differentially expressed genes showed different patterns of overlap in the 
subtypes based upon up-regulation or down-regulation. I also identified a set of mutational 
signatures in each subtype and sets of potential driver genes. 
In Chapter IV, I explored the accessibility of calling somatic variants from RNA-Seq data 
in lung cancer and identified the biological and technical reasons for inconsistencies in calling 
these variants in WES versus RNA-Seq. In this chapter, I performed a deep investigation into the 
feasibility of generating a set of somatic single nucleotide variants (SNVs) in RNA-Seq that is 
equal to SNVs called in whole exome sequencing (WES). The results in Chapter IV provided a 
greater understanding of the limitations to using this approach to call variants. I found that RNA-
Seq can be used to call variants, but many caveats exist that need to be carefully considered.  
In Chapter V, I applied the approaches from Chapter II on GWA studies for other disease 
types and populations. In this chapter, I performed the same analysis that was done in Chapter II 
in order to demonstrate the transferability of the approach. I illustrated that the same approach can 
be applied, with some small changes for non-lung related diseases, to GWAS for many different 
diseases and ethnicities. 
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Below, I highlight some intriguing discoveries found in the overall analyses and their 
contribution to the research field of lung cancer. 
 
Filling in the knowledge gap for GWAS variants 
 Many of the GWA studies introduced in Chapter I identified common variants located 
within non-coding regions of the genome. The interpretation of these variants remains challenging 
because it is not easy to identify the genes that may be affected by these variants. Additionally, 
past work (68) has demonstrated that non-coding GWAS variants are enriched for regulatory 
function. Lung cancer is one of these diseases where more significantly associated variants from 
GWA studies were in non-coding regions rather than in coding regions of the genome (52). The 
lack of insight into the biological mechanisms behind these variants has left many questions about 
the biology of lung cancer from the germline perspective unanswered. However, in Chapter II of 
this work, I used several lung-related eQTL and enhancer datasets to investigate the role of GWAS 
results for lung cancer and their LD SNPs in regulatory regions of the genome. I also determined 
the target genes for these regulatory SNPs (see Chapter II). These results indicated that some of 
these variants were acting in regulatory roles in the genome that control expression on one or 
several target genes. Specifically, I found that these variants act as SNPs in the eQTLs that control 
the gene’s expression, known as expression SNPs (eSNPs), and are also located within enhancer 
regions of the genome. Additionally, the identification of the target genes of these regulatory SNPs 
generated a set of targets that could be explored in future experimental studies. These results 
suggested that many common variants associated with all three lung cancer subtypes are in control 
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of genes with already established roles in lung cancer, such as CHRNA5, IDH3A, and PSMA4 
which were identified as target genes of regulatory variants in every subtype.  
 
The weak overlap between all three subtypes at the germline and somatic 
genomes 
 
 One discovery from this work was that across both genomes, there was a lack of overlap 
between all three lung cancer subtypes at the gene-level. Although histological analysis and cell 
type studies group these three lung cancers into distinct subtypes, they are all derived from lung 
tissue (210). Therefore, I originally hypothesized that there would be moderate overlap of the three 
subtypes. However, I discovered that across genomes and biological factors, many of the genes 
discovered in each subtype were not shared by the other two subtypes (see Chapter II and Chapter 
III). 
 I first observed the weak overlap between LUAD, LUSC, and SCLC in the germline 
genome using lung cancer GWAS results at p < 1 x 10-3. I found that only 10 SNPs (< 1%) 
overlapped all three subtypes even though each subtype had over 500 significant SNPs (see 
Chapter II). I further identified sets of germline genes that were the targets of the regulatory SNPs 
for each subtype and again found weak overall overlap and only observed one independent region 
on 15q25 that overlapped all subtypes. This region contained five germline-regulated genes that 
may be contributing risk for lung cancer independent of subtype.  
I next observed the overlap between subtypes at the somatic level. First, I identified sets of 
DEGs that were down-regulated and up-regulated in somatic lung tumor tissue compared to normal 
lung tissue in each subtype. Although 554 up-regulated DEGs overlapped all three subtypes, there 
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were still 442, 850, and 575 unique up-regulated DEGs for LUAD, LUSC, and SCLC, 
respectively. Fewer down-regulated genes overlapped all three subtypes (325), but there were also 
fewer DEGs detected overall. For both sets of DEGs, only ~ 14% of all DEGs were shared between 
all three subtypes. At the somatic mutation level, I first identified the three most significant 
mutational signatures for each subtype. Only one mutational signature (COSMIC signature 4) was 
shared between the subtypes. This mutational signature is most associated with tobacco 
mutagenesis (149). However, LUSC had Signature 13 in common with LUAD. This signature has 
been found in many cervical and bladder cancer types (7), suggesting that these subtypes may 
share functions or regulation with other cancer types. Additionally, signature 5 was shared between 
LUAD and SCLC. This signature has been found in all cancer types and exhibits T>C substitutions 
(7). I also generated a set of potential driver genes, and found that at two different thresholds, I 
found many potential driver genes unique to each subtype and only ~13% of all potential driver 
genes overlapped all three subtypes (see Chapter III). Overall, although there was a lack of strong 
overlap in the somatic genome for all three subtypes, it was not nearly as strong as the overlap 
between all three subtypes at the germline level. 
 
Linking acetylcholine receptors from the germline to somatic genomes 
 Several genomic studies (53, 116) have identified the region of 15q25 to be associated with 
multiple subtypes of lung cancer (for full discussion, see Chapter I). However, most of the variants 
were located within non-coding regions of the genome and in the vicinity of a closely related set 
of genes. These genes comprise a set of nicotinic cholinergic receptor (CHRNA) genes. Debate 
has ensued about this region’s role in lung cancer risk from a genetic versus environmental 
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perspective (128). However, using the combined results of Chapters II and III, one can gain insight 
into this region’s role in lung cancer. For example, I found several regulatory SNPs within this 
genomic region for all three subtypes. However, through my regulatory functional genomics 
approach, I identified the affected gene from these regulatory SNPs as CHRNA5. The results from 
the somatic DEG analysis further validated this finding. I discovered that CHRNA5 is up-regulated 
3.64, 3.22, and 2.52 log fold in LUAD, LUSC, and SCLC tumor tissue compared to normal lung 
tissue. This finding expands the previous knowledge about this gene’s role at the germline level 
and extends it to the somatic level. To further validate CHRNA5 as the probable target of common 
variants, I used the DEG results to investigate another CHRNA gene that has also been implicated 
at the germline level, CHRNA3. I searched the DEG results and found that although CHRNA3 is 
up-regulated in SCLC, it is not significantly up-regulated in LUSC or LUAD. In this situation, it 
was crucial to compare across the subtypes rather than just studying SCLC because identifying 
CHNRA3 only in SCLC suggests that CHRNA5 is probably the correct target. However, the 
possibility still remains that CHRNA3 is also acting solely in SCLC. Although CHRNA5 has not 
garnered much attention at the somatic level, this finding suggests it may be beneficial to explore 
the biology behind acetylcholine receptors (ACRs) in cancer in more detail. 
  
Shared pathways across germline and somatic genomes (using gene sets) 
 I combined the pathways between the germline and somatic genomes in each subtype to 
identify biological pathways perturbed in both genomes. Ignoring any overlap between other 
subtypes, I looked at the number of pathways identified in each subtype from the germline genome 
and from the somatic genome. For the germline genome, I used the germline-regulated genes in 
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each subtype, and for the somatic genome, I used the combined up-regulated and down-regulated 
DEGs. I did not filter the pathways for the germline-regulated genes because I did not have very 
large gene sets. However, for the somatic DEGs, I filtered out pathways that contained less than 
five DEGs. I found that four pathways are enriched with genes from both genomes for LUAD. For 
LUSC, I found that 18 pathways overlap the germline genome and somatic genome. Finally, for 
SCLC, I observed that three pathways overlapped both genomes. These final pathways are listed 
in Table 6.1. Interestingly, many of these pathways do not have immediate relations with cancer. 
Therefore, future studies may look to these pathways as guidance for the exploration of biological 
pathways associated with each cancer type. The evidence from both genomes gives moderate 
expectations that these pathways may be important in each cancer subtype. 
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    Table 6.1. Final overlap in enriched KEGG biological pathways shared in the germline and somatic genomes. 
LUAD LUSC SCLC 
Metabolic pathways Staphylococcus aureus infection Metabolic pathways 
Tight junction Asthma Retinol metabolism 
Endocytosis Antigen processing and presentation Focal adhesion 
Focal adhesion Graft-versus-host disease  
 Intestinal immune network for IgA production  
 Viral myocarditis  
 Leishmaniasis  
 Rheumatoid arthritis  
 Phagosome  
 Toxoplasmosis  
 Systemic lupus erythematosus  
 Cell adhesion molecules (CAMs)  
 Metabolic pathways  
 Jak-STAT signaling pathway  
 Pathways in cancer  
 NOD-like receptor signaling pathway  
 Complement and coagulation cascades  
 Hematopoietic cell lineage  
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Future directions 
 For each part of this work there are several follow up analyses that could be explored. 
However, I think that the most interesting future studies would involve the possible biological 
interactions and relationships between the germline and somatic genomes in each lung cancer 
subtype. Although this work only highlighted a few aspects of how the germline and somatic 
genomes may work together in lung cancer, there are specific follow up studies that may reveal 
closer interactions.  
One particular method that can be used is EW_dmGWAS (139). This is a network-based 
method that can be used to integrate both genomes. EW_dmGWAS uses the germline and somatic 
genomes with a protein-protein interaction (PPI) network to help identify sets of closely related 
genes from both genomes. This method uses GWAS genome-wide gene-level p-values to weigh 
each node in the network. It uses differential expression values at the somatic level to weigh the 
edges in the network. The algorithm identifies closely related modules in the network. This is one 
way that a network can be used to combine both genomes. Several iterations can be used for this 
analysis because many tools exist to generate gene-level p-values. For example, instead of using 
proximity to the SNP to generate a gene-level p-value that is done in tools such as Versatile Gene-
based Association Study (VEGAS) (211), newer approaches such as MetaXcan (212) can be used. 
MetaXcan generates a gene-level p-value based upon predicted gene expression using quantitative 
trait loci (eQTLs) derived from the GWAS SNPs. Using these values in the network may generate 
more biologically accurate results since I hypothesized, and confirmed, that many of the lung 
cancer GWAS variants are regulatory (Chapter II).  
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Finally, future studies can expand upon the biological pathways discovered in this work. 
The pathways I discovered were identified using a set of genes that were already filtered due to 
their potential role in disease. However, this can be expanded upon to generate pathways identified 
from all SNPs in the GWAS (213) and all genes in the somatic genome (214). This larger unbiased 
approach may identify additional genes that are closely associated, and may function together, in 
both genomes. 
 
Concluding remarks 
This dissertation’s deep interrogation into the molecular differences between three 
histologically distinct lung cancers suggested several potential shared and distinct mechanisms of 
disease. Although this dissertation focused on comparing the subtypes of lung cancer, these 
methods can easily be extended to other cancer types. This insight into biological differences 
between cancers that arise in the same organ, but of different cell types (210), will be of greater 
importance as sequencing technologies become more accessible and affordable to all patients 
(http://www.businesswire.com/news/home/20170109006363/en/), as we are entering to the era of 
the $100 per genome sequencing. New initiatives such as the Precision Medicine Initiative (PMI) 
(https://www.nih.gov/research-training/allofus-research-program) will generate large diverse 
genomic datasets that will help to unravel the mysteries and inner workings of the genome.  
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APPENDIX 
 
Appendix A. Locus level analyses for germline-regulated genes discovered in Chapter II. 
A.1. Independent locus level analysis for LUAD unique. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 41 14 25 
GTEx multi-tissue eQTL in lung > 0.80 43 18 28 
GTEx combined 66 18 37 
Hao single tissue lung eQTL 23 12 18 
FANTOM5 enhancer target gene 31 12 15 
IM-PET IMR90 43 12 20 
IM-PET NHLF 80 15 28 
IM-PET combined 105 16 34 
All genes 193 21 69 
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A.2. Independent locus level analysis for LUSC unique. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 47 14 23 
GTEx multi-tissue eQTL in lung > 0.80 72 18 36 
GTEx combined 95 18 42 
Hao single tissue lung eQTL 26 9 17 
FANTOM5 enhancer target gene 63 13 16 
IM-PET IMR90 59 16 27 
IM-PET NHLF 110 16 28 
IM-PET combined 150 18 37 
All genes 287 19 71 
 
 
 
 
A.3. Independent locus level analysis for SCLC unique. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 29 13 25 
GTEx multi-tissue eQTL in lung > 0.80 45 14 30 
GTEx combined 56 16 37 
Hao single tissue lung eQTL 10 6 10 
FANTOM5 enhancer target gene 30 12 15 
IM-PET IMR90 32 13 21 
IM-PET NHLF 56 13 29 
IM-PET combined 77 16 38 
All genes 154 20 69 
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A.4. Independent locus level analysis for LUAD overlap LUSC. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 0 0 0 
GTEx multi-tissue eQTL in lung > 0.80 2 2 2 
GTEx combined 2 2 2 
Hao single tissue lung eQTL 1 1 1 
FANTOM5 enhancer target gene 5 2 2 
IM-PET IMR90 2 2 2 
IM-PET NHLF 7 3 3 
IM-PET combined 7 3 3 
All genes 16 6 6 
 
 
 
 
A.5. Independent locus level analysis for LUAD overlap SCLC. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 0 0 0 
GTEx multi-tissue eQTL in lung > 0.80 0 0 0 
GTEx combined 0 0 0 
Hao single tissue lung eQTL 0 0 0 
FANTOM5 enhancer target gene 0 0 0 
IM-PET IMR90 0 0 0 
IM-PET NHLF 1 1 1 
IM-PET combined 1 1 1 
All genes 1 1 1 
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A.6. Independent locus level analysis for LUSC overlap SCLC. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 4 2 2 
GTEx multi-tissue eQTL in lung > 0.80 4 2 2 
GTEx combined 8 3 3 
Hao single tissue lung eQTL 2 1 1 
FANTOM5 enhancer target gene 0 0 0 
IM-PET IMR90 1 1 1 
IM-PET NHLF 2 1 1 
IM-PET combined 2 2 2 
All genes 12 5 5 
 
 
 
 
A.7. Independent locus level analysis for ALL OVERLAP. 
Regulatory category # unique genes # chromosomes # total unique regions 
GTEx single tissue V6 Lung eQTL 2 1 1 
GTEx multi-tissue eQTL in lung > 0.80 3 1 1 
GTEx combined 3 1 1 
Hao single tissue lung eQTL 0 0 0 
FANTOM5 enhancer target gene 0 0 0 
IM-PET IMR90 0 0 0 
IM-PET NHLF 2 1 1 
IM-PET combined 2 1 1 
All genes 5 1 1 
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Appendix B. Final germline-regulated genes and overlap at GWAS SNP p < 1 x 10-4. Below 
illustrates the set of final germline-regulated genes discovered using the more stringent p < 1 x 10-
4. The overall lack of overlap between subtypes is consistent with results at the more lenient 
threshold used in Chapter 2. 
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Appendix C. Summary of the down-regulated somatic DEGs discovered in Chapter 3 that are 
TSGs. TSGs were defined according to TSGene Database (156). 
C.1. LUAD unique TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
DACH1 dachshund family transcription 
factor 1 
protein-coding 
DCC DCC netrin 1 receptor protein-coding 
GPC3 glypican 3 protein-coding 
MME membrane metallo-
endopeptidase 
protein-coding 
PACRG PARK2 co-regulated protein-coding 
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C.2. LUSC unique TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
ADARB1 adenosine deaminase, RNA-
specific, B1 
protein-coding 
CYB5A cytochrome b5 type A 
(microsomal) 
protein-coding 
ERBB4 erb-b2 receptor tyrosine kinase 
4 
protein-coding 
FOXA2 forkhead box A2 protein-coding 
LIFR leukemia inhibitory factor 
receptor alpha 
protein-coding 
NFATC2 nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 2 
protein-coding 
NTRK3 neurotrophic tyrosine kinase, 
receptor, type 3 
protein-coding 
PGR progesterone receptor protein-coding 
SEPT4 septin 4 protein-coding 
SPTBN1 spectrin, beta, non-erythrocytic 
1 
protein-coding 
LEFTY2 left-right determination factor 2 protein-coding 
SEMA3B sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3B 
protein-coding 
NR0B2 nuclear receptor subfamily 0, 
group B, member 2 
protein-coding 
RECK reversion-inducing-cysteine-rich 
protein with kazal motifs 
protein-coding 
AKAP12 A kinase (PRKA) anchor protein 
12 
protein-coding 
RASSF2 Ras association (RalGDS/AF-6) 
domain family member 2 
protein-coding 
CADM1 cell adhesion molecule 1 protein-coding 
PCDH17 protocadherin 17 protein-coding 
ZMYND10 zinc finger, MYND-type 
containing 10 
protein-coding 
DCDC2 doublecortin domain containing 
2 
protein-coding 
CASC1 cancer susceptibility candidate 
1 
protein-coding 
FAT4 FAT atypical cadherin 4 protein-coding 
MFSD2A major facilitator superfamily 
domain containing 2A 
protein-coding 
CABLES1 Cdk5 and Abl enzyme substrate 
1 
protein-coding 
MIA2 melanoma inhibitory activity 2 protein-coding 
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SLC5A8 solute carrier family 5 
(sodium/monocarboxylate 
cotransporter), member 8 
protein-coding 
MIRLET7F1 microRNA let-7f-1 ncRNA 
MIR126 microRNA 126 ncRNA 
MIR135A2 microRNA 135a-2 ncRNA 
MIR142 microRNA 142 ncRNA 
MIR26A1 microRNA 26a-1 ncRNA 
MIR326 microRNA 326 ncRNA 
VTRNA2-1 vault RNA 2-1 ncRNA 
ADAMTS9-AS2 ADAMTS9 antisense RNA 2 ncRNA 
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C.3. SCLC unique TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
ADPRH ADP-ribosylarginine hydrolase protein-coding 
AHR aryl hydrocarbon receptor protein-coding 
AIF1 allograft inflammatory factor 1 protein-coding 
FAS Fas cell surface death receptor protein-coding 
ARG1 arginase 1 protein-coding 
RHOB ras homolog family member B protein-coding 
ATF3 activating transcription factor 3 protein-coding 
ZFP36L2 ZFP36 ring finger protein-like 2 protein-coding 
CASP5 caspase 5, apoptosis-related 
cysteine peptidase 
protein-coding 
CD4 CD4 molecule protein-coding 
CD44 CD44 molecule (Indian blood 
group) 
protein-coding 
CEBPD CCAAT/enhancer binding 
protein (C/EBP), delta 
protein-coding 
CNN1 calponin 1, basic, smooth 
muscle 
protein-coding 
MAP3K8 mitogen-activated protein 
kinase kinase kinase 8 
protein-coding 
CSF2 colony stimulating factor 2 
(granulocyte-macrophage) 
protein-coding 
CST6 cystatin E/M protein-coding 
CTGF connective tissue growth factor protein-coding 
DAB2 Dab, mitogen-responsive 
phosphoprotein, homolog 2 
(Drosophila) 
protein-coding 
DCN decorin protein-coding 
DPP4 dipeptidyl-peptidase 4 protein-coding 
DUSP6 dual specificity phosphatase 6 protein-coding 
EGR2 early growth response 2 protein-coding 
EPHA2 EPH receptor A2 protein-coding 
EMP1 epithelial membrane protein 1 protein-coding 
ESR1 estrogen receptor 1 protein-coding 
HIC1 hypermethylated in cancer 1 protein-coding 
IGF1 insulin-like growth factor 1 
(somatomedin C) 
protein-coding 
IGFBP4 insulin-like growth factor 
binding protein 4 
protein-coding 
IRF1 interferon regulatory factor 1 protein-coding 
IRF5 interferon regulatory factor 5 protein-coding 
ITGA5 integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide) 
protein-coding 
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MSMB microseminoprotein, beta- protein-coding 
MT2A metallothionein 2A protein-coding 
PLCD1 phospholipase C, delta 1 protein-coding 
PPARG peroxisome proliferator-
activated receptor gamma 
protein-coding 
PRKCD protein kinase C, delta protein-coding 
PRODH proline dehydrogenase 
(oxidase) 1 
protein-coding 
KLK10 kallikrein-related peptidase 10 protein-coding 
PTGDR prostaglandin D2 receptor (DP) protein-coding 
PTPN13 protein tyrosine phosphatase, 
non-receptor type 13 (APO-
1/CD95 (Fas)-associated 
phosphatase) 
protein-coding 
PTPRC protein tyrosine phosphatase, 
receptor type, C 
protein-coding 
S100A11 S100 calcium binding protein 
A11 
protein-coding 
CXCL12 chemokine (C-X-C motif) ligand 
12 
protein-coding 
SOD2 superoxide dismutase 2, 
mitochondrial 
protein-coding 
SP100 SP100 nuclear antigen protein-coding 
TAGLN transgelin protein-coding 
TGFB1 transforming growth factor, 
beta 1 
protein-coding 
THBS1 thrombospondin 1 protein-coding 
TNFAIP3 tumor necrosis factor, alpha-
induced protein 3 
protein-coding 
VIM vimentin protein-coding 
ZNF185 zinc finger protein 185 (LIM 
domain) 
protein-coding 
ZYX zyxin protein-coding 
SRPX sushi-repeat containing protein, 
X-linked 
protein-coding 
TNFSF9 tumor necrosis factor (ligand) 
superfamily, member 9 
protein-coding 
TNFRSF10B tumor necrosis factor receptor 
superfamily, member 10b 
protein-coding 
IER3 immediate early response 3 protein-coding 
LIMD1 LIM domains containing 1 protein-coding 
SOCS3 suppressor of cytokine signaling 
3 
protein-coding 
DLEC1 deleted in lung and esophageal 
cancer 1 
protein-coding 
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CTDSPL CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide 
A) small phosphatase-like 
protein-coding 
SPRY2 sprouty homolog 2 (Drosophila) protein-coding 
YAP1 Yes-associated protein 1 protein-coding 
ARL6IP5 ADP-ribosylation factor-like 6 
interacting protein 5 
protein-coding 
TXNIP thioredoxin interacting protein protein-coding 
PLA2G16 phospholipase A2, group XVI protein-coding 
RASSF8 Ras association (RalGDS/AF-6) 
domain family (N-terminal) 
member 8 
protein-coding 
PHLDA3 pleckstrin homology-like 
domain, family A, member 3 
protein-coding 
LATS2 large tumor suppressor kinase 2 protein-coding 
DKK3 dickkopf WNT signaling 
pathway inhibitor 3 
protein-coding 
PYCARD PYD and CARD domain 
containing 
protein-coding 
G0S2 G0/G1 switch 2 protein-coding 
TNFRSF12A tumor necrosis factor receptor 
superfamily, member 12A 
protein-coding 
ERRFI1 ERBB receptor feedback 
inhibitor 1 
protein-coding 
HRASLS2 HRAS-like suppressor 2 protein-coding 
LXN latexin protein-coding 
ADAMTS9 ADAM metallopeptidase with 
thrombospondin type 1 motif, 9 
protein-coding 
NDRG2 NDRG family member 2 protein-coding 
MTUS1 microtubule associated tumor 
suppressor 1 
protein-coding 
ZBTB4 zinc finger and BTB domain 
containing 4 
protein-coding 
EDA2R ectodysplasin A2 receptor protein-coding 
LRRC4 leucine rich repeat containing 4 protein-coding 
BHLHE41 basic helix-loop-helix family, 
member e41 
protein-coding 
TNFAIP8L2 tumor necrosis factor, alpha-
induced protein 8-like 2 
protein-coding 
CREB3L1 cAMP responsive element 
binding protein 3-like 1 
protein-coding 
CYGB cytoglobin protein-coding 
JDP2 Jun dimerization protein 2 protein-coding 
SIK1 salt-inducible kinase 1 protein-coding 
SYNPO2 synaptopodin 2 protein-coding 
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SAMD9L sterile alpha motif domain 
containing 9-like 
protein-coding 
SGMS1 sphingomyelin synthase 1 protein-coding 
HCAR2 hydroxycarboxylic acid receptor 
2 
protein-coding 
RASL11A RAS-like, family 11, member A protein-coding 
PTPLAD2 protein tyrosine phosphatase-
like A domain containing 2 
protein-coding 
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C.4. LUAD overlap LUSC TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
CDO1 cysteine dioxygenase type 1 protein-coding 
PCDH9 protocadherin 9 protein-coding 
SFRP5 secreted frizzled-related protein 
5 
protein-coding 
SLIT2 slit homolog 2 (Drosophila) protein-coding 
CMTM5 CKLF-like MARVEL 
transmembrane domain 
containing 5 
protein-coding 
MIR223 microRNA 223 ncRNA 
MIR23A microRNA 23a ncRNA 
MIR27A microRNA 27a ncRNA 
MIR34C microRNA 34c ncRNA 
 
 
 
 
C.5. LUAD overlap SCLC TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
ALOX15 arachidonate 15-lipoxygenase protein-coding 
THBD thrombomodulin protein-coding 
WNT7A wingless-type MMTV 
integration site family, member 
7A 
protein-coding 
KLF4 Kruppel-like factor 4 (gut) protein-coding 
ABCG2 ATP-binding cassette, sub-
family G (WHITE), member 2 
(Junior blood group) 
protein-coding 
THSD1 thrombospondin, type I, domain 
containing 1 
protein-coding 
AHNAK AHNAK nucleoprotein protein-coding 
SOX7 SRY (sex determining region Y)-
box 7 
protein-coding 
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C.6. LUSC overlap SCLC TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
ALOX15B arachidonate 15-lipoxygenase, 
type B 
protein-coding 
ALPL alkaline phosphatase, 
liver/bone/kidney 
protein-coding 
BMP2 bone morphogenetic protein 2 protein-coding 
BTK Bruton agammaglobulinemia 
tyrosine kinase 
protein-coding 
CAT catalase protein-coding 
CFTR cystic fibrosis transmembrane 
conductance regulator (ATP-
binding cassette sub-family C, 
member 7) 
protein-coding 
KLF6 Kruppel-like factor 6 protein-coding 
CST5 cystatin D protein-coding 
DAPK1 death-associated protein kinase 
1 
protein-coding 
DMBT1 deleted in malignant brain 
tumors 1 
protein-coding 
DUSP1 dual specificity phosphatase 1 protein-coding 
EGR1 early growth response 1 protein-coding 
FABP3 fatty acid binding protein 3, 
muscle and heart 
protein-coding 
FBP1 fructose-1,6-bisphosphatase 1 protein-coding 
GPC5 glypican 5 protein-coding 
NR4A1 nuclear receptor subfamily 4, 
group A, member 1 
protein-coding 
HPGD hydroxyprostaglandin 
dehydrogenase 15-(NAD) 
protein-coding 
IGFALS insulin-like growth factor 
binding protein, acid labile 
subunit 
protein-coding 
GADD45B growth arrest and DNA-
damage-inducible, beta 
protein-coding 
PF4 platelet factor 4 protein-coding 
PLA2G2A phospholipase A2, group IIA 
(platelets, synovial fluid) 
protein-coding 
PRKCE protein kinase C, epsilon protein-coding 
RPS6KA2 ribosomal protein S6 kinase, 
90kDa, polypeptide 2 
protein-coding 
SPI1 Spi-1 proto-oncogene protein-coding 
TBX5 T-box 5 protein-coding 
TGFBR2 transforming growth factor, 
beta receptor II (70/80kDa) 
protein-coding 
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TIMP3 TIMP metallopeptidase inhibitor 
3 
protein-coding 
ZFP36 ZFP36 ring finger protein protein-coding 
SPARCL1 SPARC-like 1 (hevin) protein-coding 
TNFSF12 tumor necrosis factor (ligand) 
superfamily, member 12 
protein-coding 
ALDH1A2 aldehyde dehydrogenase 1 
family, member A2 
protein-coding 
SELENBP1 selenium binding protein 1 protein-coding 
DOK2 docking protein 2, 56kDa protein-coding 
GPRC5A G protein-coupled receptor, 
class C, group 5, member A 
protein-coding 
ARHGAP29 Rho GTPase activating protein 
29 
protein-coding 
TSPAN32 tetraspanin 32 protein-coding 
CITED2 Cbp/p300-interacting 
transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2 
protein-coding 
RHOBTB2 Rho-related BTB domain 
containing 2 
protein-coding 
SASH1 SAM and SH3 domain 
containing 1 
protein-coding 
HSPB7 heat shock 27kDa protein 
family, member 7 
(cardiovascular) 
protein-coding 
RBMS3 RNA binding motif, single 
stranded interacting protein 3 
protein-coding 
WFDC1 WAP four-disulfide core domain 
1 
protein-coding 
SPRY4 sprouty homolog 4 (Drosophila) protein-coding 
HOPX HOP homeobox protein-coding 
SCGB3A1 secretoglobin, family 3A, 
member 1 
protein-coding 
GATA5 GATA binding protein 5 protein-coding 
SHISA3 shisa family member 3 protein-coding 
ZNF366 zinc finger protein 366 protein-coding 
GKN2 gastrokine 2 protein-coding 
BCL6B B-cell CLL/lymphoma 6, 
member B 
protein-coding 
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C.7. All overlap TSGs from somatic down-regulated DEGs. 
Gene Symbol Description Gene class 
AGTR1 angiotensin II receptor, type 1 protein-coding 
CAV1 caveolin 1, caveolae protein, 
22kDa 
protein-coding 
CDH5 cadherin 5, type 2 (vascular 
endothelium) 
protein-coding 
EDNRB endothelin receptor type B protein-coding 
EMP2 epithelial membrane protein 2 protein-coding 
EPAS1 endothelial PAS domain protein 
1 
protein-coding 
FHL1 four and a half LIM domains 1 protein-coding 
GPX3 glutathione peroxidase 3 
(plasma) 
protein-coding 
CXCR2 chemokine (C-X-C motif) 
receptor 2 
protein-coding 
MT1M metallothionein 1M protein-coding 
TGFBR3 transforming growth factor, 
beta receptor III 
protein-coding 
ZBTB16 zinc finger and BTB domain 
containing 16 
protein-coding 
NR4A3 nuclear receptor subfamily 4, 
group A, member 3 
protein-coding 
KL klotho protein-coding 
DLC1 DLC1 Rho GTPase activating 
protein 
protein-coding 
ADAMTS8 ADAM metallopeptidase with 
thrombospondin type 1 motif, 8 
protein-coding 
WIF1 WNT inhibitory factor 1 protein-coding 
DAPK2 death-associated protein kinase 
2 
protein-coding 
CSRNP1 cysteine-serine-rich nuclear 
protein 1 
protein-coding 
C2orf40 chromosome 2 open reading 
frame 40 
protein-coding 
STARD13 StAR-related lipid transfer 
(START) domain containing 13 
protein-coding 
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Appendix D. Summary of the up-regulated somatic DEGs discovered in Chapter 3 that are 
oncogenes. Oncogenes were defined based upon the ONGene database (5). 
 
D.1. LUAD unique oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
WISP1 WNT1 inducible signaling 
pathway protein 1 
protein-coding 
WNT3 wingless-type MMTV 
integration site family member 
3 
protein-coding 
MUC4 mucin 4, cell surface associated protein-coding 
MIR135B microRNA 135b ncRNA 
FHL2 four and a half LIM domains 2 protein-coding 
CDH17 cadherin 17 protein-coding 
LCN2 lipocalin 2 protein-coding 
ADAM28 ADAM metallopeptidase 
domain 28 
protein-coding 
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D.2. LUSC unique oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
SMO smoothened, frizzled class 
receptor 
protein-coding 
MOS v-mos Moloney murine sarcoma 
viral oncogene homolog 
protein-coding 
TP63 tumor protein p63 protein-coding 
WNT10A wingless-type MMTV 
integration site family member 
10A 
protein-coding 
ZNF703 zinc finger protein 703 protein-coding 
CT45A1 cancer/testis antigen family 45, 
member A1 
protein-coding 
LMX1B LIM homeobox transcription 
factor 1 beta 
protein-coding 
MAFA v-maf avian 
musculoaponeurotic 
fibrosarcoma oncogene 
homolog A 
protein-coding 
JUP junction plakoglobin protein-coding 
HOXA1 homeobox A1 protein-coding 
H19 H19, imprinted maternally 
expressed transcript (non-
protein coding) 
ncRNA 
FGF4 fibroblast growth factor 4 protein-coding 
CKS1B CDC28 protein kinase regulatory 
subunit 1B 
protein-coding 
PTTG2 pituitary tumor-transforming 2 protein-coding 
WNT10B wingless-type MMTV 
integration site family member 
10B 
protein-coding 
WNT5A wingless-type MMTV 
integration site family member 
5A 
protein-coding 
TSPY1 testis specific protein, Y-linked 1 protein-coding 
MIR663A microRNA 663a ncRNA 
BMP7 bone morphogenetic protein 7 protein-coding 
S100A8 S100 calcium binding protein A8 protein-coding 
BCL11A B-cell CLL/lymphoma 11A protein-coding 
CENPW centromere protein W protein-coding 
HSPB1 heat shock protein family B 
(small) member 1 
protein-coding 
GRM1 glutamate receptor, 
metabotropic 1 
protein-coding 
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FGF8 fibroblast growth factor 8 protein-coding 
TGM3 transglutaminase 3 protein-coding 
 
 
 
 
D.3. SCLC unique oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
BCL2 B-cell CLL/lymphoma 2 protein-coding 
ALK anaplastic lymphoma receptor 
tyrosine kinase 
protein-coding 
MYB MYB proto-oncogene, 
transcription factor 
protein-coding 
HOXA9 homeobox A9 protein-coding 
WHSC1 Wolf-Hirschhorn syndrome 
candidate 1 
protein-coding 
TAL2 T-cell acute lymphocytic 
leukemia 2 
protein-coding 
RFC3 replication factor C subunit 3 protein-coding 
MYCL v-myc avian myelocytomatosis 
viral oncogene lung carcinoma 
derived homolog 
protein-coding 
HOXD9 homeobox D9 protein-coding 
E2F1 E2F transcription factor 1 protein-coding 
DUSP26 dual specificity phosphatase 26 
(putative) 
protein-coding 
SOX4 SRY-box 4 protein-coding 
PRDM8 PR domain 8 protein-coding 
FEV FEV, ETS transcription factor protein-coding 
E2F3 E2F transcription factor 3 protein-coding 
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D.4. LUAD overlap LUSC oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
MYCN v-myc avian myelocytomatosis 
viral oncogene neuroblastoma 
derived homolog 
protein-coding 
MCF2 MCF.2 cell line derived 
transforming sequence 
protein-coding 
TNS4 tensin 4 protein-coding 
S100A7 S100 calcium binding protein A7 protein-coding 
PVT1 Pvt1 oncogene (non-protein 
coding) 
ncRNA 
STYK1 serine/threonine/tyrosine 
kinase 1 
protein-coding 
NME1 NME/NM23 nucleoside 
diphosphate kinase 1 
protein-coding 
MMP12 matrix metallopeptidase 12 protein-coding 
MAGEA11 MAGE family member A11 protein-coding 
MIR196A1 microRNA 196a-1 ncRNA 
LHX1 LIM homeobox 1 protein-coding 
SBSN suprabasin protein-coding 
UHRF1 ubiquitin like with PHD and ring 
finger domains 1 
protein-coding 
FGF3 fibroblast growth factor 3 protein-coding 
DSG3 desmoglein 3 protein-coding 
CYP24A1 cytochrome P450 family 24 
subfamily A member 1 
protein-coding 
DPPA2 developmental pluripotency 
associated 2 
protein-coding 
CDX2 caudal type homeobox 2 protein-coding 
KIAA0101 KIAA0101 protein-coding 
UCA1 urothelial cancer associated 1 
(non-protein coding) 
ncRNA 
PRDM9 PR domain 9 protein-coding 
MIR130B microRNA 130b ncRNA 
BCAR4 breast cancer anti-estrogen 
resistance 4 (non-protein 
coding) 
ncRNA 
TCL6 T-cell leukemia/lymphoma 6 
(non-protein coding) 
ncRNA 
ETV4 ETS variant 4 protein-coding 
HOTTIP HOXA distal transcript antisense 
RNA 
ncRNA 
HOTAIR HOX transcript antisense RNA ncRNA 
GREM1 gremlin 1, DAN family BMP 
antagonist 
protein-coding 
 175 
 
D.5. LUAD overlap SCLC oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
RET ret proto-oncogene protein-coding 
PAX4 paired box 4 protein-coding 
LIN28A lin-28 homolog A protein-coding 
 
 
 
 
 
D.6. LUSC overlap SCLC oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
TP73 tumor protein p73 protein-coding 
SOX2 SRY-box 2 protein-coding 
SKP2 S-phase kinase-associated 
protein 2, E3 ubiquitin protein 
ligase 
protein-coding 
KIAA1524 KIAA1524 protein-coding 
GMNN geminin, DNA replication 
inhibitor 
protein-coding 
PAX2 paired box 2 protein-coding 
LMO1 LIM domain only 1 protein-coding 
GALR2 galanin receptor 2 protein-coding 
CNTN2 contactin 2 protein-coding 
SYT1 synaptotagmin 1 protein-coding 
PAK7 p21 protein (Cdc42/Rac)-
activated kinase 7 
protein-coding 
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D.7. All overlap oncogenes from somatic up-regulated DEGs. 
Gene symbol Full name Gene type 
PTTG1 pituitary tumor-transforming 1 protein-coding 
HMGA2 high mobility group AT-hook 2 protein-coding 
AURKA aurora kinase A protein-coding 
EZH2 enhancer of zeste 2 polycomb 
repressive complex 2 subunit 
protein-coding 
CDC6 cell division cycle 6 protein-coding 
PIWIL1 piwi-like RNA-mediated gene 
silencing 1 
protein-coding 
CCNB2 cyclin B2 protein-coding 
CCNE1 cyclin E1 protein-coding 
FAM83D family with sequence similarity 
83 member D 
protein-coding 
TYMS thymidylate synthetase protein-coding 
TWIST1 twist family bHLH transcription 
factor 1 
protein-coding 
SSX1 synovial sarcoma, X breakpoint 
1 
protein-coding 
STIL SCL/TAL1 interrupting locus protein-coding 
STRA6 stimulated by retinoic acid 6 protein-coding 
SALL4 spalt-like transcription factor 4 protein-coding 
HES6 hes family bHLH transcription 
factor 6 
protein-coding 
PAX3 paired box 3 protein-coding 
LIN28B lin-28 homolog B protein-coding 
HOXD13 homeobox D13 protein-coding 
TLX1 T-cell leukemia homeobox 1 protein-coding 
HMGA1 high mobility group AT-hook 1 protein-coding 
FGF5 fibroblast growth factor 5 protein-coding 
EEF1A2 eukaryotic translation 
elongation factor 1 alpha 2 
protein-coding 
ECT2 epithelial cell transforming 2 protein-coding 
DLX5 distal-less homeobox 5 protein-coding 
UBE2C ubiquitin conjugating enzyme 
E2C 
protein-coding 
MLLT11 myeloid/lymphoid or mixed-
lineage leukemia; translocated 
to, 11 
protein-coding 
IGF2BP1 insulin like growth factor 2 
mRNA binding protein 1 
protein-coding 
CDKN3 cyclin-dependent kinase 
inhibitor 3 
protein-coding 
CDC25C cell division cycle 25C protein-coding 
CDC25A cell division cycle 25A protein-coding 
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KIF14 kinesin family member 14 protein-coding 
CDK1 cyclin-dependent kinase 1 protein-coding 
ESPL1 extra spindle pole bodies like 1, 
separase 
protein-coding 
CDK5R2 cyclin-dependent kinase 5, 
regulatory subunit 2 (p39) 
protein-coding 
CCNB1 cyclin B1 protein-coding 
ZIC2 Zic family member 2 protein-coding 
UCHL1 ubiquitin C-terminal hydrolase 
L1 
protein-coding 
FAM72A family with sequence similarity 
72 member A 
protein-coding 
SIX1 SIX homeobox 1 protein-coding 
PRDM13 PR domain 13 protein-coding 
PRDM12 PR domain 12 protein-coding 
PBK PDZ binding kinase protein-coding 
PLK1 polo like kinase 1 protein-coding 
PITX2 paired like homeodomain 2 protein-coding 
OTX2 orthodenticle homeobox 2 protein-coding 
MSI1 musashi RNA binding protein 1 protein-coding 
ASCL1 achaete-scute family bHLH 
transcription factor 1 
protein-coding 
FEZF1 FEZ family zinc finger 1 protein-coding 
PRAME preferentially expressed antigen 
in melanoma 
protein-coding 
FOXM1 forkhead box M1 protein-coding 
FOXG1 forkhead box G1 protein-coding 
EN2 engrailed homeobox 2 protein-coding 
BIRC5 baculoviral IAP repeat 
containing 5 
protein-coding 
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